ACS Publications. Most Trusted. Most Cited. Most Read
Quick View

OR SEARCH CITATIONS

My Activity
Publications
CONTENT TYPES

Figure 1Loading Img
Download Hi-Res ImageDownload to MS-PowerPointCite This:ACS Infect. Dis. 2015, 1, 1, 59-72
RETURN TO ISSUEPREVArticleNEXT

Chemical Genomics-Based Antifungal Drug Discovery: Targeting Glycosylphosphatidylinositol (GPI) Precursor Biosynthesis

View Author Information
† Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
‡ Whitehead Institute for Biomedical Research, 9 Cambridge Center, Cambridge, Massachusetts 02142, United States
§ Howard Hughes Medical Institute and Department of Biology, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States
# Banting and Best Department of Medical Research, Terrance Donnally Centre of Cellular and Biomedical Research, University of Toronto, Toronto, Ontario, Canada
⊥ Fundación Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucı́a, Medina, Parque Tecnológico de Ciencias de la Salud , Avenida Conocimiento 34, 18016 Grenada, Spain
*(T.R.) E-mail: [email protected]
Cite this: ACS Infect. Dis. 2015, 1, 1, 59–72
Publication Date (Web):December 5, 2014
https://doi.org/10.1021/id5000212

Copyright © 2014 American Chemical Society. This publication is licensed under these Terms of Use.

Request reuse permissions
  • Open Access
  • Editors Choice

Article Views

12558

Altmetric

-

Citations

65
LEARN ABOUT THESE METRICS
PDF (5 MB)
Get e-Alerts
Supporting Info (1)»
SUBJECTS:

Abstract

High Resolution Image
Download MS PowerPoint Slide

Steadily increasing antifungal drug resistance and persistent high rates of fungal-associated mortality highlight the dire need for the development of novel antifungals. Characterization of inhibitors of one enzyme in the GPI anchor pathway, Gwt1, has generated interest in the exploration of targets in this pathway for further study. Utilizing a chemical genomics-based screening platform referred to as the Candida albicans fitness test (CaFT), we have identified novel inhibitors of Gwt1 and a second enzyme in the glycosylphosphatidylinositol (GPI) cell wall anchor pathway, Mcd4. We further validate these targets using the model fungal organism Saccharomyces cerevisiae and demonstrate the utility of using the facile toolbox that has been compiled in this species to further explore target specific biology. Using these compounds as probes, we demonstrate that inhibition of Mcd4 as well as Gwt1 blocks the growth of a broad spectrum of fungal pathogens and exposes key elicitors of pathogen recognition. Interestingly, a strong chemical synergy is also observed by combining Gwt1 and Mcd4 inhibitors, mirroring the demonstrated synthetic lethality of combining conditional mutants of GWT1 and MCD4. We further demonstrate that the Mcd4 inhibitor M720 is efficacious in a murine infection model of systemic candidiasis. Our results establish Mcd4 as a promising antifungal target and confirm the GPI cell wall anchor synthesis pathway as a promising antifungal target area by demonstrating that effects of inhibiting it are more general than previously recognized.

KEYWORDS:

Note Added After ASAP Publication

ARTICLE SECTIONS
Jump To

This paper was published ASAP on December 12, 2014, with an error in Figure 2. The corrected version reposted with the issue on January 9, 2015.

The need for novel antifungal agents is undeniable. Candida albicans persists as the principal clinically relevant fungal pathogen in the United States and remains the fourth leading cause of bloodstream infections despite decades of attention and therapeutic strategies designed to eradicate it. (1) The growing trend of C. albicans azole-resistance, as recently highlighted by the Centers for Disease Control, only underscores the need for new treatment options. Mortality associated with Aspergillus fumigatus, a second clinically important fungal pathogen, is also unacceptably high and exceeds 50% despite treatment with current standard of care (SOC) antifungal agents. (2) Compounding this problem, the antifungal drug armamentarium is restricted to only three basic classes of agents, amphotericin B, azoles, and echinocandins, that target ergosterol in the plasma membrane, ergosterol biosynthesis, or synthesis of the fungal-specific cell wall polymer, β-1,3-glucan, respectively. (2, 3) Furthermore, each drug class possesses its own limitations (spectrum, administration, resistance, and/or toxicity), and with the exception of the echinocandins, was originally discovered and developed over 50 year ago. (4)
We developed the C. albicans fitness test (CaFT) assay as a genomics-based platform to screen synthetic or natural product libraries and identify target-specific inhibitors with antifungal drug-like properties (Figure 1). (5-7) The assay is based on the principle of chemically induced haploinsufficiency, first described in the diploid yeast, Saccharomyces cerevisiae, where the deletion of one allele of a target gene renders the heterozygote deletion strain hypersensitive to bioactive inhibitors specific to the depleted target. (8, 9) As such, each strain expresses half the normal level of a particular gene product versus other heterozygote mutants or the wild type diploid strain, and, consequently, less inhibitor is required to inhibit the specific heterozygote that has been genetically depleted of the drug target. To maximize the likelihood of linking a target-selective inhibitor to its cognate target, the CaFT assay contains nearly 5400 unique heterozygote strains reflecting 90% C. albicans genome coverage. (7) Each heterozygote strain also possesses two unique molecular barcodes (i.e., distinct 20 base pair strain-identifying DNA sequences). Consequently, all strains can be pooled and assayed in coculture, allowing multiplex screening of the entire heterozygote CaFT pool when challenged with a subminimum inhibitory concentration of a mechanistically uncharacterized bioactive compound or natural product extract. The relative abundance (or “fitness”) of each strain comprising the strain set exposed to drug versus mock treatment is then determined by PCR amplification and fluorescent labeling of all bar codes, microarray hybridization, and analysis. Knowledge of those genes specifically affecting an altered fitness to a particular bioactive agent provides important insight into the possible mechanism of action (MOA) of the inhibitory compound. To date, we have demonstrated the robustness of this screening paradigm, identifying novel whole cell active target-selective inhibitors to diverse cellular processes and biochemical pathways including mRNA processing, (10) proteasome function, (11) and purine metabolism, (12) as well as cell wall β-1,3-glucan, protein, and fatty acid biosynthesis. (7, 13)

Figure 1

Figure 1. Individual C. albicans heterozygous deletion mutants contain two unique barcodes (red and blue boxes) flanking the deleted allele. The CaFT strain pool contains ∼5400 heterozygote deletion mutants, comprising >90% genome coverage. Aliquots of the pool are treated with a sub-MIC of the growth inhibitory compound or mock treatment and grown for 20 generations. The relative abundance of each strain, which reflects their chemical sensitivity to the compound, is subsequently determined by DNA microarray analysis using PCR amplified barcodes of each heterozygote. The response of each heterozygote to the effects of the compound is then appraised by calculating a normalized Z score, with a positive value indicating hypersensitivity and a negative value reflecting resistance (or hyposensitivity) to the tested compound. See Xu et al. for details of Z-score calculation. (6) In this example, the strain highlighted in red is uniquely hypersensitive to the compound (C) treatment and depleted from the pool versus the mock-treated (M) control.

High Resolution Image
Download MS PowerPoint Slide
Here, we describe the discovery and characterization of two additional classes of antifungal compounds targeting specific steps in glucosylphosphatidylinositol (GPI) precursor biosynthesis. GPIs are endoplasmic reticulum (ER)-derived post-translational modifications broadly conserved in eukaryotes and serve as cell surface anchors for >100 cell wall proteins in yeast. (14) GPI-anchored proteins function in diverse processes, including adherence, virulence, septation, and cell wall biogenesis. As such, GPI biosynthesis is essential for fungal growth. (15, 16) GPI proteins transit the secretory pathway and receive GPI anchor attachment en bloc by a transamidation reaction linking the GPI to their C-terminus. (16, 17) Following attachment, GPI proteins are secreted to the cell surface, where they may remain bound to the plasma membrane or, more often, cross-linked to β-1,6-glucan polymers of the cell wall. (17) GPI biosynthetic enzymes and the precursor product itself (ethanolamine-P-6Manα1–2Manα1–6Manα1–4GlcNH2α1–6-d-myo-inositol-1-phosphate-lipid, where the lipid is diacylglycerol, acylalkylglycerol, or ceramide) are largely conserved across eukaryotes. Important functional differences, however, exist in the pathway between fungi and mammalian cells, including Gwt1-dependent acylation of inositol and Mcd4-mediated ethanolamine phosphate (EtNP) addition to mannose 1 (Man1) of the GPI core, despite the existence of human homologues Pig-W and Pig-N, respectively. (15, 17)
Applying a CaFT screening approach, the synthetic compounds, G365 and G884, are each predicted to inhibit Gwt1-mediated acylation of GPI precursors. Corroborating their proposed MOA, whole genome next-generation sequencing (NGS) of multiple G884 drug-resistant mutants isolated in the second yeast species, S. cerevisiae, reveals isolates faithfully contain single amino acid substitutions that map to GWT1 and which are cross-resistant to the known Gwt1 inhibitor, gepinacin. Biochemical evidence also supports this view as, like gepinacin, both inhibitors are shown in a cell-free system to deplete Gwt1-mediated acylation of GPI precursors in a dose-dependent manner. Similarly, we identify and mechanistically characterize the Mcd4-specific natural product inhibitor, M743, by CaFT screening unfractionated natural product extracts. M743 (previously named BE-049385A (18) as well as YM3548 (19)) is a terpenoid lactone ring-based natural product previously demonstrated to inhibit Mcd4 ethanolamine phosphotransferase activity. (20, 21) The striking hypersensitivity of the mcd4 heterozygote and unique secondary profile to M743 provide a genome-wide prediction of the specificity and unique MOA of this agent in a whole cell context. Whole genome NGS of S. cerevisiae drug-resistant mutants to M743 and a highly related semisynthetic analogue (M720) corroborates this view as single missense mutations uniquely map to MCD4. Both GWT1 and MCD4 are essential for growth in yeast (22, 23) and, accordingly, cognate inhibitors of these targets display potent microbiological activity across multiple clinically relevant diverse pathogenic fungi. Unlike current antifungal agents, GPI biosynthesis inhibitors also expose β-1,3-glucan, an important agonist of Toll-like receptors (TLRs), (24) and induce TNFα secretion in mouse macrophage co-incubated with C. albicans drug-treated cells. Finally, we demonstrate that the Mcd4 inhibitor M720 provides significant efficacy in a murine infection model of systemic candidiasis and discuss the potential of GPI inhibitors as a new mechanistic class of antifungal agents.

Results and Discussion

ARTICLE SECTIONS
Jump To

CaFT Screening and GPI Inhibitor Identification

CaFT screening was performed against >1000 pure synthetic compounds within the Merck corporate library known to inhibit C. albicans growth at drug concentrations <20 μM but for which their drug target and MOA were completely unknown. As a result of this unbiased screening approach, two compounds having CaFT profiles suggesting a GPI pathway-based MOA were identified and named G884 and G365, respectively (Figure 2A). Specifically, the C. albicans GWT1 heterozygote (encoding a GlcN-PI acyltransferase involved in early GPI precursor synthesis (25)) displays a unique and statistically significant hypersensitivity to G884 and G365 across a series of drug concentrations in a dose-dependent manner not previously seen despite extensive synthetic compound and natural product extract screening (Supporting Information, Figure S1A). G884 and G365 are structurally unrelated to each other (Figure 2C) as well as two recently described synthetic Gwt1 inhibitors, E1210 (26) and gepinacin. (27) Interestingly, two additional heterozygotes corresponding to GPI1 and SPT14 (both of which participate in the preceding and first committed step in GPI biosynthesis, namely GlcNAc-PI biosynthesis (17)) display a significant and reproducible growth advantage (i.e., enhanced fitness as judged by negative Z scores) to both G884 and G365, further implicating a GPI inhibitory MOA for these compounds. Confirmation of the altered chemical sensitivity phenotypes of each of the heterozygote deletion mutants identified by the CaFT assay was demonstrated directly by serial dilution and spotting heterozygotes onto drug-containing plates (Figure S2). Interestingly, the severity of drug sensitivity phenotypes among those heterozygotes reflecting these CaFT profiles not only matched between G884 and G365 but also gepinacin, reinforcing a possible common MOA shared by all three compounds.

Figure 2

Figure 2. CaFT-based screening identifies GPI inhibitors. (A) CaFT summary of C. albicans heterozygote hypersensitivity to G884 across multiple drug concentrations. Note increasing strain sensitivities to G884 are displayed left to right (second row), based on the sum Z score across each independent CaFT experiment. Individual Z scores for each heterozygote strain are listed (rows 3–6), with Z scores highlighted in a color scale and heat map format. Note the GWT1 heterozygote reproducibly displays greatest sensitivity to G884, and GPI1 and SPT14 heterozygotes display modest resistance to G884. (B) CaFT summary of C. albicans heterozygote hypersensitivity to M743 across multiple drug concentrations. Rank order of strain sensitivities and Z scores are highlighted as in (A). Note that the MCD4 heterozygote displays greatest hypersensitivity to M743, whereas additional sensitive heterozygotes correspond to COPI coatamer subunits. (C) Chemical structures of G884, G365, M743, M720, and gepinacin. (D) Image of the S. cerevisiae GPI precursor and predicted enzymatic steps in precursor biosynthesis targeted by the above inhibitors.

High Resolution Image
Download MS PowerPoint Slide
The CaFT screening platform has also been extensively applied to screening unfractionated natural product extracts for target-selective antifungal agents. (7, 10, 11) As part of this effort we independently identified M743 (a previously described antifungal natural product, YM3548 (18, 19)) despite its presence in a complex mixture of additional compounds comprising the unfractionated extract. Its CaFT profile complements previous genetic and biochemical studies demonstrating YM3548 inhibits GPI biosynthesis by blocking Mcd4-mediated ethanolaminephosphate (EtNP) transferase activity of mannose1 (Man1) of the GPI precursor. (20, 21, 23) Specifically, a prominently reduced fitness of the C. albicans MCD4 heterozygote strain is specifically and reproducibly detected in the CaFT assay when challenged with M743-containing extracts, purified M743, or the M743 semisynthetic analogue, M720 (Figure 2B and Figure S3). MCD4 heterozygote hypersensitivity to M743 is directly demonstrated by serial dilution spot tests on drug-containing plates (Figure S2) and further corroborated by genetic knockdown of MCD4 expression using a conditional mutant under the control of a tetracycline-regulatable promoter (Figure S4). Importantly, hypersensitivity of the C. albicans MCD4 heterozygote to M743 and M720 is highly unique and not seen despite extensive screening of the strain, reinforcing Mcd4 as the likely drug target rather than a “promiscuous” mutant broadly hypersensitive to diverse antimicrobial compounds.
M743 and M720 also produce a highly unique secondary CaFT profile reflecting a number of additional hypersensitive heterozygote mutants implicated in the MOA of these agents (Figure 2B and Figure S3). Specifically, numerous strains heterozygous for subunits of the secretory coat protein complex I (COPI) including Cop1, Sec26, Ret2, and Ret3 (28) as well as the COPII accessory factor, Sed4 (29) demonstrate hypersensitivity to M743 and M720. Drug sensitivity phenotypes of each of these heterozygote strains were confirmed by serial dilution of each mutant on either M743 or M720 containing plates (Figure S2). Interestingly, each of these heterozygotes is predicted to be compromised in their function of retention and recycling of ER-localized membrane proteins containing a “KKXX” C-terminal retention sequence and of which Mcd4 is a member. (23, 30, 31) Presumably, M743 and M720 hypersensitivity of these heterozygotes reflects their functional role in Golgi → ER retrograde transport and retrieval of ER-localized membrane proteins and is manifested indirectly by partially depleted Mcd4 levels in the ER (where early GPI synthesis events occur (17)) and concomitant mislocalization of the target to the Golgi. Accordingly, heterozygosity of genes involved in COPI-mediated retrograde transport may nonetheless produce M743 and M720 hypersensitive phenotypes that phenocopy heterozygosity of the actual (Mcd4) drug target (see below).

Drug Resistance-Based Mechanism of Action Studies

To genetically corroborate CaFT profiles that predict Gwt1 as the drug target of G884, three stable independently derived drug-resistant mutants to G884 (G884R) were isolated in a haploid S. cerevisiae strain. In each case, the minimal inhibitor concentration (MIC) of G884 was increased 8-fold (MIC = 128 μg/mL) in the G884R isolate versus the parental wild type strain (Figure 3A). Whole genome NGS revealed that each G884R isolate maintains an amino acid substitution mutation corresponding to Gwt1-G132W or Gwt1-F238C (Table 2B). As no additional nonsynonomous mutations were identified in the genome of two independent G884R isolates (Table 2B), we conclude these mutations are causal for the observed drug resistance phenotype. Gwt1-G132W and Gwt1-F238C mutations map to the fourth transmembrane domain (TMD, of which nine are predicted (22)) or a highly conserved central region of Gwt1, respectively (Figure 3B) Interestingly, a similar Gwt1 amino acid substitution, Gwt1-G132R, is reported to confer drug resistance to the progenitor compound of E1210, named BIQ. (22) Therefore, although G884 and E1210 are structurally unrelated, both compounds may share a common ligand binding site and inhibit Gwt1 activity in an analogous manner. Furthermore, the Gwt1-G132W mutant strain is highly cross-resistant to gepinacin (MIC shift >32-fold; Figure 3A), further suggesting a common Gwt1 inhibitory mechanism between each of these compounds. Drug resistance mapping of G365 was precluded by the fact that the compound only weakly inhibits S. cerevisiae growth despite its potent antifungal activity against C. albicans.

Figure 3

Figure 3. S. cerevisiae drug resistant mutant isolation and characterization of GPI inhibitors. (A) Summary of Gwt1 and Mcd4 drug resistant amino acid substitution mutants and altered susceptibility to GPI inhibitors versus control antifungal agents, amphotericin B (AmB), fluconazole (FLZ), and caspofungin (CSP). Specific amino acid substitutions and causal nucleotide mutations are shown. Note G884R mutations were isolated using wild-type (wt) strain S288c, whereas M743 R and M720 R mutants were isolated from a pdr5Δ strain otherwise isogenic to BY4700. Also note cross-resistance is specifically observed between M743 and its semisynthetic analogue, M720, among Mcd4 amino acid drug-resistant isolates as well as between G884 and gepinacin with Gwt1-G132W. (B) G884R amino acid substitutions (boxed) map to Gwt1. Predicted topology of S. cerevisiae Gwt1 is shown as recently determined with C-terminal sequence residing in cytosol. (33) (C) M743R and M720R amino acid substitutions (boxed) map to Mcd4. Predicted topology of S. cerevisiae Mcd4 is shown as previously described, (23) with the KKTQ C-terminal sequence residing in the lumen of the ER.

High Resolution Image
Download MS PowerPoint Slide
Table 1. Microbiological Spectrumab
  MB2865Ca2323Ca1055ATCC22019MY1396ATCC6258MY1381S288cMF5668
compdMOAS. aureusC. albicansC. albicansC. parapsilosisC. lusitaniaeC. kruseiC. glabrataS. cerevisiaeA. fumigatus
G365GWT1>1284 (2)4 (2)2>128>128>128>1284 (2)
G884GWT11284486412832 (16)16128 (64)
G642 gepinacinGWT1>1284 (2)4 (2)24>1284 (2)1 (0.5)(16)
M720MCD4>1280.5 (0.25)0.5 (0.25)0.50.51 (0.5)0.251 (0.5)0.5 (0.25)
M743MCD4>1280.50.5 (0.25)0.5 (0.25)11 (0.5)0.51 (0.5)0.25 (0.125)
AmBpolyene>1280.250.50.50.50.50.50.50.5
FLZazole>1280.5 (0.25)>12811328 (4)4>128
CAScandin>1280.0630.250.50.250.50.25 (0.125)0.25(0.016)
a

All MIC values are represented as μg/mL.

b

MIC-50 values (drug concentrations required to inhibit growth 50%) are in parentheses.

Table 2. Whole Genome NGS Mapping of GPI Inhibitor Drug Resistant Mutations to Their Cognate Targeta
Table a

Heat map summary of all nonsynonymous mutations identified by Illumina-based NGS (>100× genome coverage) of all independently isolated drug resistant mutants in the pdr5Δ strain, BY4700 (A) or a wild type S288C strain (B). Each column is a summary of all nonsynonymous mutations identified for a particular drug-resistant isolate; no additional nonsynonymous mutations were identified. Red, nonsynonymous mutation that maps to the predicted target Mcd4 (inhibitors M743 and M720) or Gwt1 (G884). Yellow, additional nonsynonymous mutations identified by NGS. Black, no change versus the parental wild type strain gene sequence. Nonsynonymous mutations mapping to the predicted drug target are causal for the drug resistance phenotype as they are faithfully identified in all M720R and M743R isolates from the pdr5Δ strain background as well as the G884R wild type strain background. In several cases, M720R isolates from the wild type starting strain background carry a pdr5 missense mutation (rather than mapping to Mcd4), reflecting a bypass resistance mechanism. Base changes and resulting amino acid substitutions are shown.

To obtain genetic evidence in support of MCD4 being the molecular target of M743, three alternative approaches to identifying M743R mutants were performed in S. cerevisiae. As M743 appears to be a substrate of Pdr5-mediated drug efflux in yeast (Figure 3A), genetic studies to verify this compound as a cognate inhibitor of Mcd4 were first performed in a pdr5Δ strain background, from which seven independently derived M743R isolates were identified. Following whole genome NGS, all M743R isolates were determined to contain a single missense mutation causing amino acid substitution P810L (n = 6) or Q679P (n = 1; Figure 3C and Table 2A) in Mcd4. Drug resistance mutant selection was also performed using M720, with eight independently derived M720R isolates recovered. In each case, whole genome NGS revealed only a single missense mutation in each resistor genome mapping to the MCD4 locus (including a new allele Mcd4-G792C), therefore demonstrating these Mcd4 amino acid substitution mutations as causal for M720 and M743 drug resistance. All MCD4 drug-resistant mutations map to the C-terminal region of the protein and lie within the C-terminal region of TMD11 (G792C) or within a cytosolic loop (Q679P) or ER luminal domain (F800L and P810L) based on the predicted topology of the protein (Figure 3C). (23) Notably, M720R selection performed in the pdr5Δ strain background proved highly efficient in identifying target-based drug resistance as similar studies performed using a wild type S. cerevisiae strain identified only a single isolate containing a missense mutation in the drug target (Mcd4-P810Q) (Table 2A). All other M720R isolates obtained from a wild type background contained distinct amino substitution mutations in Pdr1, a positive regulator of Pdr5, and are similar to previously described gain of function mutations to this master regulator of multidrug resistance. (32) All M720R and M743R mutant strains were uniquely cross-resistant to the corresponding analogue, demonstrating these analogues maintain a common mechanism; none of the M720R or M743R mutants demonstrated cross-resistance to Gwt1p inhibitors (gepinacin, G884, or G365) or to a panel of clinically used antifungal drugs (Figure 3A). Collectively, these studies validate the CaFT as a robust reverse genetics platform to predict the MOA of bioactive agents, regardless of whether they are derived from natural product extract mixtures or exist as pure synthetic compounds. Furthermore, genetic identification of their cognate drug target by drug resistance selection in S. cerevisiae demonstrates their conserved MOA across yeast and C. albicans.

Gwt1 Inhibitors Selectively Block Acylation of Yeast Glucosamine Phosphatidylinositol (GlcN-PI) Biosynthesis

Gwt1 acylates GlcN-PI, an essential early precursor in GPI biosynthesis. (25, 33) To demonstrate in vitro the target-specific inhibitory effects of G884 and G365, Gwt1 acylation activity was evaluated following drug treatment in a cell-free system (see Methods for details). (27) Similar to the positive control compound gepinacin, G884 and G365 both inhibited acylation of GlcN-PI, unlike the negative control compounds, M743 and M720 (Figure 4A). Furthermore, G884 and G365 both inhibited acylation of GlcN-PI in a dose-dependent manner (Figure 4B). G884 in vitro inhibition of Gwt1 acylation activity also correlated strongly with its S. cerevisiae MIC (∼16 μg/mL), consistent with genetic evidence that the compound’s whole cell activity is directly and specifically mediated through inactivation of Gwt1 function. Although G365 lacks yeast activity (S. cerevisiae MIC > 128 μg/mL), G365 similarly inhibited Gwt1 acylation activity (IC50 ∼ 20 μg/mL) in this in vitro setting. Thus, consistent with CaFT data, G365 targets Gwt1 and its lack of yeast activity is not target-based but rather due to its species-specific activity (Table 1).

Figure 4

Figure 4. G884 and G365 inhibit Gwt1 acylation. (A) TLC of products of an in vitro acylation assay using membranes from S. cerevisiae. Controls show that in the absence of ATP and CoA the acylated band is not produced. In the presence of phopholipase C only the acylated band is preserved. Inhibitors of MCD4, M720, and M743 do not inhibit Gwt1-dependent acylation. The acylation reactions were incubated with 2 μg/mL of gepinacin, M720, and M743 and 30 μg/mL of G884 and G365. All GPI inhibitor MIC values for S. cerevisiae are listed in Table 1. (B) Dose response of the acylation inhibition by G884 and G365. The amount of compound in the reaction is given above the blot as μg/mL. (C) G884 preferentially inhibits the fungal enzyme, Gwt1. Growth curves of S. cerevisiae strains contain either the human enzyme Pig-W or the fungal enzyme, Gwt1, as their sole source of inositol acylating activity. The origin of replication for the low-copy plasmids is CEN and for the high-copy plasmids is 2 μm. (27) (D) Induction of the unfolded protein response in cells carrying a GFP reporter construct showing strong induction by inhibitors of Gwt1 and Mcd4. GFP expression was monitored by flow cytometry.

High Resolution Image
Download MS PowerPoint Slide
To further examine target selectivity of Gwt1 inhibitors, we took advantage of previously published transgenic yeast strains in which a gwt1Δ strain expresses either Gwt1 or the human orthologue, Pig-W. (27) Like gepinacin, G884 displayed appreciable (>10-fold) selectivity to its fungal target versus the human counterpart (Figure 4C), consistent with the minimal cytotoxicity data observed against multiple human cell lines, including HeLa cells (G884 IC50 > 100 μM) (Tables S1 and S2). Although similar studies to address G365 target selectivity could not be performed, again due to the lack of S. cerevisiae activity, cytotoxicity of the compound against HeLa cells is approximately 30-fold lower than that of cycloheximide, a positive control compound for this assay. Furthermore, minimal G365 cytotoxicity (IC50 > 50 μM) was detected against HepG2 or THLE-2 human liver immortalized cell lines (Table S2).

GPI Inhibitors Induce the Unfolded Protein Response

The modifications to the GPI anchor by Gwt1 and Mcd4 appear to be important for their forward transport and recognition by other enzymes in the pathway. This is indicated by the CaFT secondary profile for the Mcd4 inhibitors M743 and M720, which highlights aspects of ER to Golgi trafficking, and previous studies have shown that the deletion of Mcd4 in yeast blocks the forward traffic of GPI-anchored proteins. (34) It has previously been shown that inhibition of Gwt1 by gepinacin blocks the trafficking of GPI-anchored proteins and induces a large unfolded protein response (UPR) in the ER. Incubation of yeast for 3 h with either the Gwt1 or Mcd4 inhibitor compounds in this study induced a profound UPR as measured by the expression of GFP under the control of a UPR element (Figure 4D). In contrast, the UPR is not induced by the conventional antifungal agent fluconazole. These results indicate that inhibition of these targets has a strong effect on ER protein homeostasis.

Microbiological Evaluation of GPI Inhibitors

M743 displayed potent activity against all Candida species tested, including C. albicans (MIC = 0.5 μg/mL), C. parapsilosis (MIC = 0.5 μg/mL), C. glabrata (MIC = 0.5 μg/mL), C. krusei (MIC = 1.0 μg/mL), and C. lusitaniae (MIC = 0.25 μg/mL) (Table 1). M743 also displayed remarkably potent activity against A. fumigatus (MIC = 0.25 μg/mL), paralleling the potency of caspofungin against this filamentous fungal pathogen. Broad anti-Aspergillus spp. activity was also noted on agar plates seeded with A. fumigatus, A. niger, or A. terreus and by measuring clear zones of inhibition where M743 was spotted on the surface of the plate (Figure S5). Conversely, G884, G365, and the control compound, gepinacin, all possess similar antifungal potency against C. albicans (MIC = 4 μg/mL), and only G365 also displayed strong activity against A. fumigatus (MIC = 4 μg/mL; Table 1). No appreciable antibacterial activity for any of the above compounds was observed (S. aureus MIC ≥ 128 μg/mL), reflecting the absence of orthologous drug targets and GPI biosynthesis in prokaryotes. Gwt1 inhibitors also lack obvious cytotoxicity at the highest drug concentration tested (with IC50 values ≥50 μM) against HeLa, HepG2, and THLE-2 human cell lines (Tables S1 and S2). Conversely, Mcd4 inhibitors displayed notable cytotoxicity against these cell lines, and only an approximate 10-fold therapeutic index (Tables S1 and S2). All GPI inhibitors tested (G884, G365, M743, and M720) also displayed a clear fungistatic terminal phenotype against C. albicans by standard kill curve analysis (Figure S6A), paralleling the demonstrated fungistatic nature of E1210. (35) Combining Gwt1 and Mcd4 inhibitors at 4 times the MIC of each agent, so as to chemically interdict GPI synthesis at two discrete steps in precursor synthesis, failed to convert their fungistatic effects to that of a fungicidal terminal phenotype (Figure S6B). Therefore, whereas small molecule inhibition of GPI biosynthesis affects fungal growth across diverse species, preliminary evidence suggests such agents are unlikely to achieve a broadly observed fungicidal terminal phenotype.
As we have highly selective and potent inhibitors to two distinct steps in GPI precursor biosynthesis, we tested whether pharmacological interdiction at multiple points in this pathway simultaneously achieves a synergist growth inhibitory effect. Indeed, substantial drug synergy was observed between each of the GPI inhibitor classes targeting Gwt1 and Mcd4 when examined by standard checkerboard analysis (Figure 5A,B). Fractional inhibitory concentration indices (FICI) as low as 0.25–0.313 were observed against C. albicans when G884 and M720 or G365 and M720 were combined (Figure 5C). Although no synergy between these compound classes was observed against A. fumigatus, strong chemical synergy between Gwt1 and Mcd4 inhibitors extends to S. cerevisiae (Figure 5C). On the basis of the observed synergy between Gwt1 and Mcd4 inhibitors, we predicted that GWT1 and MCD4 should exhibit a negative genetic interaction. Indeed, tetrad analysis revealed that S. cerevisiae yeast conditional mutants of GWT1 and MCD4 are synthetically lethal as double mutants, thus providing a clear genetic basis for the observed synergy of their cognate inhibitors (Figure 5D).

Figure 5

Figure 5. GWT1 and MCD4 display a synthetic lethal genetic interaction and cognate inhibitors possess highly synergistic antifungal activity. (A) Drug synergy of GPI inhibitor combinations G884 and M720 or (B) G884 and M720 determined by standard checkerboard analysis against C. albicans strain 2323. Drug concentrations and fractional inhibitory concentrations (FIC) used to evaluate synergy are indicated. Chemical synergy is achieved provided the sum FIC of the two agents (referred to as the FIC index, or FICI) is ≤0.5. FICI = 0.5 is indicated by the diagonal blue line. (C) Tabular summary of the FICI values of Gwt1 and Mcd4 inhibitors tested against C. albicans and S. cerevisiae. (D) GWT1 and MCD4 exhibit a synthetic lethal genetic interaction in yeast. Spore progeny of a gwt1-20::natMX4/GWT1, mcd4-500::kanMX4/MCD4 double-heterozygous diploid strain dissected onto synthetic complete (SC) medium and incubated at 30 °C for 4 days. Large colonies are identified as wild-type; smaller colonies are either gwt1-20 or mcd4-500 haploids (depending on drug resistance marker; natR, (black square); kanR, (white circle)), and microcolonies maintaining both markers are gwt1-20, mcd4-500 double mutants.

High Resolution Image
Download MS PowerPoint Slide

GPI Inhibitors Expose Cell Surface β-Glucan and Induce TNFα Secretion

Fungal cell wall β-glucans provide a powerful pro-inflammatory stimulus recognized by TLRs to induce a host immune response and combat infection. (24, 36) However, the β-glucan composition of the cell wall is naturally masked by surface mannoproteins and GPI-anchored proteins, thus offering a mechanism to evade immune detection. (36) As C. albicans cells treated with gepinacin display substantial changes in cell wall composition resulting in surface-exposed β-(1–3)-glucan sufficient to induce the pro-inflammatory cytokine TNFα, (27) we tested whether these observations are specific to gepinacin or instead more broadly reflect a GPI pathway depletion phenotype. Indeed, immunostaining and immunofluorescence microscopy of C. albicans cells treated at sub-MIC levels with Gwt1 inhibitors (G365 and G884) and Mcd4 inhibitors (M743 and M720) all exhibited elevated immunoreactivity by a β-(1–3)-glucan antibody equal to or greater (e.g., M720) than achieved by gepinacin drug treatment (Figure 6A). Conversely, β-(1–3)-glucan antibody was completely unreactive to mock-treated cells or the control antifungal agent, fluconazole, under identical conditions tested (Figure 6A). Importantly, failure to observe β-(1–3)-glucan antibody immunoreactivity in fluconazole-treated cells strongly argues that the effect we detect is GPI pathway-based rather than an indirect consequence of dead or lysed cells releasing β-(1–3)-glucan. Moreover, elevated exposure of β-(1–3)-glucan led to significant (2–2.5-fold) increases in secreted TNFα by mouse macrophages co-incubated with C. albicans cells when specifically drug-treated with all GPI inhibitors (Figure 6B). Thus, unlike that of other essential cellular processes targeted by current antifungal drugs, new agents targeting GPI biosynthesis may possess dual attributes in a therapeutic context, namely, antiproliferative properties against the pathogen as well as immune stimulatory effects by the host.

Figure 6

Figure 6. GPI inhibitors unmask cell surface β-glucan and induce TNFα secretion in macrophages. (A) Fluorescence photomicrographs of C. albicans and β-(1–3)-glucan (green) immunoreactivity with anti-β-(1–3)-glucan antibody following treatment with GPI inhibitors (G365, G884, M743, M720, and gepinacin), the control antifungal agent fluconazole (FLZ), or DMSO. All drug treatments were performed at a drug concentration equivalent to IC40 to ensure immunoreactivity is not indirectly due to cell death. Propidium iodide staining confirms minimal cell death for all GPI inhibitors tested at their IC40 concentration versus fluconazole. Images are merged fluorescence and phase contrast. (B) ELISA quantification of secreted TNFα by RAW264.7 macrophage co-incubated with C. albicans strain 2323 (5) treated at MIC20 and MIC40 values for each of the above agents.

High Resolution Image
Download MS PowerPoint Slide

In Vivo Efficacy of M720 in a Murine Infection Model of Candidiasis

On the basis of the superior potency and spectrum of M743 versus G365 or G884, we chose to examine its potential efficacy in a murine infection model of candidiasis. However, M743 displays significant instability in mouse plasma, where its ester-linked side chain is completely released within 2 h of incubation, rendering the product inactive (MIC shift from 0.5 to >25 μg/mL) (Figure S7). To address this issue, the M743 esterase sensitive linkage was replaced with a carbamate linkage, yielding the compound M720, which displayed highly favorable stability in mouse plasma (Figure S7) without any loss in antifungal activity (Table 1). Importantly, CaFT profiles of M720 and M743 are indistinguishable (Figure S3), and M720R analysis in yeast unequivocally identifies causal drug-resistant mutations mapping to MCD4, thus demonstrating M720 remains highly selective to its cognate target.
To evaluate M720 antifungal efficacy, C. albicans infected mice were administered M720 by intraperitoneal (ip) injection twice daily (bid) or once daily (qd) over a 2 or 4 day dosing regimen in an abbreviated candidiasis model where fungal burden was quantified within kidneys 4 days after infectious challenge. Fungal burden in sham-treated mice exceeded >6 log10 CFU/g kidney. Conversely, in each M720 dosing regimen tested fungal burden was significantly reduced in a dose-dependent manner, with nearly a 2 log10 reduction of C. albicans CFU/g kidney achieved at the 50 mg/kg dose (Figure 7). Importantly, no mice exhibited gross effects of toxicity, including ruffled fur, lethargy, tremors, or other gross effects in any of the M720 treatment groups. These data provide pharmacological demonstration that M720 provides a beneficial antifungal therapeutic effect in a systemic infection model of candidiasis and broadens the relevance of GPI biosynthesis as an important target pathway for developing new antifungal agents.

Figure 7

Figure 7. In vivo efficacy of M720 in a murine systemic infection model of candidiasis. DBA/2 mice were infected with C. albicans strain MY1055 and treated ip with M720 or caspofungin (CAS) at the indicated doses (mg/kg) either twice daily (bid) or once daily (qd). Kidneys were aseptically collected at 4 days after infectious challenge, and log reduction of colony-forming units (CFU) per gram of kidney tissue was calculated on the basis of kidney burden of vehicle-treated (5% DMSO or H2O, respectively) control group. Note the limit of detection (LOD) is 1.5 × 102 CFU/g, as indicated by the dashed line. (∗) P < 0.05, (∗∗) P < 0.01, and (∗∗∗) P < 0.001 significance versus vehicle control.

High Resolution Image
Download MS PowerPoint Slide
Here we have used a C. albicans genome-wide reverse genetics small molecule screening strategy (CaFT) combined with S. cerevisiae drug resistance mutant selection and whole genome NGS to identify and mechanistically characterize multiple antifungal inhibitors specifically targeting GPI precursor biosynthesis. G365 and G884 display potent anti-Candida activity and prominent GWT1 depletion profiles by CaFT analysis reproduced by directly examining growth rates of gwt1/GWT1 and other signature heterozygote strains with altered susceptibility to each compound. Drug resistance mutant isolation and whole genome NGS of G884 resistors provide a genetic confirmation of the compound’s hypothesized MOA as multiple independently derived G884R mutants map to GWT1 without any additional nonsynonomous mutations present in the genome of these isolates. As the Gwt1:G132W mutant displays marked cross-resistance to gepinacin, these antifungal compounds likely share a common mechanism of inhibiting Gwt1p activity. Despite our inability to isolate drug-resistant mutants to G365 due to its poor activity against bakers’ yeast (even a pdr5Δ strain; MIC > 64 μg/mL), G365 and G884 share remarkably related CaFT profiles and heterozygote strain sensitivities as observed for gepinacin. Importantly, both compounds also inhibit Gwt1-mediated acylation activity in a dose-dependent manner in a yeast cell-free system, thus unambiguously defining Gwt1 as the target of these agents.
CaFT screening of unfractionated natural product extracts also led to the identification of a second class of GPI inhibitors targeting Mcd4. Like the initial extract, M743 (the purified bioactive compound) as well as its semisynthetic analogue, M720, both revealed a striking mcd4 heterozygote chemical sensitivity phenotype as well as highly related CaFT secondary profiles biologically relevant to the MOA of these agents. In support of their predicted MOA, whole genome NGS of numerous independently derived drug-resistant yeast isolates again identified a common missense mutation, in this case mapping to MCD4, thus demonstrating these mutations are causal for the drug resistance. Reciprocally, drug resistance mutant analysis reinforces the extent of mechanistic insight CaFT profiling can provide to study the MOA of growth inhibitory small molecules. Whereas inhibitors of distinct enzymes in a common pathway such as GPI biosynthesis might be expected (at best) to share highly related CaFT profiles suggestive of the pathway inhibited by these compounds, instead it was possible to differentiate proximal (i.e., molecular target Gwt1 or Mcd4) from distal (i.e., pathway and/or terminal phenotype) effects by these agents. Collectively, these results demonstrate how “toggling” between robust whole cell screening and MOA determination strategies best suited for different fungal species may be combined to effectively identify and mechanistically characterize new target-specific growth inhibitory agents.
GPI inhibitors targeting multiple steps in GPI synthesis also provide valuable reagents to broadly explore the pharmacological consequences of interdicting this essential cellular process and examine whether the pathway is suitable for developing new antifungal agents. Gwt1-specific inhibitors are fungistatic, show potential antifungal spectrum, minimal cytotoxicity, and substantial specificity to their fungal target when tested directly in yeast expressing either Gwt1 or the human orthologue, Pig-W. Alternatively, whereas Mcd4 inhibitors are also fungistatic and demonstrate a striking potency and spectrum that parallels existing SOC antifungal drugs, notable cytotoxicity against multiple human cell lines was observed. On the basis of control antifungal agents similarly tested, the observed cytotoxicity of the M720 derivative of M743 appears somewhat between that of amphotericin B and fluconazole. Importantly, M720 displays significant efficacy in a murine infection model of candidiasis without any obvious host toxicity observed even at the highest dose tested. Indeed, the acute toxicity of M720 (i.e., the lethal dose of the drug for 50% of the mice treated (LD50)) is >300 mg/kg when administered IP; conversely, the LD50 of amphotericin B is only 4.5 mg/kg in mice. Unexpectedly, we also demonstrate that Gwt1 and Mcd4 inhibitors display strong synergistic antifungal activity, which is confirmed to be target-based as genetic studies in yeast demonstrate a synthetic lethal genetic interaction between GWT1 and MCD4.
Intriguingly, C. albicans treated with any of the identified Gwt1 or Mcd4 inhibitors also led to cell wall alterations that specifically expose β-(1–3)-glucan that is normally masked from immune recognition by cell surface GPI-anchored mannoproteins. (37) As anti-β-glucan antibodies have been characterized in mouse and human sera, (38) GPI pathway inhibitors may therefore augment pathogen recognition by the immune system. This elevated exposure of β-(1–3)-glucan also led to a significant increase in secreted TNFα secretion by mouse macrophages co-incubated with C. albicans cells when specifically treated with all GPI inhibitors tested. These results suggest that an elevated immune response may also possibly exist in a therapeutic context and that inhibitors to other steps in GPI biosynthesis may similarly display a dual benefit: directly inhibiting growth of the pathogen at higher drug concentrations and at lower concentrations indirectly enhancing the host immune response. Accordingly, GPI inhibitors may also possess a unique advantage as combination agents to enhance therapeutic efficacy if paired with existing clinically used antifungals.
M743 was first described by Riezman and colleagues (named YW3548 (17)) and Merck researchers (named BE49385A (39, 40)) as a novel terpenoid lactone-based natural product inhibitor of GPI biosynthesis in yeast. Initial studies suggested M743 likely inhibits Gpi10, responsible for the addition of the third mannose onto the GPI precursor. (18, 41) However, subsequent genetic and biochemical studies demonstrated MCD4, encoding a phosphoethanolamine transferase responsible for addition of phosphoethanolamine (EtNP) to C-2 of the first mannose (Man1) of the GPI precursor, and the mammalian orthologue, Pig-n, serve as the likely target of M743. In support of this conclusion, (i) yeast mcd4-174 mutants as well as mammalian cell lines deleted of Pig-n accumulate a GPI precursor intermediate lacking EtNP addition to Man1 and which is identically detected in M743-treated cells, (20, 21, 23) (ii) protozoa lack such a modification to Man1 and are intrinsically resistant to this agent, (18, 42) and (iii) overexpression of MCD4 suppresses the growth inhibitory effect of M743. (20) Drug resistance selection and whole genome NGS studies described here now provide an unequivocal genetic demonstration of Mcd4 as the drug target to this agent.
As GPI biosynthesis is an essential process broadly conserved between fungi and higher eukaryotes, it may seem somewhat counterintuitive how inhibitors of this pathway would have potential therapeutic potential as novel antifungal agents for clinical use. However, the Gwt1 inhibitor E1210 has recently entered antifungal clinical development, (26, 43) and potential cytotoxicity limitations appear mitigated by the high specificity of the agent to its fungal target versus its human counterpart. Gepinacin, G884, and G365 also display clear target selectivity and acceptable therapeutic index (>25-fold) between C. albicans and human cell lines, thus providing similarly desirable starting points. Therefore, like clinically successful azoles (whose human orthologues are cytochrome P450 enzymes), success in developing Gwt1 inhibitors will ultimately require exquisite target selectivity. Mcd4 inhibitors M743 and M720, on the other hand, appear to demonstrate a relatively narrow (∼10-fold) therapeutic index against C. albicans and A. fumigatus versus human cell lines tested. It is also known that M743 is a potent inhibitor of GPI biosynthesis not only in yeast but mammalian cell lines as well. (20) Thus, the compound serves as a robust and well-validated chemical probe for chemical biology studies across diverse GPI-producing organisms. However, whether the fungal selectivity of M743 may be improved by medicinal chemistry optimization is unknown and not easily assisted by applying structure-based drug design due to the complex membrane topology of Mcd4. Considering Mcd4 is demonstrated to be druggable, perhaps the identification of a new structurally distinct inhibitor series may be required, as recently reported using an analogous screening strategy developed in S. cerevisiae. (44)
Regardless of the antifungal development potential of M743, a deeper understanding of the specific phenotypes associated with the loss of MCD4 or Pig-n in yeast and mammalian cell lines offers a conceptual framework for considering new antifungal targets. For example, whereas gene knockout of yeast MCD4 is lethal and mcd4-174 temperature-sensitive mutants accumulate the GPI precursor intermediate Man2–Man1–GlcN–(acyl)PI prior to cell death at elevated temperature, (21) deletion of PIG-N in a mouse F9 cell line is not essential. (20) Furthermore, full-length GPI polymers (but lacking EtNP attachment at Man1), and GPI-anchored cell wall proteins are correctly localized to the cell surface of pig-n deleted cells. (20) One particularly attractive hypothesis to explain this disconnect lies in the potential differences in substrate specificity between yeast and mammalian GPI enzymes that function downstream of the Mcd4-dependent EtNP–Man1 modification to continue subsequent steps in GPI precursor synthesis. (20, 21) In this case, the non-EtNP-containing GPI intermediate, Man2–Man1–GlcN–(acyl)PI, which accumulates by both genetic and pharmacological inactivation of Mcd4 and mammalian PIG-N, may only adequately serve as substrate for the subsequent GPI mannosyl transferase enzyme in mammals (PIG-B) but not the yeast orthologue, Gpi10. Consistent with this view, heterologous expression of PIG-B suppressed loss of MCD4 in yeast. (21) Consequently, Mcd4 inhibitors may exhibit antifungal-specific growth inhibitory activity by the failure of Gpi10 (and not PIG-B) to sufficiently recognize the non-EtNP containing substrate GPI intermediate, which would accumulate in drug-treated fungal cells. Such functional differences and alternate substrate specificities between fungal and human orthologues may considerably broaden the current antifungal target set and may have significant implications with regard to the antifungal spectrum and cytotoxicity of cognate inhibitors to such previously neglected drug targets.

Methods

ARTICLE SECTIONS
Jump To

Materials

All GPI inhibitors were synthesized by Merck Chemistry. Fluconazole, amphotericin B, and cycloheximide were purchased from Sigma-Aldrich. All fungal strains, including the CaFT heterozygote strain set, are from the Merck or Whitehead Institute culture collections and may be obtained upon request. For more information on the strains please see Table S3 in the Supporting Information.

CaFT Screening and GPI Inhibitor Identification

C. albicans heterozygote strain construction, CaFT DNA microarrays, experiments, and data analysis linking G884 and G365 to GWT1 and linking M743 to MCD4 were performed as previously described. (13)

Microbiological Evaluation of GPI Inhibitors

All fungal susceptibility testing was performed using RPMI media according to CLSI standard protocols, M27-A3 for yeasts and M38-A2 for A. fumigatus. Bacterial susceptibility was performed in Mueller–Hinton broth according to CLSI protocol M7-A7. Time–kill assays were performed over a 24 h course with C. albicans MY1055 in RPMI media using GPI compounds at 8 times the determined MIC. Amphotericin B was used at 0.5 and 2.0 times the MIC as a cidal control. For Gwt1 and Mcd4 inhibitor combinations, each single agent was used at 4 times the MIC. Duplicate cultures were sampled at T0, T2, T6, and T24 hours, diluted and plated on YPD agar, and incubated for 48 h at 37 °C. Plates were imaged on a NuTech Flash and Go colony counter (Neutec Group, Inc.) and the average viable colony-forming units was determined and compared to those of DMSO (0.3%) and AmB controls.

Measurement of TNFα Secretion

Measurements were performed as previously described. (27) Briefly, C. albicans strain Ca2323 was grown in YPD and treated overnight at the specified sublethal concentrations of antifungal or 0.2% DMSO. Cells were washed three times in 1 mL of water, counted, and resuspended in water at 1 × 107 cells/mL, maintaining the test concentration of the antifungal. Treated cells were incubated with mouse macrophage cell line RAW264.7 (ATCC) at a ratio of 10:1 yeast/macrophage in the presence of the drug. After 2 h, supernatant was collected and TNFα concentration was measured by ELISA (kit DY410, R&D Systems) according to the manufacturer’s protocol.

β-Glucan Staining

C. albicans cells were grown in YPD overnight at the specified sublethal drug concentrations as described for the measurement of TNFα secretion. Cells were centrifuged and resuspended in 2% BSA/PBS and blocked for 30 min, then pelleted and resuspended in β-1,3-glucan antibody (1:100 in 2% BSA/PBS) and incubated at room temperature for 1 h. Cells were washed five times in phosphate-buffered saline (PBS), pelleted, and resuspended in goat anti-mouse Alexa-488 secondary antibody (1:100 in PBS containing 1 μg/mL propidium iodide) and incubated at room temperature for 1 h. Cells were washed five times in PBS and transferred to a 384-well PDL-coated imaging plate (Griener). Ten-fold dilutions were transferred to ensure proper density for visualization. Images were acquired on the BD Pathway 435 Bioimager using a 60× objective and transmitted light, Alexa 488, and propidium iodide channels. Antibody to β-1,3-glucan was purchased from Biosupplies Inc., Australia. Goat anti-mouse Alexa 488 secondary antibody and PI were purchased from Molecular Probes.

Mapping of Drug-Resistant Mutants to GPI Targets

To obtain drug-resistant mutants, S. cerevisiae strain S288c was grown in YPD broth overnight, and 1 × 108 cells were spread on YPD agar plates containing 75 μg/mL L884 or 60 μg/mL M720. To obtain mutants in the efflux-deficient background, S. cerevisiae strain BY4700/Δpdr5 was similarly grown and spread on 2 μg/mL of M720 and M743. Plates were incubated at 30 °C for 72–96 h until resistors appeared. Following confirmation of reduced drug susceptibility, genomic DNA was prepared from each isolate using Qiagen’s Blood and Tissue Genomic DNA Purification kit. Illumina-based next-generation sequencing was performed by Beijing Genomics Institute, Hong Kong, and all nonsynonymous mutations for each compound were identified and tabulated into heat maps.

Antifungal Efficacy

The in vivo efficacy of M720 was determined in a murine model of disseminated candidiasis. Briefly, groups of four or five DBA/2 mice weighing approximately 20 g were challenged intravenously with C. albicans MY1055 at 3.08 × 104 CFU/mouse. Mice were treated with M720 or vehicle control (5% DMSO in sterile water) ip twice daily (bid) for 2 days or once-daily (qd) for 4 days (four total doses) beginning immediately after infectious challenge. Caspofungin administered ip, bid × 2 days (four total doses), was included as a positive control and was compared to sterile water vehicle control. At day 4 after challenge, mice were euthanized, and both kidneys were aseptically collected, weighed, homogenized in sterile saline, serially diluted, and plated onto Sabouraud’s dextrose agar. Plates were incubated at 35 °C for 30–48 h and then colonies enumerated. Candida burden (CFU/gram kidney) in M720 or caspofungin treatment groups was compared to the relevant vehicle control, and significance was determined using the Student’s paired two-tailed t test. Comparisons were considered significant at the α = 0.05 level.
All procedures were performed in accordance with the highest standards for the humane handling, care, and treatment of research animals and were approved by the Merck Institutional Animal Care and Use Committee (IACUC).

In Vitro Acylation of Gwt1p Inhibitors

Assays were performed as described previously in a published protocol, (25) except that UDP[3H]GlcNAc was used instead of [14C] and TLC plates were imaged by autoradiography. Lipid extracts were treated overnight with phosphatidylinositol-specific phospholipase C to confirm that the band identified as GlcN-(acyl)PI was resistant to cleavage.

Mammalian Cytotoxicity Assessment

To assess potential mammalian cytotoxic effects of GPI inhibitors, two distinct cell proliferation assays were performed. One involved using the Click-iT EdU Alexa Fluor 488 HCS assay (kit C10351, Life Technologies) with minor modifications to the manufacturer’s protocol. Images were captured and analyzed using an Acumen eX3 (TTP Labtech Ltd.) laser scanning cytometer. Hoechst 33342 (H3530, LifeTech) was used as a nuclear stain to facilitate enumeration of total cell number. Briefly, HeLa cells were seeded at 4000 cells/well in 384-well poly-d-lysine (PDL)-coated plates (Greiner, 781946) in 25 μL of culture medium (Optimem I, Life Technologies) per well. A total of 20 2-fold serial dilutions of GPI compounds, cycloheximide, or vehicle control were prepared and added (0.25 μL per well) to obtain the desired working concentration. EdU was added to obtain a final concentration of 5 μM. Cycloheximide was used as a toxic control compound. Percent EdU inhibition and cell count inhibition are calculated by normalizing against the DMSO control (maximum incorporation). Alternatively, the more traditional MTT ((3-(4,5-dimethylthiazol-2-yl-2,5-diphenyltetrazolium bromide) colorimetric assay, which measures mitochondrial metabolic activity, was performed using HepG2 and THLE-2 human cells lines over a 72 h period.

Supporting Information

ARTICLE SECTIONS
Jump To

The following file is available free of charge on the ACS Publications website at DOI: 10.1021/id5000212.

  • Tables S1–S4 contain general strain information, mammalian cytotoxicity results, and expanded bacterial spectrum testing; Figures S1–S7 contain additional data describing CaFT analysis, heterozygote spot testing, Aspergillus zones of inhibition, time–kill assays, conditional mutant response, and Mcd4 inhibitor stability in plasma (PDF)

Terms & Conditions

Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: http://pubs.acs.org/page/copyright/permissions.html.

Author Information

ARTICLE SECTIONS
Jump To
  • Corresponding Author
    • Terry Roemer - Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States;  Email: [email protected]
  • Authors
    • Paul A. Mann - Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
    • Catherine A. McLellan - Whitehead Institute for Biomedical Research, 9 Cambridge Center, Cambridge, Massachusetts 02142, United States;  Howard Hughes Medical Institute and Department of Biology, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States
    • Sandra Koseoglu - Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
    • Qian Si - Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
    • Elena Kuzmin - Banting and Best Department of Medical Research, Terrance Donnally Centre of Cellular and Biomedical Research, University of Toronto, Toronto, Ontario, Canada
    • Amy Flattery - Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
    • Guy Harris - Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
    • Xinwei Sher - Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
    • Nicholas Murgolo - Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
    • Hao Wang - Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
    • Kristine Devito - Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
    • Nuria de Pedro - Fundación Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucı́a, Medina, Parque Tecnológico de Ciencias de la Salud , Avenida Conocimiento 34, 18016 Grenada, Spain
    • Olga Genilloud - Fundación Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucı́a, Medina, Parque Tecnológico de Ciencias de la Salud , Avenida Conocimiento 34, 18016 Grenada, Spain
    • Jennifer Nielsen Kahn - Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
    • Bo Jiang - Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
    • Michael Costanzo - Banting and Best Department of Medical Research, Terrance Donnally Centre of Cellular and Biomedical Research, University of Toronto, Toronto, Ontario, Canada
    • Charlie Boone - Banting and Best Department of Medical Research, Terrance Donnally Centre of Cellular and Biomedical Research, University of Toronto, Toronto, Ontario, Canada
    • Charles G. Garlisi - Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
    • Susan Lindquist - Whitehead Institute for Biomedical Research, 9 Cambridge Center, Cambridge, Massachusetts 02142, United States;  Howard Hughes Medical Institute and Department of Biology, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States
  • Notes
    The authors declare no competing financial interest.

Acknowledgment

ARTICLE SECTIONS
Jump To

We thank Carl Balibar and Juliana Malinverni for critically reading the manuscript and Luke Whitesell for technical assistance. This work was supported in part by a grant from Genome Canada and Genome Quebec.

Abbreviations

ARTICLE SECTIONS
Jump To
CaFT

C. albicans fitness test

GPI

glucosylphosphatidylinositol

MOA

mechanism of action

EtNP

ethanolamine phosphate

Man1

mannose 1

NGS

next-generation sequencing

TLRs

Toll-like receptors

COPI

coat protein complex I

MIC

minimal inhibitor concentration

GlcN-PI

glucosamine phosphatidylinositol

UPR

unfolded protein response

AmB

amphotericin B

FLZ

fluconazole

CSP

caspofungin

FIC

fractional inhibitory concentrations

SOC

standard of care

References

ARTICLE SECTIONS
Jump To

This article references 44 other publications.

  1. 1
    Pfaller, M. A. and Diekema, D. J. (2007) Epidemiology of invasive candidiasis: a persistent public health problem Clin. Microbiol. Rev. 20, 133– 163 DOI: 10.1128/CMR.00029-06
    Google Scholar
    1
    Epidemiology of invasive candidiasis: a persistent public health problem
    Pfaller, M. A.; Diekema, D. J.
    Clinical Microbiology Reviews (2007), 20 (1), 133-163CODEN: CMIREX; ISSN:0893-8512. (American Society for Microbiology)
    A review. The contemporary epidemiol. of invasive candidiasis is discussed. Trends in incidence, mortality, species distribution, and antifungal resistance are described. Issues of cost and emerging strategies for the treatment and prevention of this important invasive mycosis are also addressed.
    >> More from SciFinder ®
    https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvFKnur0%253D&md5=e0278d710f17b1fcceca25450a884c19
  2. 2
    Brown, G. D., Denning, D. W., Gow, N. A., Levitz, S. M., Netea, M. G., and White, T. C. (2012) Hidden killers: human fungal infections Sci. Transl. Med. 4, 165rv13 DOI: 10.1126/scitranslmed.3004404
    Google Scholar
    There is no corresponding record for this reference.
  3. 3
    Ostrosky-Zeichner, L., Casadevall, A., Galgiani, J. N., Odds, F. C., and Rex, J. H. (2010) An insight into the antifungal pipeline: selected new molecules and beyond Nat. Rev. Drug Discovery 9, 719– 727 DOI: 10.1038/nrd3074
    Google Scholar
    3
    An insight into the antifungal pipeline: selected new molecules and beyond
    Ostrosky-Zeichner, Luis; Casadevall, Arturo; Galgiani, John N.; Odds, Frank C.; Rex, John H.
    Nature Reviews Drug Discovery (2010), 9 (9), 719-727CODEN: NRDDAG; ISSN:1474-1776. (Nature Publishing Group)
    A review. Invasive fungal infections are increasing in incidence and are assocd. with substantial mortality. Improved diagnostics and the availability of new antifungals have revolutionized the field of medical mycol. in the past decades. This Review focuses on recent developments in the antifungal pipeline, concg. on promising candidates such as new azoles, polyenes and echinocandins, as well as agents such as nikkomycin Z and the sordarins. Developments in vaccines and antibody-based immunotherapy are also discussed. Few therapeutic products are currently in active development, and progression of therapeutic agents with fungus-specific mechanisms of action is of key importance.
    >> More from SciFinder ®
    https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVCmurvK&md5=d7ccb58b653d567179e53437061df80e
  4. 4
    Roemer, T. and Krysan, D. J. Antifungal drug development: challenges, unmet clinical needs, and new approaches. (2014) Cold Spring Harb Perspect. Med. 4 (5),  DOI: 10.1101/cshperspect.a019703 .
    Google Scholar
    There is no corresponding record for this reference.
  5. 5
    Roemer, T., Jiang, B., Davison, J., Ketela, T., Veillette, K., Breton, A., Tandia, F., Linteau, A., Sillaots, S., Marta, C., Martel, N., Veronneau, S., Lemieux, S., Kauffman, S., Becker, J., Storms, R., Boone, C., and Bussey, H. (2003) Large-scale essential gene identification in Candida albicans and applications to antifungal drug discovery Mol. Microbiol. 50, 167– 181 DOI: 10.1046/j.1365-2958.2003.03697.x
    Google Scholar
    5
    Large-scale essential gene identification in Candida albicans and applications to antifungal drug discovery
    Roemer, Terry; Jiang, Bo; Davison, John; Ketela, Troy; Veillette, Karynn; Breton, Anouk; Tandia, Fatou; Linteau, Annie; Sillaots, Susan; Marta, Catarina; Martel, Nick; Veronneau, Steeve; Lemieux, Sebastien; Kauffman, Sarah; Becker, Jeff; Storms, Reginald; Boone, Charles; Bussey, Howard
    Molecular Microbiology (2003), 50 (1), 167-181CODEN: MOMIEE; ISSN:0950-382X. (Blackwell Publishing Ltd.)
    C. albicans is the primary fungal pathogen of humans. Despite the need for novel drugs to combat fungal infections, antifungal drug discovery is currently limited by both the availability of suitable drug targets and assays to screen corresponding targets. A functional genomics approach based on the diploid C. albicans genome sequence, termed GRACE (gene replacement and conditional expression), was used to assess gene essentiality through a combination of gene replacement and conditional gene expression. In a systematic application of this approach, we identify 567 essential genes in C. albicans. Interestingly, evaluating the conditional phenotype of all identifiable C. albicans homologs of the Saccharomyces cerevisiae essential gene set by GRACE revealed only 61% to be essential in C. albicans, emphasizing the importance of performing such studies directly within the pathogen. Construction of this conditional mutant strain collection facilitates large-scale examn. of terminal phenotypes of essential genes. This information enables preferred drug targets to be selected from the C. albicans essential gene set by phenotypic information derived both in vitro, such as cidal vs. static terminal phenotypes, as well as in vivo through virulence studies using conditional strains in an animal model of infection. In addn., the combination of phenotypic and bioinformatic analyses further improves drug target selection from the C. albicans essential gene set, and their resp. conditional mutant strains may be directly used as sensitive whole-cell assays for drug screening.
    >> More from SciFinder ®
    https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXotFOhur0%253D&md5=4c1ba1bcd6ce3a32f36a89a7f5c8f4fb
  6. 6
    Xu, D., Jiang, B., Ketela, T., Lemieux, S., Veillette, K., Martel, N., Davison, J., Sillaots, S., Trosok, S., Bachewich, C., Bussey, H., Youngman, P., and Roemer, T. (2007) Genome-wide fitness test and mechanism-of-action studies of inhibitory compounds in Candida albicans PLoS Pathog. 3, e92 DOI: 10.1371/journal.ppat.0030092
    Google Scholar
    There is no corresponding record for this reference.
  7. 7
    Roemer, T., Xu, D., Singh, S. B., Parish, C. A., Harris, G., Wang, H., Davies, J. E., and Bills, G. F. (2011) Confronting the challenges of natural product-based antifungal discovery Chem. Biol. 18, 148– 164 DOI: 10.1016/j.chembiol.2011.01.009
    Google Scholar
    7
    Confronting the Challenges of Natural Product-Based Antifungal Discovery
    Roemer, Terry; Xu, Deming; Singh, Sheo B.; Parish, Craig A.; Harris, Guy; Wang, Hao; Davies, Julian E.; Bills, Gerald F.
    Chemistry & Biology (Cambridge, MA, United States) (2011), 18 (2), 148-164CODEN: CBOLE2; ISSN:1074-5521. (Cell Press)
    A review. Starting with the discovery of penicillin, the pharmaceutical industry has relied extensively on natural products (NPs) as an unparalleled source of bioactive small mols. suitable for antibiotic development. However, the discovery of structurally novel and chem. tractable NPs with suitable pharmacol. properties as antibiotic leads has waned in recent decades. Today, the repetitive "rediscovery" of previously known NP classes with limited antibiotic lead potential dominates most industrial efforts. This limited productivity, exacerbated by the significant financial and resource requirements of such activities, has led to a broad de-emphasis of NP research by most pharmaceutical companies, including most recently Merck. Here we review our strategies-both technol. and philosophical-in addressing current antifungal discovery bottlenecks in target identification and validation and how such efforts may improve NP-based antimicrobial discoveries when aligned with NP screening and dereplication.
    >> More from SciFinder ®
    https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXit1Kjtro%253D&md5=7fe45a7b27bbcf2f222631036b072e76
  8. 8
    Shoemaker, D. D., Lashkari, D. A., Morris, D., Mittmann, M., and Davis, R. W. (1996) Quantitative phenotypic analysis of yeast deletion mutants using a highly parallel molecular bar-coding strategy Nat. Genet. 14, 450– 456 DOI: 10.1038/ng1296-450
    Google Scholar
    8
    Quantitative phenotypic analysis of yeast deletion mutants using a highly parallel molecular bar-coding strategy
    Shoemaker, Daniel D.; Lashkari, Deval A.; Morris, Don; Mittmann, Mike; Davis, Ronald W.
    Nature Genetics (1996), 14 (4), 450-456CODEN: NGENEC; ISSN:1061-4036. (Nature Publishing Co.)
    A quant. and highly parallel method for analyzing deletion mutants has been developed to aid in detg. the biol. function of thousands of newly identified open reading frames (ORFs) in Saccharomyces cerevisiae. This approach uses a PCR targeting strategy to generate large nos. of deletion strains. Each deletion strain is labeled with a unique 20-base tag sequence that can be detected by hybridization to a high-d. oligonucleotide array. The tags serve as unique identifiers (mol. bar codes) that allow anal. of large nos. of deletion strains simultaneously through selective growth conditions. Hybridization expts. show that the arrays are specific, sensitive and quant. A pilot study with 11 known yeast genes suggests that the method can be extended to include all of the ORFs in the yeast genome, allowing whole genome anal. with a single selection growth condition and a single hybridization.
    >> More from SciFinder ®
    https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XntlGgt7k%253D&md5=078e8c61adac5e44de40fe221730d2d7
  9. 9
    Giaever, G., Shoemaker, D. D., Jones, T. W., Liang, H., Winzeler, E. A., Astromoff, A., and Davis, R. W. (1999) Genomic profiling of drug sensitivities via induced haploinsufficiency Nat. Genet. 21, 278– 283 DOI: 10.1038/6791
    Google Scholar
    9
    Genomic profiling of drug sensitivities via induced haploinsufficiency
    Giaever, Guri; Shoemaker, Daniel D.; Jones, Ted W.; Liang, Hong; Winzeler, Elizabeth A.; Astromoff, Anna; Davis, Ronald W.
    Nature Genetics (1999), 21 (3), 278-283CODEN: NGENEC; ISSN:1061-4036. (Nature America)
    Lowering the dosage of a single gene from two copies to one copy in diploid yeast results in a heterozygote that is sensitized to any drug that acts on the product of this gene. This haploinsufficient phenotype thereby identifies the gene product of the heterozygous locus as the likely drug target. We exploited this finding in a genomic approach to drug-target identification. Genome sequence information was used to generate molecularly tagged heterozygous yeast strains that were pooled, grown competitively in drug and analyzed for drug sensitivity using high-d. oligonucleotide arrays. Individual heterozygous strain anal. verified six known drug targets. Parallel anal. identified the known target and two hypersensitive loci in a mixed culture of 233 strains in the presence of the drug tunicamycin. Our discovery that both drug target and hypersensitive loci exhibit drug-induced haploinsufficiency may have important consequences in pharmacogenomics and variable drug toxicity obsd. in human populations.
    >> More from SciFinder ®
    https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXitVCitL0%253D&md5=2a1d1ef187aed84b3499e53af5baada4
  10. 10
    Jiang, B., Xu, D., Allocco, J., Parish, C., Davison, J., Veillette, K., Sillaots, S., Hu, W., Rodriguez-Suarez, R., Trosok, S., Zhang, L., Li, Y., Rahkhoodaee, F., Ransom, T., Martel, N., Wang, H., Gauvin, D., Wiltsie, J., Wisniewski, D., Salowe, S., Kahn, J. N., Hsu, M. J., Giacobbe, R., Abruzzo, G., Flattery, A., Gill, C., Youngman, P., Wilson, K., Bills, G., Platas, G., Pelaez, F., Diez, M. T., Kauffman, S., Becker, J., Harris, G., Liberator, P., and Roemer, T. (2008) PAP inhibitor with in vivo efficacy identified by Candida albicans genetic profiling of natural products Chem. Biol. 15, 363– 374 DOI: 10.1016/j.chembiol.2008.02.016
    Google Scholar
    10
    PAP inhibitor with in vivo efficacy identified by Candida albicans genetic profiling of natural products
    Jiang, Bo; Xu, Deming; Allocco, John; Parish, Craig; Davison, John; Veillette, Karynn; Sillaots, Susan; Hu, Wenqi; Rodriguez-Suarez, Roberto; Trosok, Steve; Zhang, Li; Li, Yang; Rahkhoodaee, Fariba; Ransom, Tara; Martel, Nick; Wang, Hao; Gauvin, Daniel; Wiltsie, Judyann; Wisniewski, Douglas; Salowe, Scott; Nielsen-Kahn, Jennifer; Hsu, Ming-Jo; Giacobbe, Robert; Abruzzo, George; Flattery, Amy; Gill, Charles; Youngman, Phil; Wilson, Ken; Bills, Gerald; Platas, Gonzalo; Pelaez, Fernando; Diez, Maria Teresa; Kauffman, Sarah; Becker, Jeff; Harris, Guy; Liberator, Paul; Roemer, Terry
    Chemistry & Biology (Cambridge, MA, United States) (2008), 15 (4), 363-374CODEN: CBOLE2; ISSN:1074-5521. (Cell Press)
    Natural products provide an unparalleled source of chem. scaffolds with diverse biol. activities and have profoundly impacted antimicrobial drug discovery. To further explore the full potential of their chem. diversity, we survey natural products for antifungal, target-specific inhibitors by using a chem.-genetic approach adapted to the human fungal pathogen C. albicans and demonstrate that natural-product fermn. exts. can be mechanistically annotated according to heterozygote strain responses. Applying this approach, we report the discovery and characterization of a natural product, parnafungin, which we demonstrate, by both biochem. and genetic means, to inhibit poly(A) polymerase. Parnafungin displays potent and broad spectrum activity against diverse, clin. relevant fungal pathogens and reduces fungal burden in a murine model of disseminated candidiasis. Thus, mechanism-of-action detn. of crude fermn. exts. by chem.-genetic profiling brings a powerful strategy to natural-product-based drug discovery.
    >> More from SciFinder ®
    https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXkvFWqt7w%253D&md5=a092e9c8eb95781e38397709bf005ca7
  11. 11
    Xu, D., Ondeyka, J., Harris, G. H., Zink, D., Kahn, J. N., Wang, H., Bills, G., Platas, G., Wang, W., Szewczak, A. A., Liberator, P., Roemer, T., and Singh, S. B. (2011) Isolation, structure, and biological activities of fellutamides C and D from an undescribed Metulocladosporiella (Chaetothyriales) using the genome-wide Candida albicans fitness test J. Nat. Prod. 74, 1721– 1730 DOI: 10.1021/np2001573
    Google Scholar
    11
    Isolation, structure, and biological activities of fellutamides C and D from an undescribed Metulocladosporiella (Chaetothyriales) using the genome-wide Candida albicans fitness test
    Xu, Deming; Ondeyka, John; Harris, Guy H.; Zink, Deborah; Kahn, Jennifer Nielsen; Wang, Hao; Bills, Gerald; Platas, Gonzalo; Wang, Wenxian; Szewczak, Alexander A.; Liberator, Paul; Roemer, Terry; Singh, Sheo B.
    Journal of Natural Products (2011), 74 (8), 1721-1730CODEN: JNPRDF; ISSN:0163-3864. (American Chemical Society-American Society of Pharmacognosy)
    In a whole-cell mechanism of action (MOA)-based screening strategy for discovery of antifungal agents, Candida albicans was used, followed by testing of active exts. in the C. albicans fitness test (CaFT), which provides insight into the mechanism of action. A fermn. ext. of an undescribed species of Metulocladosporiella that inhibited proteasome activity in a C. albicans fitness test was identified. The chem. genomic profile of the ext. contained hypersensitivity of heterozygous deletion strains (strains that had one of the genes of the diploid genes knocked down) of genes represented by multiple subunits of the 25S proteasome. Two structurally related peptide aldehydes, named fellutamides C and D, were isolated from the ext. Fellutamides were active against C. albicans and Aspergillus fumigatus with MICs ranging from 4 to 16 μg/mL and against fungal proteasome (IC50 0.2 μg/mL). Both compds. showed proteasome activity against human tumor cell lines, potently inhibiting the growth of PC-3 prostate carcinoma cells, but not A549 lung carcinoma cells. In PC-3 cells compd. treatment produced a G2M cell cycle block and induced apoptosis. Preliminary SAR studies indicated that the aldehyde group is crit. for the antifungal activity and that the 2 hydroxy groups are quant. important for potency.
    >> More from SciFinder ®
    https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXovVegsbo%253D&md5=1092cdc7bc2967a84bafa70c05d2696e
  12. 12
    Rodriguez-Suarez, R., Xu, D., Veillette, K., Davison, J., Sillaots, S., Kauffman, S., Hu, W., Bowman, J., Martel, N., Trosok, S., Wang, H., Zhang, L., Huang, L. Y., Li, Y., Rahkhoodaee, F., Ransom, T., Gauvin, D., Douglas, C., Youngman, P., Becker, J., Jiang, B., and Roemer, T. (2007) Mechanism-of-action determination of GMP synthase inhibitors and target validation in Candida albicans and Aspergillus fumigatus Chem. Biol. 14, 1163– 1175 DOI: 10.1016/j.chembiol.2007.09.009
    Google Scholar
    12
    Mechanism-of-Action Determination of GMP Synthase Inhibitors and Target Validation in Candida albicans and Aspergillus fumigatus
    Rodriguez-Suarez, Roberto; Xu, Deming; Veillette, Karynn; Davison, John; Sillaots, Susan; Kauffman, Sarah; Hu, Wenqi; Bowman, Joel; Martel, Nick; Trosok, Steve; Wang, Hao; Zhang, Li; Huang, Li-Yin; Li, Yang; Rahkhoodaee, Fariba; Ransom, Tara; Gauvin, Daniel; Douglas, Cameron; Youngman, Phil; Becker, Jeff; Jiang, Bo; Roemer, Terry
    Chemistry & Biology (Cambridge, MA, United States) (2007), 14 (10), 1163-1175CODEN: CBOLE2; ISSN:1074-5521. (Cell Press)
    Mechanism-of-action (MOA) studies of bioactive compds. are fundamental to drug discovery. However, in vitro studies alone may not recapitulate a compd.'s MOA in whole cells. Here, we apply a chemogenomics approach in Candida albicans to evaluate compds. affecting purine metab. They include the IMP dehydrogenase inhibitors mycophenolic acid and mizoribine and the previously reported GMP synthase inhibitors acivicin and 6-diazo-5-oxo-L-norleucine (DON). We report important aspects of their whole-cell activity, including their primary target, off-target activity, and drug metab. Further, we describe ECC1385, an inhibitor of GMP synthase, and provide biochem. and genetic evidence supporting its MOA to be distinct from acivicin or DON. Importantly, GMP synthase activity is conditionally essential in C. albicans and Aspergillus fumigatus and is required for virulence of both pathogens, thus constituting an unexpected antifungal target.
    >> More from SciFinder ®
    https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1amt77J&md5=92f53ba0b67720ee485d730fa129ac65
  13. 13
    Xu, D., Sillaots, S., Davison, J., Hu, W., Jiang, B., Kauffman, S., Martel, N., Ocampo, P., Oh, C., Trosok, S., Veillette, K., Wang, H., Yang, M., Zhang, L., Becker, J., Martin, C. E., and Roemer, T. (2009) Chemical genetic profiling and characterization of small-molecule compounds that affect the biosynthesis of unsaturated fatty acids in Candida albicans J. Biol. Chem. 284, 19754– 19764 DOI: 10.1074/jbc.M109.019877
    Google Scholar
    There is no corresponding record for this reference.
  14. 14
    Richard, M. L. and Plaine, A. (2007) Comprehensive analysis of glycosylphosphatidylinositol-anchored proteins in Candida albicans Eukaryot. Cell. 6, 119– 133 DOI: 10.1128/EC.00297-06
    Google Scholar
    14
    Comprehensive analysis of glycosylphosphatidylinositol-anchored proteins in Candida albicans
    Richard, Mathias L.; Plaine, Armel
    Eukaryotic Cell (2007), 6 (2), 119-133CODEN: ECUEA2; ISSN:1535-9778. (American Society for Microbiology)
    A review that focuses on the function of glycosylphosphatidylinositol-anchored proteins in Candida albicans.
    >> More from SciFinder ®
    https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitVersbc%253D&md5=afa6c59bf87ddae8c48facae2229da07
  15. 15
    Pittet, M. and Conzelmann, A. (2007) Biosynthesis and function of GPI proteins in the yeast Saccharomyces cerevisiae Biochim. Biophys. Acta 1771, 405– 420 DOI: 10.1016/j.bbalip.2006.05.015
    Google Scholar
    15
    Biosynthesis and function of GPI proteins in the yeast Saccharomyces cerevisiae
    Pittet, Martine; Conzelmann, Andreas
    Biochimica et Biophysica Acta, Molecular and Cell Biology of Lipids (2007), 1771 (3), 405-420CODEN: BBMLFG; ISSN:1388-1981. (Elsevier Ltd.)
    A review. Like most other eukaryotes, Saccharomyces cerevisiae harbors a GPI anchoring machinery and uses it to attach proteins to membranes. While a few GPI proteins reside permanently at the plasma membrane, a majority of them gets further processed and is integrated into the cell wall by a covalent attachment to cell wall glucans. The GPI biosynthetic pathway is necessary for growth and survival of yeast cells. The GPI lipids are synthesized in the ER and added onto proteins by a pathway comprising 12 steps, carried out by 23 gene products, 19 of which are essential. Some of the estd. 60 GPI proteins predicted from the genome sequence serve enzymic functions required for the biosynthesis and the continuous shape adaptations of the cell wall, others seem to be structural elements of the cell wall and yet others mediate cell adhesion. Because of its genetic tractability S. cerevisiae is an attractive model organism not only for studying GPI biosynthesis in general, but equally for investigating the intracellular transport of GPI proteins and the peculiar role of GPI anchoring in the elaboration of fungal cell walls.
    >> More from SciFinder ®
    https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsVeru70%253D&md5=eb0ba642fce1f308d70f85d9458748fd
  16. 16
    Klis, F. M., Sosinska, G. J., de Groot, P. W., and Brul, S. (2009) Covalently linked cell wall proteins of Candida albicans and their role in fitness and virulence FEMS Yeast Res. 9, 1013– 1028 DOI: 10.1111/j.1567-1364.2009.00541.x
    Google Scholar
    16
    Covalently linked cell wall proteins of Candida albicans and their role in fitness and virulence
    Klis, Frans M.; Sosinska, Grazyna J.; de Groot, Piet W. J.; Brul, Stanley
    FEMS Yeast Research (2009), 9 (7), 1013-1028CODEN: FYREAG; ISSN:1567-1356. (Wiley-Blackwell)
    A review. The cell wall of Candida albicans consists of an internal skeletal layer and an external protein coat. This coat has a mosaic-like nature, contg. c. 20 different protein species covalently linked to the skeletal layer. Most of them are GPI proteins. Coat proteins vary widely in function. Many of them are involved in the primary interactions between C. albicans and the host and mediate adhesive steps or invasion of host cells. Others are involved in biofilm formation and cell-cell aggregation. They further include iron acquisition proteins, superoxide dismutases, and yapsin-like aspartic proteases. In addn., several covalently linked carbohydrate-active enzymes are present, whose precise functions remain hitherto largely elusive. The expression levels of the genes that encode covalently linked cell wall proteins (CWPs) can vary enormously. They depend on the mode of growth and the combined inputs of several signaling pathways that sense environmental conditions. This is reflected in the unusually long intergenic regions of most of these genes. Finally, the precise location of several covalently linked CWPs is temporally and spatially regulated. It is concluded that covalently linked CWPs of C. albicans play a crucial role in fitness and virulence and that their expression is tightly controlled.
    >> More from SciFinder ®
    https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlOis7bK&md5=03afa73bf2dfb2456c3420b9aa94c729
  17. 17
    Orlean, P. and Menon, A. K. (2007) Thematic review series: Lipid posttranslational modifications. GPI anchoring of protein in yeast and mammalian cells, or: how we learned to stop worrying and love glycophospholipids J. Lipid Res. 48, 993– 1011 DOI: 10.1194/jlr.R700002-JLR200
    Google Scholar
    17
    GPI anchoring of protein in yeast and mammalian cells, or: how we learned to stop worrying and love glycophospholipids
    Orlean, Peter; Menon, Anant K.
    Journal of Lipid Research (2007), 48 (5), 993-1011CODEN: JLPRAW; ISSN:0022-2275. (American Society for Biochemistry and Molecular Biology, Inc.)
    A review. Glycosylphosphatidylinositol (GPI) anchoring of cell surface proteins is the most complex and metabolically expensive of the lipid posttranslational modifications described to date. The GPI anchor is synthesized via a membrane-bound multistep pathway in the endoplasmic reticulum (ER) requiring >20 gene products. The pathway is initiated on the cytoplasmic side of the ER and completed in the ER lumen, necessitating flipping of a glycolipid intermediate across the membrane. The completed GPI anchor is attached to proteins that were translocated across the ER membrane nd that display a GPI signal anchor sequence pathway to the cell surface; in yeast, many become covalently attached to the cell wall. Genes encoding proteins involved in all but 1 of the predicted steps in the assembly of the GPI precursor glycolipid and its transfer to protein in mammals and yeast have now been identified. Most of these genes encode polytopic membrane proteins, some of which are organized in complexes. The steps in GPI assembly, and the enzymes that carry them, are highly conserved. GPI biosynthesis is essential for viability in yeast and for embryonic development in mammals. In this review, the authors describe the biosynthesis of mammalian and yeast GPIs, their transfer to protein, and their subsequent processing.
    >> More from SciFinder ®
    https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXls1ejtLo%253D&md5=cdba29bd6397497683c83925fb816ca5
  18. 18
    Sütterlin, C., Horvath, A., Gerold, P., Schwarz, R. T., Wang, Y., Dreyfuss, M., and Riezman, H. (1997) Identification of a species-specific inhibitor of glycosylphosphatidylinositol synthesis EMBO J. 16, 6374– 6383 DOI: 10.1093/emboj/16.21.6374
    Google Scholar
    There is no corresponding record for this reference.
  19. 19
    Wang, Y., Dreyfuss, M., Ponelle, M., Oberer, L., and Riezman, H. A Glycosylphosphatidylinositol-anchoring inhibitor with an unusual tetracarboxocyclic sesterpene skeleton from the fungus Codinaea simplex. Tetrahedron 54, 6415– 6426. DOI: 10.1016/S0040-4020(98)00322-6
    Google Scholar
    There is no corresponding record for this reference.
  20. 20
    Hong, Y., Maeda, Y., Watanabe, R., Ohishi, K., Mishkind, M., Riezman, H., and Kinoshita, T. (1999) Pig-n, a mammalian homologue of yeast Mcd4p, is involved in transferring phosphoethanolamine to the first mannose of the glycosylphosphatidylinositol J. Biol. Chem. 274, 35099– 35106 DOI: 10.1074/jbc.274.49.35099
    Google Scholar
    There is no corresponding record for this reference.
  21. 21
    Wiedman, J. M., Fabre, A. L., Taron, B. W., Taron, C. H., and Orlean, P. (2007) In vivo characterization of the GPI assembly defect in yeast mcd4–174 mutants and bypass of the Mcd4p-dependent step in mcd4Delta cells FEMS Yeast Res. 7, 78– 83 DOI: 10.1111/j.1567-1364.2006.00139.x
    Google Scholar
    21
    In vivo characterization of the GPI assembly defect in yeast mcd4-174 mutants and bypass of the Mcd4p-dependent step in mcd4Δ cells
    Wiedman, Jill M.; Fabre, Anne-Lise; Taron, Barbara W.; Taron, Christopher H.; Orlean, Peter
    FEMS Yeast Research (2007), 7 (1), 78-83CODEN: FYREAG; ISSN:1567-1356. (Blackwell Publishing Ltd.)
    Yeast mcd4-174 mutants are blocked in glycosylphosphatidylinositol (GPI) anchoring of protein, but the stage at which GPI biosynthesis is interrupted in vivo has not been identified, and Mcd4p has also been implicated in phosphatidylserine and ATP transport. The authors report that the major GPI that accumulates in mcd4-174 in vivo is Man2-GlcN-(acyl-Ins)PI, consistent with proposals that Mcd4p adds phosphoethanolamine to the 1st mannose of yeast GPI precursors. Mcd4p-dependent modification of GPIs can partially be bypassed in the mcd4-174/gpi11 double mutant and in mcd4Δ mutants by high-level expression of PIG-B and GPI10, which resp. encode the human and yeast mannosyltransferases that add the 3rd mannose of the GPI precursor. Rescue of mcd4Δ by GPI10 indicates that Mcd4p-dependent addn. of EthN-P to the 1st mannose of GPIs is not obligatory for transfer of the 3rd mannose by Gpi10p.
    >> More from SciFinder ®
    https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhslyhuro%253D&md5=be87a6b02cd4021df9acfca6ebd728d4
  22. 22
    Tsukahara, K., Hata, K., Nakamoto, K., Sagane, K., Watanabe, N. A., Kuromitsu, J., Kai, J., Tsuchiya, M., Ohba, F., Jigami, Y., Yoshimatsu, K., and Nagasu, T. (2003) Medicinal genetics approach towards identifying the molecular target of a novel inhibitor of fungal cell wall assembly Mol. Microbiol. 48, 1029– 1042 DOI: 10.1046/j.1365-2958.2003.03481.x
    Google Scholar
    22
    Medicinal genetics approach towards identifying the molecular target of a novel inhibitor of fungal cell wall assembly
    Tsukahara, Kappei; Hata, Katsura; Nakamoto, Kazutaka; Sagane, Koji; Watanabe, Nao-aki; Kuromitsu, Junro; Kai, Junko; Tsuchiya, Mamiko; Ohba, Fuminori; Jigami, Yoshifumi; Yoshimatsu, Kentaro; Nagasu, Takeshi
    Molecular Microbiology (2003), 48 (4), 1029-1042CODEN: MOMIEE; ISSN:0950-382X. (Blackwell Publishing Ltd.)
    Glycosylphosphatidylinositol (GPI)-anchored cell wall mannoproteins are required for the adhesion of pathogenic fungi, such as Candida albicans, to human epithelium. Small mol. inhibitors of the cell surface presentation of GPI-anchored mannoproteins would be promising candidate drugs to block the establishment of fungal infections. Here, we describe a medicinal genetics approach to identifying the gene encoding a novel target protein that is required for the localization of GPI-anchored cell wall mannoproteins. By means of a yeast cell-based screening procedure, we discovered a compd., 1-[4-butylbenzyl]isoquinoline (I), that inhibits cell wall localization of GPI-anchored mannoproteins in Saccharomyces cerevisiae. Treatment of C. albicans cells with this compd. resulted in reduced adherence to a rat intestine epithelial cell monolayer. A previously uncharacterized gene YJL091c, named GWT1, was cloned as a dosage-dependent suppressor of the I-induced phenotypes. GWT1 knock-out cells showed similar phenotypes to I-treated wild-type cells in terms of cell wall structure and transcriptional profiles. Two different mutants resistant to I each contained a single missense mutation in the coding region of the GWT1 gene. These results all suggest that the GWT1 gene product is the primary target of the compd.
    >> More from SciFinder ®
    https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXktV2gsL4%253D&md5=1049da3e97c3df636219d903cc2f939c
  23. 23
    Gaynor, E. C., Mondésert, G., Grimme, S. J., Reed, S. I., Orlean, P., and Emr, S. D. (1999) MCD4 encodes a conserved endoplasmic reticulum membrane protein essential for glycosylphosphatidylinositol anchor synthesis in yeast Mol. Biol. Cell 10, 627– 648 DOI: 10.1091/mbc.10.3.627
    Google Scholar
    23
    MCD4 encodes a conserved endoplasmic reticulum membrane protein essential for glycosylphosphatidylinositol anchor synthesis in yeast
    Gaynor, Erin C.; Mondesert, Guillaume; Grimme, Stephen J.; Reed, Steve I.; Orlean, Peter; Emr, Scott D.
    Molecular Biology of the Cell (1999), 10 (3), 627-648CODEN: MBCEEV; ISSN:1059-1524. (American Society for Cell Biology)
    Glycosylphosphatidylinositol (GPI)-anchored proteins are cell surface-localized proteins that serve many important cellular functions. The pathway mediating synthesis and attachment of the GPI anchor to these proteins in eukaryotic cells is complex, highly conserved, and plays a crit. role in the proper targeting, transport, and function of all GPI-anchored protein family members. In this article, we demonstrate that MCD4, an essential gene that was initially identified in a genetic screen to isolate Saccharomyces cerevisiae mutants defective for bud emergence, encodes a previously unidentified component of the GPI anchor synthesis pathway. Mcd4p is a multimembrane-spanning protein that localizes to the endoplasmic reticulum (ER) and contains a large NH2-terminal ER lumenal domain. We have also cloned the human MCD4 gene and found that Mcd4p is both highly conserved throughout eukaryotes and has two yeast homologues. Mcd4p's lumenal domain contains three conserved motifs found in mammalian phosphodiesterases and nucleotide pyrophosphases; notably, the temp.-conditional MCD4 allele used for our studies (mcd4-174) harbors a single amino acid change in motif 2. The mcd4-174 mutant (1) is defective in ER-to-Golgi transport of GPI-anchored proteins (i.e., Gas1p) while other proteins (i.e., CPY) are unaffected; (2) secretes and releases (potentially up-regulated cell wall) proteins into the medium, suggesting a defect in cell wall integrity; and (3) exhibits marked morphol. defects, most notably the accumulation of distorted, ER- and vesicle-like membranes. Mcd4-174 cells synthesize all classes of inositolphosphoceramides, indicating that the GPI protein transport block is not due to deficient ceramide synthesis. However, mcd4-174 cells have a severe defect in incorporation of [3H]inositol into proteins and accumulate several previously uncharacterized [3H]inositol-labeled lipids whose properties are consistent with their being GPI precursors. Together, these studies demonstrate that MCD4 encodes a new, conserved component of the GPI anchor synthesis pathway and highlight the intimate connections between GPI anchoring, bud emergence, cell wall function, and feedback mechanisms likely to be involved in regulating each of these essential processes. A putative role for Mcd4p as participating in the modification of GPI anchors with side chain phosphoethanolamine is also discussed.
    >> More from SciFinder ®
    https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhvVyku7c%253D&md5=cc36193454987edf3eea47f0c292fa83
  24. 24
    Dennehy, K. M. and Brown, G. D. (2007) The role of the beta-glucan receptor dectin-1 in control of fungal infection J. Leukoc. Biol. 82, 253– 258 DOI: 10.1189/jlb.1206753
    Google Scholar
    24
    The role of the β-glucan receptor Dectin-1 in control of fungal infection
    Dennehy, Kevin M.; Brown, Gordon D.
    Journal of Leukocyte Biology (2007), 82 (2), 253-258CODEN: JLBIE7; ISSN:0741-5400. (Federation of American Societies for Experimental Biology)
    A review. During fungal infection, a variety of receptors initiates immune responses, including TLR and the β-glucan receptor Dectin-1. TLR recognition of fungal ligands and subsequent signaling through the MyD88 pathway were thought to be the most important interactions required for the control of fungal infection. However, recent papers have challenged this view, highlighting the role of Dectin-1 in induction of cytokine responses and the respiratory burst. Two papers, using independently derived, Dectin-1-deficient mice, address the role of Dectin-1 in control of fungal infection. Saijo et al. (Nat. Immunol., 2007, 8, 39-46) argue that Dectin-1 plays a minor role in control of Pneumocystis carinii by direct killing and that TLR-mediated cytokine prodn. controls P. carinii and Candida albicans. By contrast, Taylor et al. (Nat. Immunol, 2007, 8, 31-38) argue that Dectin-1-mediated cytokine and chemokine prodn., leading to efficient recruitment of inflammatory cells, is required for control of fungal infection. Here, the authors argue that collaborative responses induced during infection may partially explain these apparently contradictory results. They propose that Dectin-1 is the first of many pattern recognition receptors that can mediate their own signaling, as well as synergize with TLR to initiate specific responses to infectious agents.
    >> More from SciFinder ®
    https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXos12rtbk%253D&md5=369bd2e12247f8cc55c6a65bfaa63432
  25. 25
    Umemura, M., Okamoto, M., Nakayama, K., Sagane, K., Tsukahara, K., Hata, K., and Jigami, Y. (2003) GWT1 gene is required for inositol acylation of glycosylphosphatidylinositol anchors in yeast J. Biol. Chem. 278, 23639– 23647 DOI: 10.1074/jbc.M301044200
    Google Scholar
    There is no corresponding record for this reference.
  26. 26
    Watanabe, N. A., Miyazaki, M., Horii, T., Sagane, K., Tsukahara, K., and Hata, K. (2012) E1210, a new broad-spectrum antifungal, suppresses Candida albicans hyphal growth through inhibition of glycosylphosphatidylinositol biosynthesis Antimicrob. Agents Chemother. 56, 960– 971 DOI: 10.1128/AAC.00731-11
    Google Scholar
    26
    E1210, a new broad-spectrum antifungal, suppresses Candida albicans hyphal growth through inhibition of glycosylphosphatidylinositol biosynthesis
    Watanabe, Nao-aki; Miyazaki, Mamiko; Horii, Takaaki; Sagane, Koji; Tsukahara, Kappei; Hata, Katsura
    Antimicrobial Agents and Chemotherapy (2012), 56 (2), 960-971CODEN: AMACCQ; ISSN:0066-4804. (American Society for Microbiology)
    Continued research toward the development of new antifungals that act via inhibition of glycosylphosphatidylinositol (GPI) biosynthesis led to the design of E1210. In this study, we assessed the selectivity of the inhibitory activity of E1210 against Candida albicans GWT1 (Orf19.6884) protein, Aspergillus fumigatus GWT1 (AFUA_1G14870) protein, and human PIG-W protein, which can catalyze the inositol acylation of GPI early in the GPI biosynthesis pathway, and then we assessed the effects of E1210 on key C. albicans virulence factors. E1210 inhibited the inositol acylation activity of C. albicans Gwt1p and A. fumigatus Gwt1p with 50% inhibitory concns. (IC50s) of 0.3 to 0.6 μM but had no inhibitory activity against human Pig-Wp even at concns. as high as 100 μM. To confirm the inhibition of fungal GPI biosynthesis, expression of ALS1 protein, a GPI-anchored protein, on the surfaces of C. albicans cells treated with E1210 was studied and shown to be significantly lower than that on untreated cells. However, the ALS1 protein levels in the crude ext. and the RHO1 protein levels on the cell surface were found to be almost the same. Furthermore, E1210 inhibited germ tube formation, adherence to polystyrene surfaces, and biofilm formation of C. albicans at concns. above its MIC. These results suggested that E1210 selectively inhibited inositol acylation of fungus-specific GPI which would be catalyzed by Gwt1p, leading to the inhibition of GPI-anchored protein maturation, and also that E1210 suppressed the expression of some important virulence factors of C. albicans, through its GPI biosynthesis inhibition.
    >> More from SciFinder ®
    https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Gruro%253D&md5=a489c9d19296eaa8b65513de5b133ce3
  27. 27
    McLellan, C. A., Whitesell, L., King, O. D., Lancaster, A. K., Mazitschek, R., and Lindquist, S. (2012) Inhibiting GPI anchor biosynthesis in fungi stresses the endoplasmic reticulum and enhances immunogenicity ACS Chem. Biol. 7, 1520– 1528 DOI: 10.1021/cb300235m
    Google Scholar
    27
    Inhibiting GPI Anchor Biosynthesis in Fungi Stresses the Endoplasmic Reticulum and Enhances Immunogenicity
    McLellan, Catherine A.; Whitesell, Luke; King, Oliver D.; Lancaster, Alex K.; Mazitschek, Ralph; Lindquist, Susan
    ACS Chemical Biology (2012), 7 (9), 1520-1528CODEN: ACBCCT; ISSN:1554-8929. (American Chemical Society)
    In fungi, the anchoring of proteins to the plasma membrane via their covalent attachment to glycosylphosphatidylinositol (GPI) is essential and thus provides a valuable point of attack for the development of antifungal therapeutics. Unfortunately, studying the underlying biol. of GPI-anchor synthesis is difficult, esp. in medically relevant fungal pathogens because they are not genetically tractable. Compounding difficulties, many of the genes in this pathway are essential in Saccharomyces cerevisiae. Here, the discovery of a new small mol. christened gepinacin (for GPI acylation inhibitor) which selectively inhibits Gwt1, a crit. acyltransferase required for the biosynthesis of fungal GPI anchors, is reported. After delineating the target specificity of gepinacin using genetic and biochem. techniques, it was used to probe key, therapeutically relevant consequences of disrupting GPI anchor metab. in fungi. It was found that, unlike all three major classes of antifungals in current use, the direct antimicrobial activity of this compd. results predominantly from its ability to induce overwhelming stress to the endoplasmic reticulum. Gepinacin did not affect the viability of mammalian cells nor did it inhibit their orthologous acyltransferase. This enabled its use in co-culture expts. to examine Gwt1's effects on host-pathogen interactions. In isolates of Candida albicans, the most common fungal pathogen in humans, exposure to gepinacin at sublethal concns. impaired filamentation and unmasked cell wall β-glucan to stimulate a pro-inflammatory cytokine response in macrophages. Gwt1 is a promising antifungal drug target, and gepinacin is a useful probe for studying how disrupting GPI-anchor synthesis impairs viability and alters host-pathogen interactions in genetically intractable fungi.
    >> More from SciFinder ®
    https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XovFaktr0%253D&md5=f5d23f76cbc1942730dce3af6b2af115
  28. 28
    Lee, M. C., Miller, E. A., Goldberg, J., Orci, L., and Schekman, R. (2004) Bi-directional protein transport between the ER and Golgi Annu. Rev. Cell Dev. Biol. 20, 87– 123 DOI: 10.1146/annurev.cellbio.20.010403.105307
    Google Scholar
    28
    Bi-directional protein transport between the ER and Golgi
    Lee, Marcus C. S.; Miller, Elizabeth A.; Goldberg, Jonathan; Orci, Lelio; Schekman, Randy
    Annual Review of Cell and Developmental Biology (2004), 20 (), 87-123CODEN: ARDBF8; ISSN:1081-0706. (Annual Reviews Inc.)
    A review. The endoplasmic reticulum (ER) and the Golgi app. comprise the 1st 2 steps in protein secretion. Vesicular carriers mediate a continuous flux of proteins and lipids between these compartments, reflecting the transport of newly synthesized proteins out of the ER and the retrieval of escaped ER residents and vesicle machinery. Anterograde and retrograde transport is mediated by distinct sets of cytosolic coat proteins, the COPII and COPI coats, resp., which act on the membrane to capture cargo proteins into nascent vesicles. Here, the authors review the mechanisms that govern coat recruitment to the membrane, cargo capture into a transport vesicle, and accurate delivery to the target organelle.
    >> More from SciFinder ®
    https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVaqu7bM&md5=ae02d65edd306dafa84ef899b1d628cd
  29. 29
    Kodera, C., Yorimitsu, T., Nakano, A., and Sato, K. (2011) Sed4p stimulates Sar1p GTP hydrolysis and promotes limited coat disassembly Traffic 12, 591– 599 DOI: 10.1111/j.1600-0854.2011.01173.x
    Google Scholar
    There is no corresponding record for this reference.
  30. 30
    Letourneur, F., Gaynor, E. C., Hennecke, S., Demolliere, C., Duden, R., Emr, S. D., Riezman, H., and Cosson, P. (1994) Coatomer is essential for retrieval of dilysine-tagged proteins to the endoplasmic reticulum Cell 79, 1199– 1207 DOI: 10.1016/0092-8674(94)90011-6
    Google Scholar
    There is no corresponding record for this reference.
  31. 31
    Ma, W. and Goldberg, J. (2013) Rules for the recognition of dilysine retrieval motifs by coatomer EMBO J. 32, 926– 937 DOI: 10.1038/emboj.2013.41
    Google Scholar
    There is no corresponding record for this reference.
  32. 32
    Carvajal, E., van den Hazel, H. B., Cybularz-Kolaczkowska, A., Balzi, E., and Goffeau, A. (1997) Molecular and phenotypic characterization of yeast PDR1 mutants that show hyperactive transcription of various ABC multidrug transporter genes Mol. Gen Genet. 256, 406– 415 DOI: 10.1007/s004380050584
    Google Scholar
    32
    Molecular and phenotypic characterization of yeast PDR1 mutants that show hyperactive transcription of various ABC multidrug transporter genes
    Carvajal, E.; Van Den Hazel, H. B.; Cybularz-Kolaczkowska, A.; Balzi, E.; Goffeau, A.
    Molecular & General Genetics (1997), 256 (4), 406-415CODEN: MGGEAE; ISSN:0026-8925. (Springer-Verlag)
    Mutations at the yeast PDR1 transcriptional regulator locus are responsible for overexpression of the three ABC transporter genes PDR5, SNQ2 and YOR1, assocd. with the appearance of multiple drug resistance. The nucleotide sequences of 13 alleles of PDR1, comprising 6 multidrug resistance mutants, 1 intragenic suppressor and 6 wild types, have been detd. Single amino acid substitutions were shown to result from the mutations pdr1-2 (M308I), pdr1-3 (F815S), pdr1-6 (K302Q), pdr1-7 (P298A) and pdr1-8 (L1036W), whereas the intragenic suppressor mutant pdr1-100 is deleted for the two amino acids L537 and A538. An isogenic series of strains was constructed contg. the mutant alleles pdr1-3, pdr1-6 and pdr1-8 integrated into the genome. It was found that the levels of resistance to cycloheximide, oligomycin, 4-nitroquinoline-N-oxide and ketoconazole were increased in all three mutants. The increase was more pronounced in the pdr1-3 than in the pdr1-6 and pdr1-8 mutants. Studies of the activity of the promoters of the ABC genes PDR5, SNQ2 and YOR1 demonstrated that the combination of the PDR5 promoter and the pdr1-3 mutation resulted in the highest level of promoter induction. Concomitantly. the level of PDR5 mRNA, of Pdr5p protein, and of its assocd. nucleoside triphosphatase activity, was strongly increased in the plasma membranes of the PDR1 mutants. Again, the pdr1-3 allele was assocd. with a stronger effect than the pdr1-8 and pdr1-6 alleles. The locations of the mutations in the PDR1 gene indicate that at least three different regions distributed throughout the Pdr1p transcription factor may be mutated to generate a Pdr1p with considerably increased transcriptional activation potency. These gain-of-function mutations support the concept, recently proposed, that in members of the large family of yeast Zn2Cys6 transcription factors a central inhibitory domain exists (delineated by the pdr1-7, pdr1-6 and pdr1-2 mutations). This domain may interact in a locked conformation with a putative, more C-terminally located inhibitory domain (mutated in pdr1-3), and with the putative activation domain (mutated in pdr1-8).
    >> More from SciFinder ®
    https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXhsl2juw%253D%253D&md5=fb7163231216cf3d46323b51f5490ede
  33. 33
    Sagane, K., Umemura, M., Ogawa-Mitsuhashi, K., Tsukahara, K., Yoko-o, T., and Jigami, Y. (2011) Analysis of membrane topology and identification of essential residues for the yeast endoplasmic reticulum inositol acyltransferase Gwt1p J. Biol. Chem. 286, 14649– 14658 DOI: 10.1074/jbc.M110.193490
    Google Scholar
    There is no corresponding record for this reference.
  34. 34
    Zhu, Y., Vionnet, C., and Conzelmann, A. (2006) Ethanolaminephosphate side chain added to glycosylphosphatidylinositol (GPI) anchor by mcd4p is required for ceramide remodeling and forward transport of GPI proteins from endoplasmic reticulum to Golgi J. Biol. Chem. 281, 19830– 19839 DOI: 10.1074/jbc.M601425200
    Google Scholar
    There is no corresponding record for this reference.
  35. 35
    Miyazaki, M., Horii, T., Hata, K., Watanabe, N. A., Nakamoto, K., Tanaka, K., Shirotori, S., Murai, N., Inoue, S., Matsukura, M., Abe, S., Yoshimatsu, K., and Asada, M. (2011) In vitro activity of E1210, a novel antifungal, against clinically important yeasts and molds Antimicrob. Agents Chemother. 55, 4652– 4658 DOI: 10.1128/AAC.00291-11
    Google Scholar
    35
    In vitro activity of E1210, a novel antifungal, against clinically important yeasts and molds
    Miyazaki, Mamiko; Horii, Takaaki; Hata, Katsura; Watanabe, Nao-aki; Nakamoto, Kazutaka; Tanaka, Keigo; Shirotori, Syuji; Murai, Norio; Inoue, Satoshi; Matsukura, Masayuki; Abe, Shinya; Yoshimatsu, Kentaro; Asada, Makoto
    Antimicrobial Agents and Chemotherapy (2011), 55 (10), 4652-4658CODEN: AMACCQ; ISSN:0066-4804. (American Society for Microbiology)
    E1210 is a new antifungal compd. with a novel mechanism of action and broad spectrum of antifungal activity. We investigated the in vitro antifungal activities of E1210 compared to those of fluconazole, itraconazole, voriconazole, amphotericin B, and micafungin against clin. fungal isolates. E1210 showed potent activities against most Candida spp. (MIC90 of ≤0.008 to 0.06 μg/mL), except for Candida krusei (MICs of 2 to >32 μg/mL). E1210 showed equally potent activities against fluconazole-resistant and fluconazole-susceptible Candida strains. E1210 also had potent activities against various filamentous fungi, including Aspergillus fumigatus (MIC90 of 0.13 μg/mL). E1210 was also active against Fusarium solani and some black molds. Of note, E1210 showed the greatest activities against Pseudallescheria boydii (MICs of 0.03 to 0.13 μg/mL), Scedosporium prolificans (MIC of 0.03 μg/mL), and Paecilomyces lilacinus (MICs of 0.06 μg/mL) among the compds. tested. The antifungal action of E1210 was fungistatic, but E1210 showed no trailing growth of Candida albicans, which has often been obsd. with fluconazole. In a cytotoxicity assay using human HK-2 cells, E1210 showed toxicity as low as that of fluconazole. Based on these results, E1210 is likely to be a promising antifungal agent for the treatment of invasive fungal infections.
    >> More from SciFinder ®
    https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtl2nsL%252FP&md5=cb380963b1f986ed2e0d72ed5067e19d
  36. 36
    Poulain, D. and Jouault, T. (2004) Candida albicans cell wall glycans, host receptors and responses: elements for a decisive crosstalk Curr. Opin. Microbiol. 7, 342– 349 DOI: 10.1016/j.mib.2004.06.011
    Google Scholar
    36
    Candida albicans cell wall glycans, host receptors and responses: elements for a decisive crosstalk
    Poulain, Daniel; Jouault, Thierry
    Current Opinion in Microbiology (2004), 7 (4), 342-349CODEN: COMIF7; ISSN:1369-5274. (Elsevier Ltd.)
    A review. Candida albicans has adapted to live on the mucosal surfaces of animals. The human species has accepted it. By contrast to numerous other commensals, C. albicans has a prominent ability to invade virtually all tissues of a host presenting with natural or acquired defects in homeostasis. C. albicans uses considerable energy to synthesize glycans, which are present either as polymers or as glyconjugates. These glycan mols. play a prominent role in the biol. of C. albicans by controlling the structure and plasticity of the cell wall, and are also involved in yeast-host interactions. These glycans are recognized as non-self by host innate and adaptative immunity. The signal they induce in the host depends on the glycan code, which is detd. by the nature of the sugar, the anomer type of linkage and branching, and the length of the oligosaccharide chains. However, this model is not static because the nature of the C. albicans mol. carrying such glycan codes and their expression at the cell wall surface also dets. the host response, and, in turn, the regulation of cell wall glycan arrangement dynamics in C. albicans depends on host stimuli. Candida glycans therefore play an important role in the continuous interchange that regulates the balance between saprophytism and parasitism, and resistance and infection. A goal of current research concerning the virulence attributes of C. albicans will be to det. to what extent this species is able to regulate its glycan code as a response to the host.
    >> More from SciFinder ®
    https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmt1Omsbg%253D&md5=f563b4eb9e95bb8616d8e58dc707d8c1
  37. 37
    Wheeler, R. T. and Fink, G. R. (2006) A drug-sensitive genetic network masks fungi from the immune system PLoS Pathog. 2, e35 DOI: 10.1371/journal.ppat.0020035
    Google Scholar
    There is no corresponding record for this reference.
  38. 38
    Ishibashi, K., Yoshida, M., Nakabayashi, I., Shinohara, H., Miura, N. N., Adachi, Y., and Ohno, N. (2005) Role of anti-beta-glucan antibody in host defense against fungi FEMS Immunol. 44, 99– 109 DOI: 10.1016/j.femsim.2004.12.012
    Google Scholar
    38
    Role of anti-β-glucan antibody in host defense against fungi
    Ishibashi, Ken-Ichi; Yoshida, Masaharu; Nakabayashi, Iwao; Shinohara, Hiroyasu; Miura, Noriko N.; Adachi, Yoshiyuki; Ohno, Naohito
    FEMS Immunology and Medical Microbiology (2005), 44 (1), 99-109CODEN: FIMIEV; ISSN:0928-8244. (Elsevier B.V.)
    The authors have recently detected an anti-β-glucan antibody in normal human and normal mouse sera. The anti-β-glucan antibody showed reactivity to pathogenic fungal Aspergillus and Candida cell wall glucan. Anti-β-glucan antibody could bind whole Candida cells. It also enhanced the candidacidal activity of macrophages in vitro. The anti-β-glucan antibody titer of DBA/2 mice i.v. administered either Candida or Aspergillus solubilized cell wall β-glucan decreased remarkably dependent on dose. Moreover, in deep mycosis patients, the anti-β-glucan antibody titer decreased, and this change correlated with clin. symptoms and other parameters such as C-reactive protein. It was suggested that the anti-β-glucan antibody formed an antigen-antibody complex and participated in the immune response as a mol. recognizing pathogenic fungi.
    >> More from SciFinder ®
    https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXisVajsr8%253D&md5=9ad0c2384b1b3f5833b60d8b88d9f592
  39. 39
    Kushida, H., Nakajima, S., Uchiyama, S., Nagashima, M., Kojiri, K., Kawamura, K., and Suda, H. (1999) Antifungal substances BE-49385 and process for their production. U.S. Patent 5,928,910.
    Google Scholar
    There is no corresponding record for this reference.
  40. 40
    Hirano, A., Sugiyama, E., Kondo, H., Suda, H., Ogawa, H., and Kojiri, K. (2001) Sesterterpene derivatives exhibiting antifungal activities U.S. Patent 6,303,797 B1.
    Google Scholar
    There is no corresponding record for this reference.
  41. 41
    Sütterlin, C., Escribano, M. V., Gerold, P., Maeda, Y., Mazon, M. J., Kinoshita, T., Schwarz, R. T., and Riezman, H. (1998) Saccharomyces cerevisiae GPI10, the functional homologue of human PIG-B, is required for glycosylphosphatidylinositol-anchor synthesis Biochem. J. 332, 153– 159
    Google Scholar
    There is no corresponding record for this reference.
  42. 42
    McConville, M. J. and ad Ferguson, M. A. J. (1993) The structure, biosynthesis and function of glycosylated phosphatidylinositols in the parasitic protozoa and higher eukaryotes Biochem. J. 294, 305– 324
    Google Scholar
    42
    The structure, biosynthesis and function of glycosylated phosphatidylinositols in the parasitic protozoa and higher eukaryotes
    McConville, Malcolm J.; Ferguson, Michael A. J.
    Biochemical Journal (1993), 294 (2), 305-24CODEN: BIJOAK; ISSN:0264-6021.
    A review with >200 refs. on the structure, function and biosynthesis of glycosyl-phosphatidylinositol (GPI) anchors in the title organisms. There may be significant differences in the function of GPI protein anchors in unicellular vs. metazoan organisms. Some parasitic protozoa synthesize exotic GPI-related structures which are not attached to proteins. Evolutionary aspects of the GPI family are also discussed.
    >> More from SciFinder ®
    https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXlvF2hs70%253D&md5=23f9cf6089c12012eaa42693daafc790
  43. 43
    Hata, K., Horii, T., Miyazaki, M., Watanabe, N. A., Okubo, M., Sonoda, J., Nakamoto, K., Tanaka, K., Shirotori, S., Murai, N., Inoue, S., Matsukura, M., Abe, S., Yoshimatsu, K., and Asada, M. (2011) Efficacy of oral E1210, a new broad-spectrum antifungal with a novel mechanism of action, in murine models of candidiasis, aspergillosis, and fusariosis Antimicrob. Agents Chemother. 55, 4543– 4551 DOI: 10.1128/AAC.00366-11
    Google Scholar
    43
    Efficacy of oral E1210, a new broad-spectrum antifungal with a novel mechanism of action, in murine models of candidiasis, aspergillosis, and fusariosis
    Hata, Katsura; Horii, Takaaki; Miyazaki, Mamiko; Watanabe, Nao-aki; Okubo, Miyuki; Sonoda, Jiro; Nakamoto, Kazutaka; Tanaka, Keigo; Shirotori, Syuji; Murai, Norio; Inoue, Satoshi; Matsukura, Masayuki; Abe, Shinya; Yoshimatsu, Kentaro; Asada, Makoto
    Antimicrobial Agents and Chemotherapy (2011), 55 (10), 4543-4551CODEN: AMACCQ; ISSN:0066-4804. (American Society for Microbiology)
    E1210 is a 1st-in-class, broad-spectrum antifungal with a novel mechanism of action-inhibition of fungal glycosylphosphatidylinositol biosynthesis. In this study, the efficacies of E1210 and ref. antifungals were evaluated in murine models of oropharyngeal and disseminated candidiasis, pulmonary aspergillosis, and disseminated fusariosis. Oral E1210 demonstrated dose-dependent efficacy in infections caused by Candida species, Aspergillus spp., and Fusarium solani. In the treatment of oropharyngeal candidiasis, E1210 and fluconazole each caused a significantly greater redn. in the no. of oral CFU than the control treatment. In the disseminated candidiasis model, mice treated with E1210, fluconazole, caspofungin, or liposomal amphotericin B showed significantly higher survival rates than the control mice. E1210 was also highly effective in treating disseminated candidiasis caused by azole-resistant Candida albicans or Candida tropicalis. A 24-h delay in treatment onset minimally affected the efficacy outcome of E1210 in the treatment of disseminated candidiasis. In the Aspergillus flavus pulmonary aspergillosis model, mice treated with E1210, voriconazole, or caspofungin showed significantly higher survival rates than the control mice. E1210 was also effective in the treatment of Aspergillus fumigatus pulmonary aspergillosis. In contrast to many antifungals, E1210 was also effective against disseminated fusariosis caused by F. solani. In conclusion, E1210 demonstrated consistent efficacy in murine models of oropharyngeal and disseminated candidiasis, pulmonary aspergillosis, and disseminated fusariosis. These data suggest that further studies to det. E1210's potential for the treatment of disseminated fungal infections are indicated.
    >> More from SciFinder ®
    https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtl2ns7fE&md5=ff015a73a4108a15fe6474a7411a6044
  44. 44
    Lee, A. Y., St. Onge, R. P., Proctor, M. J., Wallace, I. M., Nile, A. H., Spagnuolo, P. A., Jitkova, Y., Gronda, M., Wu, Y., Kim, M. K., Cheung-Ong, K., Torres, N. P., Spear, E. D., Han, M. K., Schlecht, U., Suresh, S., Duby, G., Heisler, L. E., Surendra, A., Fung, E., Urbanus, M. L., Gebbia, M., Lissina, E., Miranda, M., Chiang, J. H., Aparicio, A. M., Zeghouf, M., Davis, R. W., Cherfils, J., Boutry, M., Kaiser, C. A., Cummins, C. L., Trimble, W. S., Brown, G. W., Schimmer, A. D., Bankaitis, V. A., Nislow, C., Bader, G. D., and Giaever, G. (2014) Mapping the cellular response to small molecules using chemogenomic fitness signatures Science 344, 208– 211 DOI: 10.1126/science.1250217
    Google Scholar
    44
    Mapping the Cellular Response to Small Molecules Using Chemogenomic Fitness Signatures
    Lee, Anna Y.; St. Onge, Robert P.; Proctor, Michael J.; Wallace, Iain M.; Nile, Aaron H.; Spagnuolo, Paul A.; Jitkova, Yulia; Gronda, Marcela; Wu, Yan; Kim, Moshe K.; Cheung-Ong, Kahlin; Torres, Nikko P.; Spear, Eric D.; Han, Mitchell K. L.; Schlecht, Ulrich; Suresh, Sundari; Duby, Geoffrey; Heisler, Lawrence E.; Surendra, Anuradha; Fung, Eula; Urbanus, Malene L.; Gebbia, Marinella; Lissina, Elena; Miranda, Molly; Chiang, Jennifer H.; Aparicio, Ana Maria; Zeghouf, Mahel; Davis, Ronald W.; Cherfils, Jacqueline; Boutry, Marc; Kaiser, Chris A.; Cummins, Carolyn L.; Trimble, William S.; Brown, Grant W.; Schimmer, Aaron D.; Bankaitis, Vytas A.; Nislow, Corey; Bader, Gary D.; Giaever, Guri
    Science (Washington, DC, United States) (2014), 344 (6180), 208-211CODEN: SCIEAS; ISSN:0036-8075. (American Association for the Advancement of Science)
    Genome-wide characterization of the in vivo cellular response to perturbation is fundamental to understanding how cells survive stress. Identifying the proteins and pathways perturbed by small mols. affects biol. and medicine by revealing the mechanisms of drug action. We used a yeast chemogenomics platform that quantifies the requirement for each gene for resistance to a compd. in vivo to profile 3250 small mols. in a systematic and unbiased manner. We identified 317 compds. that specifically perturb the function of 121 genes and characterized the mechanism of specific compds. Global anal. revealed that the cellular response to small mols. is limited and described by a network of 45 major chemogenomic signatures. Our results provide a resource for the discovery of functional interactions among genes, chems., and biol. processes.
    >> More from SciFinder ®
    https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlslSmtbw%253D&md5=543c8d40d54c94f789521ed29859d403

Cited By

ARTICLE SECTIONS
Jump To

This article is cited by 65 publications.

  1. Wei Liu, Lin Yuan, Shengzheng Wang. Recent Progress in the Discovery of Antifungal Agents Targeting the Cell Wall. Journal of Medicinal Chemistry 2020, 63 (21) , 12429-12459. https://doi.org/10.1021/acs.jmedchem.0c00748
  2. Bruno Perlatti, Guy Harris, Connie B. Nichols, Dulamini I. Ekanayake, J. Andrew Alspaugh, James B. Gloer, Gerald F. Bills. Campafungins: Inhibitors of Candida albicans and Cryptococcus neoformans Hyphal Growth. Journal of Natural Products 2020, 83 (9) , 2718-2726. https://doi.org/10.1021/acs.jnatprod.0c00641
  3. Na Liu, Jie Tu, Guoqiang Dong, Yan Wang, Chunquan Sheng. Emerging New Targets for the Treatment of Resistant Fungal Infections. Journal of Medicinal Chemistry 2018, 61 (13) , 5484-5511. https://doi.org/10.1021/acs.jmedchem.7b01413
  4. Jingjing Hong, Tingting Li, Yulin Chao, Yidan Xu, Zhini Zhu, Zixuan Zhou, Weijie Gu, Qianhui Qu, Dianfan Li. Molecular basis of the inositol deacylase PGAP1 involved in quality control of GPI-AP biogenesis. Nature Communications 2024, 15 (1) https://doi.org/10.1038/s41467-023-44568-2
  5. Yuan Yuan, Peiyuan Li, Jianghui Li, Qiu Zhao, Ying Chang, Xingxing He. Protein lipidation in health and disease: molecular basis, physiological function and pathological implication. Signal Transduction and Targeted Therapy 2024, 9 (1) https://doi.org/10.1038/s41392-024-01759-7
  6. Jin Zhang, Ameeta K. Agarwal, Qin Feng, Siddharth K. Tripathi, Ikhlas A. Khan, Nirmal D. Pugh. Identification of Botanicals that Unmask β-Glucan from the Cell Surface of an Opportunistic Fungal Pathogen. Journal of Dietary Supplements 2024, 21 (2) , 154-166. https://doi.org/10.1080/19390211.2023.2201355
  7. Jie Tu, Tianbao Zhu, Qingwen Wang, Wanzhen Yang, Yahui Huang, Defeng Xu, Na Liu, Chunquan Sheng. Discovery of a new chemical scaffold for the treatment of superbug Candida auris infections. Emerging Microbes & Infections 2023, 12 (1) https://doi.org/10.1080/22221751.2023.2208687
  8. Hao Cong, Changgen Li, Yiming Wang, Yongjing Zhang, Daifu Ma, Lianwei Li, Jihong Jiang. The Mechanism of Transcription Factor Swi6 in Regulating Growth and Pathogenicity of Ceratocystis fimbriata: Insights from Non-Targeted Metabolomics. Microorganisms 2023, 11 (11) , 2666. https://doi.org/10.3390/microorganisms11112666
  9. Hui Lu, Ting Hong, Yuanying Jiang, Malcolm Whiteway, Shiqun Zhang. Candidiasis: From cutaneous to systemic, new perspectives of potential targets and therapeutic strategies. Advanced Drug Delivery Reviews 2023, 199 , 114960. https://doi.org/10.1016/j.addr.2023.114960
  10. Na Liu, Jie Tu, Yahui Huang, Wanzhen Yang, Qingwen Wang, Zhuang Li, Chunquan Sheng. Target- and prodrug-based design for fungal diseases and cancer-associated fungal infections. Advanced Drug Delivery Reviews 2023, 197 , 114819. https://doi.org/10.1016/j.addr.2023.114819
  11. Zhou Heng, Qian You, Baojuan Sun, Zhiliang Li, Xiaoqing Sun, Junlin Huang, Ying Li, Hengming Wang, Xiaowan Xu, Zhenxing Li, Chao Gong, Tao Li. Quantitative proteomics provides an insight into germination‐related proteins in the plant pathogenic fungi Phomopsis vexans. European Journal of Plant Pathology 2023, 166 (1) , 65-75. https://doi.org/10.1007/s10658-023-02643-w
  12. Paloma Osset-Trénor, Amparo Pascual-Ahuir, Markus Proft. Fungal Drug Response and Antimicrobial Resistance. Journal of Fungi 2023, 9 (5) , 565. https://doi.org/10.3390/jof9050565
  13. Megha Kaushik, Arvind Sharma, Shefali Gupta, Pooja Gulati. Current Antifungal Drugs. 2023, 125-166. https://doi.org/10.2174/9789815080056123020008
  14. Ricardo Cruz, William M. Wuest. Beyond ergosterol: Strategies for combatting antifungal resistance in Aspergillus fumigatus and Candida auris. Tetrahedron 2023, 133 , 133268. https://doi.org/10.1016/j.tet.2023.133268
  15. Elham Ghobadi, Seyedeh Mahdieh Hashemi, Hamed Fakhim, Zahra Hosseini-khah, Hamid Badali, Saeed Emami. Design, synthesis and biological activity of hybrid antifungals derived from fluconazole and mebendazole. European Journal of Medicinal Chemistry 2023, 249 , 115146. https://doi.org/10.1016/j.ejmech.2023.115146
  16. Nicole Robbins, Troy Ketela, Sang Hu Kim, Leah E. Cowen. Chemical-Genetic Approaches for Exploring Mode of Action of Antifungal Compounds in the Fungal Pathogen Candida albicans. 2023, 145-165. https://doi.org/10.1007/978-1-0716-3155-3_10
  17. Jamil Ahmed, Md Maruf Raihan, Tanjin Barketullah Robin, Md. Razwan Sardar Sami, Saklayeen Mahfuz, Nabioun Haque, Hafsa Akter, Md Nazmul Islam Bappy, Dilruba Afrin, Mahmuda Akther Moli. A computational approach to identify novel plant metabolites against Aspergillus fumigatus. Informatics in Medicine Unlocked 2023, 42 , 101385. https://doi.org/10.1016/j.imu.2023.101385
  18. Megha Choudhary, Vijay Kumar, Bindu Naik, Ankit Verma, Per Erik Joakim Saris, Vivek Kumar, Sanjay Gupta. Antifungal metabolites, their novel sources, and targets to combat drug resistance. Frontiers in Microbiology 2022, 13 https://doi.org/10.3389/fmicb.2022.1061603
  19. Sean D. Liston, Luke Whitesell, Mili Kapoor, Karen J. Shaw, Leah E. Cowen. Calcineurin Inhibitors Synergize with Manogepix to Kill Diverse Human Fungal Pathogens. Journal of Fungi 2022, 8 (10) , 1102. https://doi.org/10.3390/jof8101102
  20. Nicole Robbins, Leah E. Cowen. Genomic Approaches to Antifungal Drug Target Identification and Validation. Annual Review of Microbiology 2022, 76 (1) , 369-388. https://doi.org/10.1146/annurev-micro-041020-094524
  21. Cheng Zhen, Hui Lu, Yuanying Jiang. Novel Promising Antifungal Target Proteins for Conquering Invasive Fungal Infections. Frontiers in Microbiology 2022, 13 https://doi.org/10.3389/fmicb.2022.911322
  22. Marija Ivanov, Ana Ćirić, Dejan Stojković. Emerging Antifungal Targets and Strategies. International Journal of Molecular Sciences 2022, 23 (5) , 2756. https://doi.org/10.3390/ijms23052756
  23. Jie Mei, Na Ning, Hanxiang Wu, Xiaolin Chen, Zhiqiang Li, Wende Liu. Glycosylphosphatidylinositol Anchor Biosynthesis Pathway-Related Protein GPI7 Is Required for the Vegetative Growth and Pathogenicity of Colletotrichum graminicola. International Journal of Molecular Sciences 2022, 23 (6) , 2985. https://doi.org/10.3390/ijms23062985
  24. Chibuike Ibe, Rita O. Oladele, Omran Alamir. Our pursuit for effective antifungal agents targeting fungal cell wall components: where are we?. International Journal of Antimicrobial Agents 2022, 59 (1) , 106477. https://doi.org/10.1016/j.ijantimicag.2021.106477
  25. Ghada Bouz, Martin Doležal. Advances in Antifungal Drug Development: An Up-To-Date Mini Review. Pharmaceuticals 2021, 14 (12) , 1312. https://doi.org/10.3390/ph14121312
  26. Rui Gao, Haojie Pan, Jiazhang Lian. Recent advances in the discovery, characterization, and engineering of poly(ethylene terephthalate) (PET) hydrolases. Enzyme and Microbial Technology 2021, 150 , 109868. https://doi.org/10.1016/j.enzmictec.2021.109868
  27. Adam G. Stewart, David L. Paterson. How urgent is the need for new antifungals?. Expert Opinion on Pharmacotherapy 2021, 22 (14) , 1857-1870. https://doi.org/10.1080/14656566.2021.1935868
  28. Fu-Juan SUN, Min LI, Liang GU, Ming-Ling WANG, Ming-Hua YANG. Recent progress on anti-Candida natural products. Chinese Journal of Natural Medicines 2021, 19 (8) , 561-579. https://doi.org/10.1016/S1875-5364(21)60057-2
  29. M. Ángeles Curto, Estefanía Butassi, Juan C. Ribas, Laura A. Svetaz, Juan C.G. Cortés. Natural products targeting the synthesis of β(1,3)-D-glucan and chitin of the fungal cell wall. Existing drugs and recent findings. Phytomedicine 2021, 88 , 153556. https://doi.org/10.1016/j.phymed.2021.153556
  30. Alice Xue, Nicole Robbins, Leah E. Cowen. Advances in fungal chemical genomics for the discovery of new antifungal agents. Annals of the New York Academy of Sciences 2021, 1496 (1) , 5-22. https://doi.org/10.1111/nyas.14484
  31. Masahiro Hatamoto, Ryo Aizawa, Kogomi Koda, Toshiki Fukuchi. Aminopyrifen, a novel 2-aminonicotinate fungicide with a unique effect and broad-spectrum activity against plant pathogenic fungi. Journal of Pesticide Science 2021, 46 (2) , 198-205. https://doi.org/10.1584/jpestics.D20-094
  32. Chibuike Ibe, Carol A. Munro, . Fungal cell wall: An underexploited target for antifungal therapies. PLOS Pathogens 2021, 17 (4) , e1009470. https://doi.org/10.1371/journal.ppat.1009470
  33. Yue Fu, David Estoppey, Silvio Roggo, Dominik Pistorius, Florian Fuchs, Christian Studer, Ashraf S. Ibrahim, Thomas Aust, Frederic Grandjean, Manuel Mihalic, Klaus Memmert, Vivian Prindle, Etienne Richard, Ralph Riedl, Sven Schuierer, Eric Weber, Jürg Hunziker, Frank Petersen, Jianshi Tao, Dominic Hoepfner. Jawsamycin exhibits in vivo antifungal properties by inhibiting Spt14/Gpi3-mediated biosynthesis of glycosylphosphatidylinositol. Nature Communications 2020, 11 (1) https://doi.org/10.1038/s41467-020-17221-5
  34. Kali R. Iyer, Kaddy Camara, Martin Daniel-Ivad, Richard Trilles, Sheila M. Pimentel-Elardo, Jen L. Fossen, Karen Marchillo, Zhongle Liu, Shakti Singh, José F. Muñoz, Sang Hu Kim, John A. Porco, Christina A. Cuomo, Noelle S. Williams, Ashraf S. Ibrahim, John E. Edwards, David R. Andes, Justin R. Nodwell, Lauren E. Brown, Luke Whitesell, Nicole Robbins, Leah E. Cowen. An oxindole efflux inhibitor potentiates azoles and impairs virulence in the fungal pathogen Candida auris. Nature Communications 2020, 11 (1) https://doi.org/10.1038/s41467-020-20183-3
  35. Karen Joy Shaw, Ashraf S. Ibrahim. Fosmanogepix: A Review of the First-in-Class Broad Spectrum Agent for the Treatment of Invasive Fungal Infections. Journal of Fungi 2020, 6 (4) , 239. https://doi.org/10.3390/jof6040239
  36. Sean D. Liston, Luke Whitesell, Catherine A. McLellan, Ralph Mazitschek, Vidmantas Petraitis, Ruta Petraitiene, Povilas Kavaliauskas, Thomas J. Walsh, Leah E. Cowen. Antifungal Activity of Gepinacin Scaffold Glycosylphosphatidylinositol Anchor Biosynthesis Inhibitors with Improved Metabolic Stability. Antimicrobial Agents and Chemotherapy 2020, 64 (10) https://doi.org/10.1128/AAC.00899-20
  37. Xin Huang, Yu Liu, Tingjunhong Ni, Liping Li, Lan Yan, Maomao An, Dazhi Zhang, Yuanying Jiang. 11g, a Potent Antifungal Candidate, Enhances Candida albicans Immunogenicity by Unmasking β-Glucan in Fungal Cell Wall. Frontiers in Microbiology 2020, 11 https://doi.org/10.3389/fmicb.2020.01324
  38. Sean D. Liston, Luke Whitesell, Mili Kapoor, Karen Joy Shaw, Leah E. Cowen. Enhanced Efflux Pump Expression in Candida Mutants Results in Decreased Manogepix Susceptibility. Antimicrobial Agents and Chemotherapy 2020, 64 (5) https://doi.org/10.1128/AAC.00261-20
  39. Zhuozhi Chen, Yanyan Wang, Yingying Cheng, Xue Wang, Shanwei Tong, Haitao Yang, Zefang Wang. Efficient biodegradation of highly crystallized polyethylene terephthalate through cell surface display of bacterial PETase. Science of The Total Environment 2020, 709 , 136138. https://doi.org/10.1016/j.scitotenv.2019.136138
  40. Mili Kapoor, Molly Moloney, Quinlyn A. Soltow, Chris M. Pillar, Karen Joy Shaw. Evaluation of Resistance Development to the Gwt1 Inhibitor Manogepix (APX001A) in Candida Species. Antimicrobial Agents and Chemotherapy 2019, 64 (1) https://doi.org/10.1128/AAC.01387-19
  41. Michael Trzoss, Jonathan A. Covel, Mili Kapoor, Molly K. Moloney, Quinlyn A. Soltow, Peter J. Webb, Karen Joy Shaw. Synthesis of analogs of the Gwt1 inhibitor manogepix (APX001A) and in vitro evaluation against Cryptococcus spp. Bioorganic & Medicinal Chemistry Letters 2019, 29 (23) , 126713. https://doi.org/10.1016/j.bmcl.2019.126713
  42. Haomiao Ouyang, Ting Du, Hui Zhou, Iain B. H. Wilson, Jinghua Yang, Jean-Paul Latgé, Cheng Jin. Aspergillus fumigatus phosphoethanolamine transferase gene gpi7 is required for proper transportation of the cell wall GPI-anchored proteins and polarized growth. Scientific Reports 2019, 9 (1) https://doi.org/10.1038/s41598-019-42344-1
  43. Annie N. Cowell, Elizabeth A. Winzeler. Advances in omics-based methods to identify novel targets for malaria and other parasitic protozoan infections. Genome Medicine 2019, 11 (1) https://doi.org/10.1186/s13073-019-0673-3
  44. Juan Carlos G. Cortés, M.-Ángeles Curto, Vanessa S.D. Carvalho, Pilar Pérez, Juan Carlos Ribas. The fungal cell wall as a target for the development of new antifungal therapies. Biotechnology Advances 2019, 37 (6) , 107352. https://doi.org/10.1016/j.biotechadv.2019.02.008
  45. Satoru Hasegawa, Yuimi Yamada, Noboru Iwanami, Yusuke Nakayama, Hironobu Nakayama, Shun Iwatani, Takahiro Oura, Susumu Kajiwara. Identification and functional characterization of Candida albicans mannose–ethanolamine phosphotransferase (Mcd4p). Current Genetics 2019, 65 (5) , 1251-1261. https://doi.org/10.1007/s00294-019-00987-7
  46. Olena P. Ishchuk, Khadija Mohamed Ahmad, Katarina Koruza, Klara Bojanovič, Marcel Sprenger, Lydia Kasper, Sascha Brunke, Bernhard Hube, Torbjörn Säll, Thomas Hellmark, Birgitta Gullstrand, Christian Brion, Kelle Freel, Joseph Schacherer, Birgitte Regenberg, Wolfgang Knecht, Jure Piškur. RNAi as a Tool to Study Virulence in the Pathogenic Yeast Candida glabrata. Frontiers in Microbiology 2019, 10 https://doi.org/10.3389/fmicb.2019.01679
  47. Masahiro Hatamoto, Ryo Aizawa, Yuta Kobayashi, Makoto Fujimura. A novel fungicide aminopyrifen inhibits GWT-1 protein in glycosylphosphatidylinositol-anchor biosynthesis in Neurospora crassa. Pesticide Biochemistry and Physiology 2019, 156 , 1-8. https://doi.org/10.1016/j.pestbp.2019.02.013
  48. Dorothy Wong, James Plumb, Hosamiddine Talab, Mouhamad Kurdi, Keshav Pokhrel, Peter Oelkers. Genetically Compromising Phospholipid Metabolism Limits Candida albicans’ Virulence. Mycopathologia 2019, 184 (2) , 213-226. https://doi.org/10.1007/s11046-019-00320-3
  49. David S. Perlin. Cell Wall-Modifying Antifungal Drugs. 2019, 255-275. https://doi.org/10.1007/82_2019_188
  50. Yuan Zhang, Vijai Kumar Reddy Tangadanchu, Rammohan R. Yadav Bheemanaboina, Yu Cheng, Cheng-He Zhou. Novel carbazole-triazole conjugates as DNA-targeting membrane active potentiators against clinical isolated fungi. European Journal of Medicinal Chemistry 2018, 155 , 579-589. https://doi.org/10.1016/j.ejmech.2018.06.022
  51. Sneha Sudha Komath, Sneh Lata Singh, Vavilala A. Pratyusha, Sudisht Kumar Sah. Generating anchors only to lose them: The unusual story of glycosylphosphatidylinositol anchor biosynthesis and remodeling in yeast and fungi. IUBMB Life 2018, 70 (5) , 355-383. https://doi.org/10.1002/iub.1734
  52. Usha Yadav, Mohd Ashraf Khan. Targeting the GPI biosynthetic pathway. Pathogens and Global Health 2018, 112 (3) , 115-122. https://doi.org/10.1080/20477724.2018.1442764
  53. Brendan Snarr, Salman Qureshi, Donald Sheppard. Immune Recognition of Fungal Polysaccharides. Journal of Fungi 2017, 3 (3) , 47. https://doi.org/10.3390/jof3030047
  54. Scott S. Walker, Marc Labroli, Ronald E. Painter, Judyann Wiltsie, Brad Sherborne, Nicholas Murgolo, Xinwei Sher, Paul Mann, Paul Zuck, Charles G. Garlisi, Jing Su, Stacia Kargman, Li Xiao, Giovanna Scapin, Scott Salowe, Kristine Devito, Payal Sheth, Nichole Buist, Christopher M. Tan, Todd A. Black, Terry Roemer, . Antibacterial small molecules targeting the conserved TOPRIM domain of DNA gyrase. PLOS ONE 2017, 12 (7) , e0180965. https://doi.org/10.1371/journal.pone.0180965
  55. Ellen Bushell, Ana Rita Gomes, Theo Sanderson, Burcu Anar, Gareth Girling, Colin Herd, Tom Metcalf, Katarzyna Modrzynska, Frank Schwach, Rowena E. Martin, Michael W. Mather, Geoffrey I. McFadden, Leopold Parts, Gavin G. Rutledge, Akhil B. Vaidya, Kai Wengelnik, Julian C. Rayner, Oliver Billker. Functional Profiling of a Plasmodium Genome Reveals an Abundance of Essential Genes. Cell 2017, 170 (2) , 260-272.e8. https://doi.org/10.1016/j.cell.2017.06.030
  56. Sonia Campoy, José L. Adrio. Antifungals. Biochemical Pharmacology 2017, 133 , 86-96. https://doi.org/10.1016/j.bcp.2016.11.019
  57. Tingjunhong Ni, Ran Li, Fei Xie, Jing Zhao, Xin Huang, Maomao An, Chengxu Zang, Zhan Cai, Dazhi Zhang, Yuanying Jiang. Synthesis and Biological Evaluation of Novel 2‐Aminonicotinamide Derivatives as Antifungal Agents. ChemMedChem 2017, 12 (4) , 319-326. https://doi.org/10.1002/cmdc.201600545
  58. Volkmar Passoth. Lipids of Yeasts and Filamentous Fungi and Their Importance for Biotechnology. 2017, 149-204. https://doi.org/10.1007/978-3-319-58829-2_6
  59. Sławomir Milewski. Molecular Targets for Anticandidal Chemotherapy. 2017, 429-469. https://doi.org/10.1007/978-3-319-50409-4_21
  60. Chibuike Ibe, Louise A. Walker, Neil A. R. Gow, Carol A. Munro. Unlocking the Therapeutic Potential of the Fungal Cell Wall: Clinical Implications and Drug Resistance. 2017, 313-346. https://doi.org/10.1007/978-3-319-50409-4_16
  61. Daniel Ayine-Tora, Robert Kingsford-Adaboh, William Asomaning, Jerry Harrison, Felix Mills-Robertson, Yahaya Bukari, Patrick Sakyi, Sylvester Kaminta, Jóhannes Reynisson. Coumarin Antifungal Lead Compounds from Millettia thonningii and Their Predicted Mechanism of Action. Molecules 2016, 21 (10) , 1369. https://doi.org/10.3390/molecules21101369
  62. Mitchell Mutz, Terry Roemer. The GPI anchor pathway: a promising antifungal target?. Future Medicinal Chemistry 2016, 8 (12) , 1387-1391. https://doi.org/10.4155/fmc-2016-0110
  63. Josef Jampilek. How can we bolster the antifungal drug discovery pipeline?. Future Medicinal Chemistry 2016, 8 (12) , 1393-1397. https://doi.org/10.4155/fmc-2016-0124
  64. Carl J. Balibar, Terry Roemer. Yeast: a microbe with macro-implications to antimicrobial drug discovery. Briefings in Functional Genomics 2016, 15 (2) , 147-154. https://doi.org/10.1093/bfgp/elv038
  65. Huy X. Ngo, Sylvie Garneau-Tsodikova, Keith D. Green. A complex game of hide and seek: the search for new antifungals. MedChemComm 2016, 7 (7) , 1285-1306. https://doi.org/10.1039/C6MD00222F
Download PDF

  • Abstract

    High Resolution Image
    Download MS PowerPoint Slide

    Figure 1

    Figure 1. Individual C. albicans heterozygous deletion mutants contain two unique barcodes (red and blue boxes) flanking the deleted allele. The CaFT strain pool contains ∼5400 heterozygote deletion mutants, comprising >90% genome coverage. Aliquots of the pool are treated with a sub-MIC of the growth inhibitory compound or mock treatment and grown for 20 generations. The relative abundance of each strain, which reflects their chemical sensitivity to the compound, is subsequently determined by DNA microarray analysis using PCR amplified barcodes of each heterozygote. The response of each heterozygote to the effects of the compound is then appraised by calculating a normalized Z score, with a positive value indicating hypersensitivity and a negative value reflecting resistance (or hyposensitivity) to the tested compound. See Xu et al. for details of Z-score calculation. (6) In this example, the strain highlighted in red is uniquely hypersensitive to the compound (C) treatment and depleted from the pool versus the mock-treated (M) control.

    High Resolution Image
    Download MS PowerPoint Slide

    Figure 2

    Figure 2. CaFT-based screening identifies GPI inhibitors. (A) CaFT summary of C. albicans heterozygote hypersensitivity to G884 across multiple drug concentrations. Note increasing strain sensitivities to G884 are displayed left to right (second row), based on the sum Z score across each independent CaFT experiment. Individual Z scores for each heterozygote strain are listed (rows 3–6), with Z scores highlighted in a color scale and heat map format. Note the GWT1 heterozygote reproducibly displays greatest sensitivity to G884, and GPI1 and SPT14 heterozygotes display modest resistance to G884. (B) CaFT summary of C. albicans heterozygote hypersensitivity to M743 across multiple drug concentrations. Rank order of strain sensitivities and Z scores are highlighted as in (A). Note that the MCD4 heterozygote displays greatest hypersensitivity to M743, whereas additional sensitive heterozygotes correspond to COPI coatamer subunits. (C) Chemical structures of G884, G365, M743, M720, and gepinacin. (D) Image of the S. cerevisiae GPI precursor and predicted enzymatic steps in precursor biosynthesis targeted by the above inhibitors.

    High Resolution Image
    Download MS PowerPoint Slide

    Figure 3

    Figure 3. S. cerevisiae drug resistant mutant isolation and characterization of GPI inhibitors. (A) Summary of Gwt1 and Mcd4 drug resistant amino acid substitution mutants and altered susceptibility to GPI inhibitors versus control antifungal agents, amphotericin B (AmB), fluconazole (FLZ), and caspofungin (CSP). Specific amino acid substitutions and causal nucleotide mutations are shown. Note G884R mutations were isolated using wild-type (wt) strain S288c, whereas M743 R and M720 R mutants were isolated from a pdr5Δ strain otherwise isogenic to BY4700. Also note cross-resistance is specifically observed between M743 and its semisynthetic analogue, M720, among Mcd4 amino acid drug-resistant isolates as well as between G884 and gepinacin with Gwt1-G132W. (B) G884R amino acid substitutions (boxed) map to Gwt1. Predicted topology of S. cerevisiae Gwt1 is shown as recently determined with C-terminal sequence residing in cytosol. (33) (C) M743R and M720R amino acid substitutions (boxed) map to Mcd4. Predicted topology of S. cerevisiae Mcd4 is shown as previously described, (23) with the KKTQ C-terminal sequence residing in the lumen of the ER.

    High Resolution Image
    Download MS PowerPoint Slide

    Figure 4

    Figure 4. G884 and G365 inhibit Gwt1 acylation. (A) TLC of products of an in vitro acylation assay using membranes from S. cerevisiae. Controls show that in the absence of ATP and CoA the acylated band is not produced. In the presence of phopholipase C only the acylated band is preserved. Inhibitors of MCD4, M720, and M743 do not inhibit Gwt1-dependent acylation. The acylation reactions were incubated with 2 μg/mL of gepinacin, M720, and M743 and 30 μg/mL of G884 and G365. All GPI inhibitor MIC values for S. cerevisiae are listed in Table 1. (B) Dose response of the acylation inhibition by G884 and G365. The amount of compound in the reaction is given above the blot as μg/mL. (C) G884 preferentially inhibits the fungal enzyme, Gwt1. Growth curves of S. cerevisiae strains contain either the human enzyme Pig-W or the fungal enzyme, Gwt1, as their sole source of inositol acylating activity. The origin of replication for the low-copy plasmids is CEN and for the high-copy plasmids is 2 μm. (27) (D) Induction of the unfolded protein response in cells carrying a GFP reporter construct showing strong induction by inhibitors of Gwt1 and Mcd4. GFP expression was monitored by flow cytometry.

    High Resolution Image
    Download MS PowerPoint Slide

    Figure 5

    Figure 5. GWT1 and MCD4 display a synthetic lethal genetic interaction and cognate inhibitors possess highly synergistic antifungal activity. (A) Drug synergy of GPI inhibitor combinations G884 and M720 or (B) G884 and M720 determined by standard checkerboard analysis against C. albicans strain 2323. Drug concentrations and fractional inhibitory concentrations (FIC) used to evaluate synergy are indicated. Chemical synergy is achieved provided the sum FIC of the two agents (referred to as the FIC index, or FICI) is ≤0.5. FICI = 0.5 is indicated by the diagonal blue line. (C) Tabular summary of the FICI values of Gwt1 and Mcd4 inhibitors tested against C. albicans and S. cerevisiae. (D) GWT1 and MCD4 exhibit a synthetic lethal genetic interaction in yeast. Spore progeny of a gwt1-20::natMX4/GWT1, mcd4-500::kanMX4/MCD4 double-heterozygous diploid strain dissected onto synthetic complete (SC) medium and incubated at 30 °C for 4 days. Large colonies are identified as wild-type; smaller colonies are either gwt1-20 or mcd4-500 haploids (depending on drug resistance marker; natR, (black square); kanR, (white circle)), and microcolonies maintaining both markers are gwt1-20, mcd4-500 double mutants.

    High Resolution Image
    Download MS PowerPoint Slide

    Figure 6

    Figure 6. GPI inhibitors unmask cell surface β-glucan and induce TNFα secretion in macrophages. (A) Fluorescence photomicrographs of C. albicans and β-(1–3)-glucan (green) immunoreactivity with anti-β-(1–3)-glucan antibody following treatment with GPI inhibitors (G365, G884, M743, M720, and gepinacin), the control antifungal agent fluconazole (FLZ), or DMSO. All drug treatments were performed at a drug concentration equivalent to IC40 to ensure immunoreactivity is not indirectly due to cell death. Propidium iodide staining confirms minimal cell death for all GPI inhibitors tested at their IC40 concentration versus fluconazole. Images are merged fluorescence and phase contrast. (B) ELISA quantification of secreted TNFα by RAW264.7 macrophage co-incubated with C. albicans strain 2323 (5) treated at MIC20 and MIC40 values for each of the above agents.

    High Resolution Image
    Download MS PowerPoint Slide

    Figure 7

    Figure 7. In vivo efficacy of M720 in a murine systemic infection model of candidiasis. DBA/2 mice were infected with C. albicans strain MY1055 and treated ip with M720 or caspofungin (CAS) at the indicated doses (mg/kg) either twice daily (bid) or once daily (qd). Kidneys were aseptically collected at 4 days after infectious challenge, and log reduction of colony-forming units (CFU) per gram of kidney tissue was calculated on the basis of kidney burden of vehicle-treated (5% DMSO or H2O, respectively) control group. Note the limit of detection (LOD) is 1.5 × 102 CFU/g, as indicated by the dashed line. (∗) P < 0.05, (∗∗) P < 0.01, and (∗∗∗) P < 0.001 significance versus vehicle control.

    High Resolution Image
    Download MS PowerPoint Slide

  • References

    ARTICLE SECTIONS
    Jump To

    This article references 44 other publications.

    1. 1
      Pfaller, M. A. and Diekema, D. J. (2007) Epidemiology of invasive candidiasis: a persistent public health problem Clin. Microbiol. Rev. 20, 133– 163 DOI: 10.1128/CMR.00029-06
      1
      Epidemiology of invasive candidiasis: a persistent public health problem
      Pfaller, M. A.; Diekema, D. J.
      Clinical Microbiology Reviews (2007), 20 (1), 133-163CODEN: CMIREX; ISSN:0893-8512. (American Society for Microbiology)
      A review. The contemporary epidemiol. of invasive candidiasis is discussed. Trends in incidence, mortality, species distribution, and antifungal resistance are described. Issues of cost and emerging strategies for the treatment and prevention of this important invasive mycosis are also addressed.
      >> More from SciFinder ®
      https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvFKnur0%253D&md5=e0278d710f17b1fcceca25450a884c19
    2. 2
      Brown, G. D., Denning, D. W., Gow, N. A., Levitz, S. M., Netea, M. G., and White, T. C. (2012) Hidden killers: human fungal infections Sci. Transl. Med. 4, 165rv13 DOI: 10.1126/scitranslmed.3004404
      There is no corresponding record for this reference.
    3. 3
      Ostrosky-Zeichner, L., Casadevall, A., Galgiani, J. N., Odds, F. C., and Rex, J. H. (2010) An insight into the antifungal pipeline: selected new molecules and beyond Nat. Rev. Drug Discovery 9, 719– 727 DOI: 10.1038/nrd3074
      3
      An insight into the antifungal pipeline: selected new molecules and beyond
      Ostrosky-Zeichner, Luis; Casadevall, Arturo; Galgiani, John N.; Odds, Frank C.; Rex, John H.
      Nature Reviews Drug Discovery (2010), 9 (9), 719-727CODEN: NRDDAG; ISSN:1474-1776. (Nature Publishing Group)
      A review. Invasive fungal infections are increasing in incidence and are assocd. with substantial mortality. Improved diagnostics and the availability of new antifungals have revolutionized the field of medical mycol. in the past decades. This Review focuses on recent developments in the antifungal pipeline, concg. on promising candidates such as new azoles, polyenes and echinocandins, as well as agents such as nikkomycin Z and the sordarins. Developments in vaccines and antibody-based immunotherapy are also discussed. Few therapeutic products are currently in active development, and progression of therapeutic agents with fungus-specific mechanisms of action is of key importance.
      >> More from SciFinder ®
      https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVCmurvK&md5=d7ccb58b653d567179e53437061df80e
    4. 4
      Roemer, T. and Krysan, D. J. Antifungal drug development: challenges, unmet clinical needs, and new approaches. (2014) Cold Spring Harb Perspect. Med. 4 (5),  DOI: 10.1101/cshperspect.a019703 .
      There is no corresponding record for this reference.
    5. 5
      Roemer, T., Jiang, B., Davison, J., Ketela, T., Veillette, K., Breton, A., Tandia, F., Linteau, A., Sillaots, S., Marta, C., Martel, N., Veronneau, S., Lemieux, S., Kauffman, S., Becker, J., Storms, R., Boone, C., and Bussey, H. (2003) Large-scale essential gene identification in Candida albicans and applications to antifungal drug discovery Mol. Microbiol. 50, 167– 181 DOI: 10.1046/j.1365-2958.2003.03697.x
      5
      Large-scale essential gene identification in Candida albicans and applications to antifungal drug discovery
      Roemer, Terry; Jiang, Bo; Davison, John; Ketela, Troy; Veillette, Karynn; Breton, Anouk; Tandia, Fatou; Linteau, Annie; Sillaots, Susan; Marta, Catarina; Martel, Nick; Veronneau, Steeve; Lemieux, Sebastien; Kauffman, Sarah; Becker, Jeff; Storms, Reginald; Boone, Charles; Bussey, Howard
      Molecular Microbiology (2003), 50 (1), 167-181CODEN: MOMIEE; ISSN:0950-382X. (Blackwell Publishing Ltd.)
      C. albicans is the primary fungal pathogen of humans. Despite the need for novel drugs to combat fungal infections, antifungal drug discovery is currently limited by both the availability of suitable drug targets and assays to screen corresponding targets. A functional genomics approach based on the diploid C. albicans genome sequence, termed GRACE (gene replacement and conditional expression), was used to assess gene essentiality through a combination of gene replacement and conditional gene expression. In a systematic application of this approach, we identify 567 essential genes in C. albicans. Interestingly, evaluating the conditional phenotype of all identifiable C. albicans homologs of the Saccharomyces cerevisiae essential gene set by GRACE revealed only 61% to be essential in C. albicans, emphasizing the importance of performing such studies directly within the pathogen. Construction of this conditional mutant strain collection facilitates large-scale examn. of terminal phenotypes of essential genes. This information enables preferred drug targets to be selected from the C. albicans essential gene set by phenotypic information derived both in vitro, such as cidal vs. static terminal phenotypes, as well as in vivo through virulence studies using conditional strains in an animal model of infection. In addn., the combination of phenotypic and bioinformatic analyses further improves drug target selection from the C. albicans essential gene set, and their resp. conditional mutant strains may be directly used as sensitive whole-cell assays for drug screening.
      >> More from SciFinder ®
      https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXotFOhur0%253D&md5=4c1ba1bcd6ce3a32f36a89a7f5c8f4fb
    6. 6
      Xu, D., Jiang, B., Ketela, T., Lemieux, S., Veillette, K., Martel, N., Davison, J., Sillaots, S., Trosok, S., Bachewich, C., Bussey, H., Youngman, P., and Roemer, T. (2007) Genome-wide fitness test and mechanism-of-action studies of inhibitory compounds in Candida albicans PLoS Pathog. 3, e92 DOI: 10.1371/journal.ppat.0030092
      There is no corresponding record for this reference.
    7. 7
      Roemer, T., Xu, D., Singh, S. B., Parish, C. A., Harris, G., Wang, H., Davies, J. E., and Bills, G. F. (2011) Confronting the challenges of natural product-based antifungal discovery Chem. Biol. 18, 148– 164 DOI: 10.1016/j.chembiol.2011.01.009
      7
      Confronting the Challenges of Natural Product-Based Antifungal Discovery
      Roemer, Terry; Xu, Deming; Singh, Sheo B.; Parish, Craig A.; Harris, Guy; Wang, Hao; Davies, Julian E.; Bills, Gerald F.
      Chemistry & Biology (Cambridge, MA, United States) (2011), 18 (2), 148-164CODEN: CBOLE2; ISSN:1074-5521. (Cell Press)
      A review. Starting with the discovery of penicillin, the pharmaceutical industry has relied extensively on natural products (NPs) as an unparalleled source of bioactive small mols. suitable for antibiotic development. However, the discovery of structurally novel and chem. tractable NPs with suitable pharmacol. properties as antibiotic leads has waned in recent decades. Today, the repetitive "rediscovery" of previously known NP classes with limited antibiotic lead potential dominates most industrial efforts. This limited productivity, exacerbated by the significant financial and resource requirements of such activities, has led to a broad de-emphasis of NP research by most pharmaceutical companies, including most recently Merck. Here we review our strategies-both technol. and philosophical-in addressing current antifungal discovery bottlenecks in target identification and validation and how such efforts may improve NP-based antimicrobial discoveries when aligned with NP screening and dereplication.
      >> More from SciFinder ®
      https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXit1Kjtro%253D&md5=7fe45a7b27bbcf2f222631036b072e76
    8. 8
      Shoemaker, D. D., Lashkari, D. A., Morris, D., Mittmann, M., and Davis, R. W. (1996) Quantitative phenotypic analysis of yeast deletion mutants using a highly parallel molecular bar-coding strategy Nat. Genet. 14, 450– 456 DOI: 10.1038/ng1296-450
      8
      Quantitative phenotypic analysis of yeast deletion mutants using a highly parallel molecular bar-coding strategy
      Shoemaker, Daniel D.; Lashkari, Deval A.; Morris, Don; Mittmann, Mike; Davis, Ronald W.
      Nature Genetics (1996), 14 (4), 450-456CODEN: NGENEC; ISSN:1061-4036. (Nature Publishing Co.)
      A quant. and highly parallel method for analyzing deletion mutants has been developed to aid in detg. the biol. function of thousands of newly identified open reading frames (ORFs) in Saccharomyces cerevisiae. This approach uses a PCR targeting strategy to generate large nos. of deletion strains. Each deletion strain is labeled with a unique 20-base tag sequence that can be detected by hybridization to a high-d. oligonucleotide array. The tags serve as unique identifiers (mol. bar codes) that allow anal. of large nos. of deletion strains simultaneously through selective growth conditions. Hybridization expts. show that the arrays are specific, sensitive and quant. A pilot study with 11 known yeast genes suggests that the method can be extended to include all of the ORFs in the yeast genome, allowing whole genome anal. with a single selection growth condition and a single hybridization.
      >> More from SciFinder ®
      https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XntlGgt7k%253D&md5=078e8c61adac5e44de40fe221730d2d7
    9. 9
      Giaever, G., Shoemaker, D. D., Jones, T. W., Liang, H., Winzeler, E. A., Astromoff, A., and Davis, R. W. (1999) Genomic profiling of drug sensitivities via induced haploinsufficiency Nat. Genet. 21, 278– 283 DOI: 10.1038/6791
      9
      Genomic profiling of drug sensitivities via induced haploinsufficiency
      Giaever, Guri; Shoemaker, Daniel D.; Jones, Ted W.; Liang, Hong; Winzeler, Elizabeth A.; Astromoff, Anna; Davis, Ronald W.
      Nature Genetics (1999), 21 (3), 278-283CODEN: NGENEC; ISSN:1061-4036. (Nature America)
      Lowering the dosage of a single gene from two copies to one copy in diploid yeast results in a heterozygote that is sensitized to any drug that acts on the product of this gene. This haploinsufficient phenotype thereby identifies the gene product of the heterozygous locus as the likely drug target. We exploited this finding in a genomic approach to drug-target identification. Genome sequence information was used to generate molecularly tagged heterozygous yeast strains that were pooled, grown competitively in drug and analyzed for drug sensitivity using high-d. oligonucleotide arrays. Individual heterozygous strain anal. verified six known drug targets. Parallel anal. identified the known target and two hypersensitive loci in a mixed culture of 233 strains in the presence of the drug tunicamycin. Our discovery that both drug target and hypersensitive loci exhibit drug-induced haploinsufficiency may have important consequences in pharmacogenomics and variable drug toxicity obsd. in human populations.
      >> More from SciFinder ®
      https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXitVCitL0%253D&md5=2a1d1ef187aed84b3499e53af5baada4
    10. 10
      Jiang, B., Xu, D., Allocco, J., Parish, C., Davison, J., Veillette, K., Sillaots, S., Hu, W., Rodriguez-Suarez, R., Trosok, S., Zhang, L., Li, Y., Rahkhoodaee, F., Ransom, T., Martel, N., Wang, H., Gauvin, D., Wiltsie, J., Wisniewski, D., Salowe, S., Kahn, J. N., Hsu, M. J., Giacobbe, R., Abruzzo, G., Flattery, A., Gill, C., Youngman, P., Wilson, K., Bills, G., Platas, G., Pelaez, F., Diez, M. T., Kauffman, S., Becker, J., Harris, G., Liberator, P., and Roemer, T. (2008) PAP inhibitor with in vivo efficacy identified by Candida albicans genetic profiling of natural products Chem. Biol. 15, 363– 374 DOI: 10.1016/j.chembiol.2008.02.016
      10
      PAP inhibitor with in vivo efficacy identified by Candida albicans genetic profiling of natural products
      Jiang, Bo; Xu, Deming; Allocco, John; Parish, Craig; Davison, John; Veillette, Karynn; Sillaots, Susan; Hu, Wenqi; Rodriguez-Suarez, Roberto; Trosok, Steve; Zhang, Li; Li, Yang; Rahkhoodaee, Fariba; Ransom, Tara; Martel, Nick; Wang, Hao; Gauvin, Daniel; Wiltsie, Judyann; Wisniewski, Douglas; Salowe, Scott; Nielsen-Kahn, Jennifer; Hsu, Ming-Jo; Giacobbe, Robert; Abruzzo, George; Flattery, Amy; Gill, Charles; Youngman, Phil; Wilson, Ken; Bills, Gerald; Platas, Gonzalo; Pelaez, Fernando; Diez, Maria Teresa; Kauffman, Sarah; Becker, Jeff; Harris, Guy; Liberator, Paul; Roemer, Terry
      Chemistry & Biology (Cambridge, MA, United States) (2008), 15 (4), 363-374CODEN: CBOLE2; ISSN:1074-5521. (Cell Press)
      Natural products provide an unparalleled source of chem. scaffolds with diverse biol. activities and have profoundly impacted antimicrobial drug discovery. To further explore the full potential of their chem. diversity, we survey natural products for antifungal, target-specific inhibitors by using a chem.-genetic approach adapted to the human fungal pathogen C. albicans and demonstrate that natural-product fermn. exts. can be mechanistically annotated according to heterozygote strain responses. Applying this approach, we report the discovery and characterization of a natural product, parnafungin, which we demonstrate, by both biochem. and genetic means, to inhibit poly(A) polymerase. Parnafungin displays potent and broad spectrum activity against diverse, clin. relevant fungal pathogens and reduces fungal burden in a murine model of disseminated candidiasis. Thus, mechanism-of-action detn. of crude fermn. exts. by chem.-genetic profiling brings a powerful strategy to natural-product-based drug discovery.
      >> More from SciFinder ®
      https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXkvFWqt7w%253D&md5=a092e9c8eb95781e38397709bf005ca7
    11. 11
      Xu, D., Ondeyka, J., Harris, G. H., Zink, D., Kahn, J. N., Wang, H., Bills, G., Platas, G., Wang, W., Szewczak, A. A., Liberator, P., Roemer, T., and Singh, S. B. (2011) Isolation, structure, and biological activities of fellutamides C and D from an undescribed Metulocladosporiella (Chaetothyriales) using the genome-wide Candida albicans fitness test J. Nat. Prod. 74, 1721– 1730 DOI: 10.1021/np2001573
      11
      Isolation, structure, and biological activities of fellutamides C and D from an undescribed Metulocladosporiella (Chaetothyriales) using the genome-wide Candida albicans fitness test
      Xu, Deming; Ondeyka, John; Harris, Guy H.; Zink, Deborah; Kahn, Jennifer Nielsen; Wang, Hao; Bills, Gerald; Platas, Gonzalo; Wang, Wenxian; Szewczak, Alexander A.; Liberator, Paul; Roemer, Terry; Singh, Sheo B.
      Journal of Natural Products (2011), 74 (8), 1721-1730CODEN: JNPRDF; ISSN:0163-3864. (American Chemical Society-American Society of Pharmacognosy)
      In a whole-cell mechanism of action (MOA)-based screening strategy for discovery of antifungal agents, Candida albicans was used, followed by testing of active exts. in the C. albicans fitness test (CaFT), which provides insight into the mechanism of action. A fermn. ext. of an undescribed species of Metulocladosporiella that inhibited proteasome activity in a C. albicans fitness test was identified. The chem. genomic profile of the ext. contained hypersensitivity of heterozygous deletion strains (strains that had one of the genes of the diploid genes knocked down) of genes represented by multiple subunits of the 25S proteasome. Two structurally related peptide aldehydes, named fellutamides C and D, were isolated from the ext. Fellutamides were active against C. albicans and Aspergillus fumigatus with MICs ranging from 4 to 16 μg/mL and against fungal proteasome (IC50 0.2 μg/mL). Both compds. showed proteasome activity against human tumor cell lines, potently inhibiting the growth of PC-3 prostate carcinoma cells, but not A549 lung carcinoma cells. In PC-3 cells compd. treatment produced a G2M cell cycle block and induced apoptosis. Preliminary SAR studies indicated that the aldehyde group is crit. for the antifungal activity and that the 2 hydroxy groups are quant. important for potency.
      >> More from SciFinder ®
      https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXovVegsbo%253D&md5=1092cdc7bc2967a84bafa70c05d2696e
    12. 12
      Rodriguez-Suarez, R., Xu, D., Veillette, K., Davison, J., Sillaots, S., Kauffman, S., Hu, W., Bowman, J., Martel, N., Trosok, S., Wang, H., Zhang, L., Huang, L. Y., Li, Y., Rahkhoodaee, F., Ransom, T., Gauvin, D., Douglas, C., Youngman, P., Becker, J., Jiang, B., and Roemer, T. (2007) Mechanism-of-action determination of GMP synthase inhibitors and target validation in Candida albicans and Aspergillus fumigatus Chem. Biol. 14, 1163– 1175 DOI: 10.1016/j.chembiol.2007.09.009
      12
      Mechanism-of-Action Determination of GMP Synthase Inhibitors and Target Validation in Candida albicans and Aspergillus fumigatus
      Rodriguez-Suarez, Roberto; Xu, Deming; Veillette, Karynn; Davison, John; Sillaots, Susan; Kauffman, Sarah; Hu, Wenqi; Bowman, Joel; Martel, Nick; Trosok, Steve; Wang, Hao; Zhang, Li; Huang, Li-Yin; Li, Yang; Rahkhoodaee, Fariba; Ransom, Tara; Gauvin, Daniel; Douglas, Cameron; Youngman, Phil; Becker, Jeff; Jiang, Bo; Roemer, Terry
      Chemistry & Biology (Cambridge, MA, United States) (2007), 14 (10), 1163-1175CODEN: CBOLE2; ISSN:1074-5521. (Cell Press)
      Mechanism-of-action (MOA) studies of bioactive compds. are fundamental to drug discovery. However, in vitro studies alone may not recapitulate a compd.'s MOA in whole cells. Here, we apply a chemogenomics approach in Candida albicans to evaluate compds. affecting purine metab. They include the IMP dehydrogenase inhibitors mycophenolic acid and mizoribine and the previously reported GMP synthase inhibitors acivicin and 6-diazo-5-oxo-L-norleucine (DON). We report important aspects of their whole-cell activity, including their primary target, off-target activity, and drug metab. Further, we describe ECC1385, an inhibitor of GMP synthase, and provide biochem. and genetic evidence supporting its MOA to be distinct from acivicin or DON. Importantly, GMP synthase activity is conditionally essential in C. albicans and Aspergillus fumigatus and is required for virulence of both pathogens, thus constituting an unexpected antifungal target.
      >> More from SciFinder ®
      https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1amt77J&md5=92f53ba0b67720ee485d730fa129ac65
    13. 13
      Xu, D., Sillaots, S., Davison, J., Hu, W., Jiang, B., Kauffman, S., Martel, N., Ocampo, P., Oh, C., Trosok, S., Veillette, K., Wang, H., Yang, M., Zhang, L., Becker, J., Martin, C. E., and Roemer, T. (2009) Chemical genetic profiling and characterization of small-molecule compounds that affect the biosynthesis of unsaturated fatty acids in Candida albicans J. Biol. Chem. 284, 19754– 19764 DOI: 10.1074/jbc.M109.019877
      There is no corresponding record for this reference.
    14. 14
      Richard, M. L. and Plaine, A. (2007) Comprehensive analysis of glycosylphosphatidylinositol-anchored proteins in Candida albicans Eukaryot. Cell. 6, 119– 133 DOI: 10.1128/EC.00297-06
      14
      Comprehensive analysis of glycosylphosphatidylinositol-anchored proteins in Candida albicans
      Richard, Mathias L.; Plaine, Armel
      Eukaryotic Cell (2007), 6 (2), 119-133CODEN: ECUEA2; ISSN:1535-9778. (American Society for Microbiology)
      A review that focuses on the function of glycosylphosphatidylinositol-anchored proteins in Candida albicans.
      >> More from SciFinder ®
      https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitVersbc%253D&md5=afa6c59bf87ddae8c48facae2229da07
    15. 15
      Pittet, M. and Conzelmann, A. (2007) Biosynthesis and function of GPI proteins in the yeast Saccharomyces cerevisiae Biochim. Biophys. Acta 1771, 405– 420 DOI: 10.1016/j.bbalip.2006.05.015
      15
      Biosynthesis and function of GPI proteins in the yeast Saccharomyces cerevisiae
      Pittet, Martine; Conzelmann, Andreas
      Biochimica et Biophysica Acta, Molecular and Cell Biology of Lipids (2007), 1771 (3), 405-420CODEN: BBMLFG; ISSN:1388-1981. (Elsevier Ltd.)
      A review. Like most other eukaryotes, Saccharomyces cerevisiae harbors a GPI anchoring machinery and uses it to attach proteins to membranes. While a few GPI proteins reside permanently at the plasma membrane, a majority of them gets further processed and is integrated into the cell wall by a covalent attachment to cell wall glucans. The GPI biosynthetic pathway is necessary for growth and survival of yeast cells. The GPI lipids are synthesized in the ER and added onto proteins by a pathway comprising 12 steps, carried out by 23 gene products, 19 of which are essential. Some of the estd. 60 GPI proteins predicted from the genome sequence serve enzymic functions required for the biosynthesis and the continuous shape adaptations of the cell wall, others seem to be structural elements of the cell wall and yet others mediate cell adhesion. Because of its genetic tractability S. cerevisiae is an attractive model organism not only for studying GPI biosynthesis in general, but equally for investigating the intracellular transport of GPI proteins and the peculiar role of GPI anchoring in the elaboration of fungal cell walls.
      >> More from SciFinder ®
      https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsVeru70%253D&md5=eb0ba642fce1f308d70f85d9458748fd
    16. 16
      Klis, F. M., Sosinska, G. J., de Groot, P. W., and Brul, S. (2009) Covalently linked cell wall proteins of Candida albicans and their role in fitness and virulence FEMS Yeast Res. 9, 1013– 1028 DOI: 10.1111/j.1567-1364.2009.00541.x
      16
      Covalently linked cell wall proteins of Candida albicans and their role in fitness and virulence
      Klis, Frans M.; Sosinska, Grazyna J.; de Groot, Piet W. J.; Brul, Stanley
      FEMS Yeast Research (2009), 9 (7), 1013-1028CODEN: FYREAG; ISSN:1567-1356. (Wiley-Blackwell)
      A review. The cell wall of Candida albicans consists of an internal skeletal layer and an external protein coat. This coat has a mosaic-like nature, contg. c. 20 different protein species covalently linked to the skeletal layer. Most of them are GPI proteins. Coat proteins vary widely in function. Many of them are involved in the primary interactions between C. albicans and the host and mediate adhesive steps or invasion of host cells. Others are involved in biofilm formation and cell-cell aggregation. They further include iron acquisition proteins, superoxide dismutases, and yapsin-like aspartic proteases. In addn., several covalently linked carbohydrate-active enzymes are present, whose precise functions remain hitherto largely elusive. The expression levels of the genes that encode covalently linked cell wall proteins (CWPs) can vary enormously. They depend on the mode of growth and the combined inputs of several signaling pathways that sense environmental conditions. This is reflected in the unusually long intergenic regions of most of these genes. Finally, the precise location of several covalently linked CWPs is temporally and spatially regulated. It is concluded that covalently linked CWPs of C. albicans play a crucial role in fitness and virulence and that their expression is tightly controlled.
      >> More from SciFinder ®
      https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlOis7bK&md5=03afa73bf2dfb2456c3420b9aa94c729
    17. 17
      Orlean, P. and Menon, A. K. (2007) Thematic review series: Lipid posttranslational modifications. GPI anchoring of protein in yeast and mammalian cells, or: how we learned to stop worrying and love glycophospholipids J. Lipid Res. 48, 993– 1011 DOI: 10.1194/jlr.R700002-JLR200
      17
      GPI anchoring of protein in yeast and mammalian cells, or: how we learned to stop worrying and love glycophospholipids
      Orlean, Peter; Menon, Anant K.
      Journal of Lipid Research (2007), 48 (5), 993-1011CODEN: JLPRAW; ISSN:0022-2275. (American Society for Biochemistry and Molecular Biology, Inc.)
      A review. Glycosylphosphatidylinositol (GPI) anchoring of cell surface proteins is the most complex and metabolically expensive of the lipid posttranslational modifications described to date. The GPI anchor is synthesized via a membrane-bound multistep pathway in the endoplasmic reticulum (ER) requiring >20 gene products. The pathway is initiated on the cytoplasmic side of the ER and completed in the ER lumen, necessitating flipping of a glycolipid intermediate across the membrane. The completed GPI anchor is attached to proteins that were translocated across the ER membrane nd that display a GPI signal anchor sequence pathway to the cell surface; in yeast, many become covalently attached to the cell wall. Genes encoding proteins involved in all but 1 of the predicted steps in the assembly of the GPI precursor glycolipid and its transfer to protein in mammals and yeast have now been identified. Most of these genes encode polytopic membrane proteins, some of which are organized in complexes. The steps in GPI assembly, and the enzymes that carry them, are highly conserved. GPI biosynthesis is essential for viability in yeast and for embryonic development in mammals. In this review, the authors describe the biosynthesis of mammalian and yeast GPIs, their transfer to protein, and their subsequent processing.
      >> More from SciFinder ®
      https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXls1ejtLo%253D&md5=cdba29bd6397497683c83925fb816ca5
    18. 18
      Sütterlin, C., Horvath, A., Gerold, P., Schwarz, R. T., Wang, Y., Dreyfuss, M., and Riezman, H. (1997) Identification of a species-specific inhibitor of glycosylphosphatidylinositol synthesis EMBO J. 16, 6374– 6383 DOI: 10.1093/emboj/16.21.6374
      There is no corresponding record for this reference.
    19. 19
      Wang, Y., Dreyfuss, M., Ponelle, M., Oberer, L., and Riezman, H. A Glycosylphosphatidylinositol-anchoring inhibitor with an unusual tetracarboxocyclic sesterpene skeleton from the fungus Codinaea simplex. Tetrahedron 54, 6415– 6426. DOI: 10.1016/S0040-4020(98)00322-6
      There is no corresponding record for this reference.
    20. 20
      Hong, Y., Maeda, Y., Watanabe, R., Ohishi, K., Mishkind, M., Riezman, H., and Kinoshita, T. (1999) Pig-n, a mammalian homologue of yeast Mcd4p, is involved in transferring phosphoethanolamine to the first mannose of the glycosylphosphatidylinositol J. Biol. Chem. 274, 35099– 35106 DOI: 10.1074/jbc.274.49.35099
      There is no corresponding record for this reference.
    21. 21
      Wiedman, J. M., Fabre, A. L., Taron, B. W., Taron, C. H., and Orlean, P. (2007) In vivo characterization of the GPI assembly defect in yeast mcd4–174 mutants and bypass of the Mcd4p-dependent step in mcd4Delta cells FEMS Yeast Res. 7, 78– 83 DOI: 10.1111/j.1567-1364.2006.00139.x
      21
      In vivo characterization of the GPI assembly defect in yeast mcd4-174 mutants and bypass of the Mcd4p-dependent step in mcd4Δ cells
      Wiedman, Jill M.; Fabre, Anne-Lise; Taron, Barbara W.; Taron, Christopher H.; Orlean, Peter
      FEMS Yeast Research (2007), 7 (1), 78-83CODEN: FYREAG; ISSN:1567-1356. (Blackwell Publishing Ltd.)
      Yeast mcd4-174 mutants are blocked in glycosylphosphatidylinositol (GPI) anchoring of protein, but the stage at which GPI biosynthesis is interrupted in vivo has not been identified, and Mcd4p has also been implicated in phosphatidylserine and ATP transport. The authors report that the major GPI that accumulates in mcd4-174 in vivo is Man2-GlcN-(acyl-Ins)PI, consistent with proposals that Mcd4p adds phosphoethanolamine to the 1st mannose of yeast GPI precursors. Mcd4p-dependent modification of GPIs can partially be bypassed in the mcd4-174/gpi11 double mutant and in mcd4Δ mutants by high-level expression of PIG-B and GPI10, which resp. encode the human and yeast mannosyltransferases that add the 3rd mannose of the GPI precursor. Rescue of mcd4Δ by GPI10 indicates that Mcd4p-dependent addn. of EthN-P to the 1st mannose of GPIs is not obligatory for transfer of the 3rd mannose by Gpi10p.
      >> More from SciFinder ®
      https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhslyhuro%253D&md5=be87a6b02cd4021df9acfca6ebd728d4
    22. 22
      Tsukahara, K., Hata, K., Nakamoto, K., Sagane, K., Watanabe, N. A., Kuromitsu, J., Kai, J., Tsuchiya, M., Ohba, F., Jigami, Y., Yoshimatsu, K., and Nagasu, T. (2003) Medicinal genetics approach towards identifying the molecular target of a novel inhibitor of fungal cell wall assembly Mol. Microbiol. 48, 1029– 1042 DOI: 10.1046/j.1365-2958.2003.03481.x
      22
      Medicinal genetics approach towards identifying the molecular target of a novel inhibitor of fungal cell wall assembly
      Tsukahara, Kappei; Hata, Katsura; Nakamoto, Kazutaka; Sagane, Koji; Watanabe, Nao-aki; Kuromitsu, Junro; Kai, Junko; Tsuchiya, Mamiko; Ohba, Fuminori; Jigami, Yoshifumi; Yoshimatsu, Kentaro; Nagasu, Takeshi
      Molecular Microbiology (2003), 48 (4), 1029-1042CODEN: MOMIEE; ISSN:0950-382X. (Blackwell Publishing Ltd.)
      Glycosylphosphatidylinositol (GPI)-anchored cell wall mannoproteins are required for the adhesion of pathogenic fungi, such as Candida albicans, to human epithelium. Small mol. inhibitors of the cell surface presentation of GPI-anchored mannoproteins would be promising candidate drugs to block the establishment of fungal infections. Here, we describe a medicinal genetics approach to identifying the gene encoding a novel target protein that is required for the localization of GPI-anchored cell wall mannoproteins. By means of a yeast cell-based screening procedure, we discovered a compd., 1-[4-butylbenzyl]isoquinoline (I), that inhibits cell wall localization of GPI-anchored mannoproteins in Saccharomyces cerevisiae. Treatment of C. albicans cells with this compd. resulted in reduced adherence to a rat intestine epithelial cell monolayer. A previously uncharacterized gene YJL091c, named GWT1, was cloned as a dosage-dependent suppressor of the I-induced phenotypes. GWT1 knock-out cells showed similar phenotypes to I-treated wild-type cells in terms of cell wall structure and transcriptional profiles. Two different mutants resistant to I each contained a single missense mutation in the coding region of the GWT1 gene. These results all suggest that the GWT1 gene product is the primary target of the compd.
      >> More from SciFinder ®
      https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXktV2gsL4%253D&md5=1049da3e97c3df636219d903cc2f939c
    23. 23
      Gaynor, E. C., Mondésert, G., Grimme, S. J., Reed, S. I., Orlean, P., and Emr, S. D. (1999) MCD4 encodes a conserved endoplasmic reticulum membrane protein essential for glycosylphosphatidylinositol anchor synthesis in yeast Mol. Biol. Cell 10, 627– 648 DOI: 10.1091/mbc.10.3.627
      23
      MCD4 encodes a conserved endoplasmic reticulum membrane protein essential for glycosylphosphatidylinositol anchor synthesis in yeast
      Gaynor, Erin C.; Mondesert, Guillaume; Grimme, Stephen J.; Reed, Steve I.; Orlean, Peter; Emr, Scott D.
      Molecular Biology of the Cell (1999), 10 (3), 627-648CODEN: MBCEEV; ISSN:1059-1524. (American Society for Cell Biology)
      Glycosylphosphatidylinositol (GPI)-anchored proteins are cell surface-localized proteins that serve many important cellular functions. The pathway mediating synthesis and attachment of the GPI anchor to these proteins in eukaryotic cells is complex, highly conserved, and plays a crit. role in the proper targeting, transport, and function of all GPI-anchored protein family members. In this article, we demonstrate that MCD4, an essential gene that was initially identified in a genetic screen to isolate Saccharomyces cerevisiae mutants defective for bud emergence, encodes a previously unidentified component of the GPI anchor synthesis pathway. Mcd4p is a multimembrane-spanning protein that localizes to the endoplasmic reticulum (ER) and contains a large NH2-terminal ER lumenal domain. We have also cloned the human MCD4 gene and found that Mcd4p is both highly conserved throughout eukaryotes and has two yeast homologues. Mcd4p's lumenal domain contains three conserved motifs found in mammalian phosphodiesterases and nucleotide pyrophosphases; notably, the temp.-conditional MCD4 allele used for our studies (mcd4-174) harbors a single amino acid change in motif 2. The mcd4-174 mutant (1) is defective in ER-to-Golgi transport of GPI-anchored proteins (i.e., Gas1p) while other proteins (i.e., CPY) are unaffected; (2) secretes and releases (potentially up-regulated cell wall) proteins into the medium, suggesting a defect in cell wall integrity; and (3) exhibits marked morphol. defects, most notably the accumulation of distorted, ER- and vesicle-like membranes. Mcd4-174 cells synthesize all classes of inositolphosphoceramides, indicating that the GPI protein transport block is not due to deficient ceramide synthesis. However, mcd4-174 cells have a severe defect in incorporation of [3H]inositol into proteins and accumulate several previously uncharacterized [3H]inositol-labeled lipids whose properties are consistent with their being GPI precursors. Together, these studies demonstrate that MCD4 encodes a new, conserved component of the GPI anchor synthesis pathway and highlight the intimate connections between GPI anchoring, bud emergence, cell wall function, and feedback mechanisms likely to be involved in regulating each of these essential processes. A putative role for Mcd4p as participating in the modification of GPI anchors with side chain phosphoethanolamine is also discussed.
      >> More from SciFinder ®
      https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhvVyku7c%253D&md5=cc36193454987edf3eea47f0c292fa83
    24. 24
      Dennehy, K. M. and Brown, G. D. (2007) The role of the beta-glucan receptor dectin-1 in control of fungal infection J. Leukoc. Biol. 82, 253– 258 DOI: 10.1189/jlb.1206753
      24
      The role of the β-glucan receptor Dectin-1 in control of fungal infection
      Dennehy, Kevin M.; Brown, Gordon D.
      Journal of Leukocyte Biology (2007), 82 (2), 253-258CODEN: JLBIE7; ISSN:0741-5400. (Federation of American Societies for Experimental Biology)
      A review. During fungal infection, a variety of receptors initiates immune responses, including TLR and the β-glucan receptor Dectin-1. TLR recognition of fungal ligands and subsequent signaling through the MyD88 pathway were thought to be the most important interactions required for the control of fungal infection. However, recent papers have challenged this view, highlighting the role of Dectin-1 in induction of cytokine responses and the respiratory burst. Two papers, using independently derived, Dectin-1-deficient mice, address the role of Dectin-1 in control of fungal infection. Saijo et al. (Nat. Immunol., 2007, 8, 39-46) argue that Dectin-1 plays a minor role in control of Pneumocystis carinii by direct killing and that TLR-mediated cytokine prodn. controls P. carinii and Candida albicans. By contrast, Taylor et al. (Nat. Immunol, 2007, 8, 31-38) argue that Dectin-1-mediated cytokine and chemokine prodn., leading to efficient recruitment of inflammatory cells, is required for control of fungal infection. Here, the authors argue that collaborative responses induced during infection may partially explain these apparently contradictory results. They propose that Dectin-1 is the first of many pattern recognition receptors that can mediate their own signaling, as well as synergize with TLR to initiate specific responses to infectious agents.
      >> More from SciFinder ®
      https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXos12rtbk%253D&md5=369bd2e12247f8cc55c6a65bfaa63432
    25. 25
      Umemura, M., Okamoto, M., Nakayama, K., Sagane, K., Tsukahara, K., Hata, K., and Jigami, Y. (2003) GWT1 gene is required for inositol acylation of glycosylphosphatidylinositol anchors in yeast J. Biol. Chem. 278, 23639– 23647 DOI: 10.1074/jbc.M301044200
      There is no corresponding record for this reference.
    26. 26
      Watanabe, N. A., Miyazaki, M., Horii, T., Sagane, K., Tsukahara, K., and Hata, K. (2012) E1210, a new broad-spectrum antifungal, suppresses Candida albicans hyphal growth through inhibition of glycosylphosphatidylinositol biosynthesis Antimicrob. Agents Chemother. 56, 960– 971 DOI: 10.1128/AAC.00731-11
      26
      E1210, a new broad-spectrum antifungal, suppresses Candida albicans hyphal growth through inhibition of glycosylphosphatidylinositol biosynthesis
      Watanabe, Nao-aki; Miyazaki, Mamiko; Horii, Takaaki; Sagane, Koji; Tsukahara, Kappei; Hata, Katsura
      Antimicrobial Agents and Chemotherapy (2012), 56 (2), 960-971CODEN: AMACCQ; ISSN:0066-4804. (American Society for Microbiology)
      Continued research toward the development of new antifungals that act via inhibition of glycosylphosphatidylinositol (GPI) biosynthesis led to the design of E1210. In this study, we assessed the selectivity of the inhibitory activity of E1210 against Candida albicans GWT1 (Orf19.6884) protein, Aspergillus fumigatus GWT1 (AFUA_1G14870) protein, and human PIG-W protein, which can catalyze the inositol acylation of GPI early in the GPI biosynthesis pathway, and then we assessed the effects of E1210 on key C. albicans virulence factors. E1210 inhibited the inositol acylation activity of C. albicans Gwt1p and A. fumigatus Gwt1p with 50% inhibitory concns. (IC50s) of 0.3 to 0.6 μM but had no inhibitory activity against human Pig-Wp even at concns. as high as 100 μM. To confirm the inhibition of fungal GPI biosynthesis, expression of ALS1 protein, a GPI-anchored protein, on the surfaces of C. albicans cells treated with E1210 was studied and shown to be significantly lower than that on untreated cells. However, the ALS1 protein levels in the crude ext. and the RHO1 protein levels on the cell surface were found to be almost the same. Furthermore, E1210 inhibited germ tube formation, adherence to polystyrene surfaces, and biofilm formation of C. albicans at concns. above its MIC. These results suggested that E1210 selectively inhibited inositol acylation of fungus-specific GPI which would be catalyzed by Gwt1p, leading to the inhibition of GPI-anchored protein maturation, and also that E1210 suppressed the expression of some important virulence factors of C. albicans, through its GPI biosynthesis inhibition.
      >> More from SciFinder ®
      https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Gruro%253D&md5=a489c9d19296eaa8b65513de5b133ce3
    27. 27
      McLellan, C. A., Whitesell, L., King, O. D., Lancaster, A. K., Mazitschek, R., and Lindquist, S. (2012) Inhibiting GPI anchor biosynthesis in fungi stresses the endoplasmic reticulum and enhances immunogenicity ACS Chem. Biol. 7, 1520– 1528 DOI: 10.1021/cb300235m
      27
      Inhibiting GPI Anchor Biosynthesis in Fungi Stresses the Endoplasmic Reticulum and Enhances Immunogenicity
      McLellan, Catherine A.; Whitesell, Luke; King, Oliver D.; Lancaster, Alex K.; Mazitschek, Ralph; Lindquist, Susan
      ACS Chemical Biology (2012), 7 (9), 1520-1528CODEN: ACBCCT; ISSN:1554-8929. (American Chemical Society)
      In fungi, the anchoring of proteins to the plasma membrane via their covalent attachment to glycosylphosphatidylinositol (GPI) is essential and thus provides a valuable point of attack for the development of antifungal therapeutics. Unfortunately, studying the underlying biol. of GPI-anchor synthesis is difficult, esp. in medically relevant fungal pathogens because they are not genetically tractable. Compounding difficulties, many of the genes in this pathway are essential in Saccharomyces cerevisiae. Here, the discovery of a new small mol. christened gepinacin (for GPI acylation inhibitor) which selectively inhibits Gwt1, a crit. acyltransferase required for the biosynthesis of fungal GPI anchors, is reported. After delineating the target specificity of gepinacin using genetic and biochem. techniques, it was used to probe key, therapeutically relevant consequences of disrupting GPI anchor metab. in fungi. It was found that, unlike all three major classes of antifungals in current use, the direct antimicrobial activity of this compd. results predominantly from its ability to induce overwhelming stress to the endoplasmic reticulum. Gepinacin did not affect the viability of mammalian cells nor did it inhibit their orthologous acyltransferase. This enabled its use in co-culture expts. to examine Gwt1's effects on host-pathogen interactions. In isolates of Candida albicans, the most common fungal pathogen in humans, exposure to gepinacin at sublethal concns. impaired filamentation and unmasked cell wall β-glucan to stimulate a pro-inflammatory cytokine response in macrophages. Gwt1 is a promising antifungal drug target, and gepinacin is a useful probe for studying how disrupting GPI-anchor synthesis impairs viability and alters host-pathogen interactions in genetically intractable fungi.
      >> More from SciFinder ®
      https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XovFaktr0%253D&md5=f5d23f76cbc1942730dce3af6b2af115
    28. 28
      Lee, M. C., Miller, E. A., Goldberg, J., Orci, L., and Schekman, R. (2004) Bi-directional protein transport between the ER and Golgi Annu. Rev. Cell Dev. Biol. 20, 87– 123 DOI: 10.1146/annurev.cellbio.20.010403.105307
      28
      Bi-directional protein transport between the ER and Golgi
      Lee, Marcus C. S.; Miller, Elizabeth A.; Goldberg, Jonathan; Orci, Lelio; Schekman, Randy
      Annual Review of Cell and Developmental Biology (2004), 20 (), 87-123CODEN: ARDBF8; ISSN:1081-0706. (Annual Reviews Inc.)
      A review. The endoplasmic reticulum (ER) and the Golgi app. comprise the 1st 2 steps in protein secretion. Vesicular carriers mediate a continuous flux of proteins and lipids between these compartments, reflecting the transport of newly synthesized proteins out of the ER and the retrieval of escaped ER residents and vesicle machinery. Anterograde and retrograde transport is mediated by distinct sets of cytosolic coat proteins, the COPII and COPI coats, resp., which act on the membrane to capture cargo proteins into nascent vesicles. Here, the authors review the mechanisms that govern coat recruitment to the membrane, cargo capture into a transport vesicle, and accurate delivery to the target organelle.
      >> More from SciFinder ®
      https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVaqu7bM&md5=ae02d65edd306dafa84ef899b1d628cd
    29. 29
      Kodera, C., Yorimitsu, T., Nakano, A., and Sato, K. (2011) Sed4p stimulates Sar1p GTP hydrolysis and promotes limited coat disassembly Traffic 12, 591– 599 DOI: 10.1111/j.1600-0854.2011.01173.x
      There is no corresponding record for this reference.
    30. 30
      Letourneur, F., Gaynor, E. C., Hennecke, S., Demolliere, C., Duden, R., Emr, S. D., Riezman, H., and Cosson, P. (1994) Coatomer is essential for retrieval of dilysine-tagged proteins to the endoplasmic reticulum Cell 79, 1199– 1207 DOI: 10.1016/0092-8674(94)90011-6
      There is no corresponding record for this reference.
    31. 31
      Ma, W. and Goldberg, J. (2013) Rules for the recognition of dilysine retrieval motifs by coatomer EMBO J. 32, 926– 937 DOI: 10.1038/emboj.2013.41
      There is no corresponding record for this reference.
    32. 32
      Carvajal, E., van den Hazel, H. B., Cybularz-Kolaczkowska, A., Balzi, E., and Goffeau, A. (1997) Molecular and phenotypic characterization of yeast PDR1 mutants that show hyperactive transcription of various ABC multidrug transporter genes Mol. Gen Genet. 256, 406– 415 DOI: 10.1007/s004380050584
      32
      Molecular and phenotypic characterization of yeast PDR1 mutants that show hyperactive transcription of various ABC multidrug transporter genes
      Carvajal, E.; Van Den Hazel, H. B.; Cybularz-Kolaczkowska, A.; Balzi, E.; Goffeau, A.
      Molecular & General Genetics (1997), 256 (4), 406-415CODEN: MGGEAE; ISSN:0026-8925. (Springer-Verlag)
      Mutations at the yeast PDR1 transcriptional regulator locus are responsible for overexpression of the three ABC transporter genes PDR5, SNQ2 and YOR1, assocd. with the appearance of multiple drug resistance. The nucleotide sequences of 13 alleles of PDR1, comprising 6 multidrug resistance mutants, 1 intragenic suppressor and 6 wild types, have been detd. Single amino acid substitutions were shown to result from the mutations pdr1-2 (M308I), pdr1-3 (F815S), pdr1-6 (K302Q), pdr1-7 (P298A) and pdr1-8 (L1036W), whereas the intragenic suppressor mutant pdr1-100 is deleted for the two amino acids L537 and A538. An isogenic series of strains was constructed contg. the mutant alleles pdr1-3, pdr1-6 and pdr1-8 integrated into the genome. It was found that the levels of resistance to cycloheximide, oligomycin, 4-nitroquinoline-N-oxide and ketoconazole were increased in all three mutants. The increase was more pronounced in the pdr1-3 than in the pdr1-6 and pdr1-8 mutants. Studies of the activity of the promoters of the ABC genes PDR5, SNQ2 and YOR1 demonstrated that the combination of the PDR5 promoter and the pdr1-3 mutation resulted in the highest level of promoter induction. Concomitantly. the level of PDR5 mRNA, of Pdr5p protein, and of its assocd. nucleoside triphosphatase activity, was strongly increased in the plasma membranes of the PDR1 mutants. Again, the pdr1-3 allele was assocd. with a stronger effect than the pdr1-8 and pdr1-6 alleles. The locations of the mutations in the PDR1 gene indicate that at least three different regions distributed throughout the Pdr1p transcription factor may be mutated to generate a Pdr1p with considerably increased transcriptional activation potency. These gain-of-function mutations support the concept, recently proposed, that in members of the large family of yeast Zn2Cys6 transcription factors a central inhibitory domain exists (delineated by the pdr1-7, pdr1-6 and pdr1-2 mutations). This domain may interact in a locked conformation with a putative, more C-terminally located inhibitory domain (mutated in pdr1-3), and with the putative activation domain (mutated in pdr1-8).
      >> More from SciFinder ®
      https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXhsl2juw%253D%253D&md5=fb7163231216cf3d46323b51f5490ede
    33. 33
      Sagane, K., Umemura, M., Ogawa-Mitsuhashi, K., Tsukahara, K., Yoko-o, T., and Jigami, Y. (2011) Analysis of membrane topology and identification of essential residues for the yeast endoplasmic reticulum inositol acyltransferase Gwt1p J. Biol. Chem. 286, 14649– 14658 DOI: 10.1074/jbc.M110.193490
      There is no corresponding record for this reference.
    34. 34
      Zhu, Y., Vionnet, C., and Conzelmann, A. (2006) Ethanolaminephosphate side chain added to glycosylphosphatidylinositol (GPI) anchor by mcd4p is required for ceramide remodeling and forward transport of GPI proteins from endoplasmic reticulum to Golgi J. Biol. Chem. 281, 19830– 19839 DOI: 10.1074/jbc.M601425200
      There is no corresponding record for this reference.
    35. 35
      Miyazaki, M., Horii, T., Hata, K., Watanabe, N. A., Nakamoto, K., Tanaka, K., Shirotori, S., Murai, N., Inoue, S., Matsukura, M., Abe, S., Yoshimatsu, K., and Asada, M. (2011) In vitro activity of E1210, a novel antifungal, against clinically important yeasts and molds Antimicrob. Agents Chemother. 55, 4652– 4658 DOI: 10.1128/AAC.00291-11
      35
      In vitro activity of E1210, a novel antifungal, against clinically important yeasts and molds
      Miyazaki, Mamiko; Horii, Takaaki; Hata, Katsura; Watanabe, Nao-aki; Nakamoto, Kazutaka; Tanaka, Keigo; Shirotori, Syuji; Murai, Norio; Inoue, Satoshi; Matsukura, Masayuki; Abe, Shinya; Yoshimatsu, Kentaro; Asada, Makoto
      Antimicrobial Agents and Chemotherapy (2011), 55 (10), 4652-4658CODEN: AMACCQ; ISSN:0066-4804. (American Society for Microbiology)
      E1210 is a new antifungal compd. with a novel mechanism of action and broad spectrum of antifungal activity. We investigated the in vitro antifungal activities of E1210 compared to those of fluconazole, itraconazole, voriconazole, amphotericin B, and micafungin against clin. fungal isolates. E1210 showed potent activities against most Candida spp. (MIC90 of ≤0.008 to 0.06 μg/mL), except for Candida krusei (MICs of 2 to >32 μg/mL). E1210 showed equally potent activities against fluconazole-resistant and fluconazole-susceptible Candida strains. E1210 also had potent activities against various filamentous fungi, including Aspergillus fumigatus (MIC90 of 0.13 μg/mL). E1210 was also active against Fusarium solani and some black molds. Of note, E1210 showed the greatest activities against Pseudallescheria boydii (MICs of 0.03 to 0.13 μg/mL), Scedosporium prolificans (MIC of 0.03 μg/mL), and Paecilomyces lilacinus (MICs of 0.06 μg/mL) among the compds. tested. The antifungal action of E1210 was fungistatic, but E1210 showed no trailing growth of Candida albicans, which has often been obsd. with fluconazole. In a cytotoxicity assay using human HK-2 cells, E1210 showed toxicity as low as that of fluconazole. Based on these results, E1210 is likely to be a promising antifungal agent for the treatment of invasive fungal infections.
      >> More from SciFinder ®
      https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtl2nsL%252FP&md5=cb380963b1f986ed2e0d72ed5067e19d
    36. 36
      Poulain, D. and Jouault, T. (2004) Candida albicans cell wall glycans, host receptors and responses: elements for a decisive crosstalk Curr. Opin. Microbiol. 7, 342– 349 DOI: 10.1016/j.mib.2004.06.011
      36
      Candida albicans cell wall glycans, host receptors and responses: elements for a decisive crosstalk
      Poulain, Daniel; Jouault, Thierry
      Current Opinion in Microbiology (2004), 7 (4), 342-349CODEN: COMIF7; ISSN:1369-5274. (Elsevier Ltd.)
      A review. Candida albicans has adapted to live on the mucosal surfaces of animals. The human species has accepted it. By contrast to numerous other commensals, C. albicans has a prominent ability to invade virtually all tissues of a host presenting with natural or acquired defects in homeostasis. C. albicans uses considerable energy to synthesize glycans, which are present either as polymers or as glyconjugates. These glycan mols. play a prominent role in the biol. of C. albicans by controlling the structure and plasticity of the cell wall, and are also involved in yeast-host interactions. These glycans are recognized as non-self by host innate and adaptative immunity. The signal they induce in the host depends on the glycan code, which is detd. by the nature of the sugar, the anomer type of linkage and branching, and the length of the oligosaccharide chains. However, this model is not static because the nature of the C. albicans mol. carrying such glycan codes and their expression at the cell wall surface also dets. the host response, and, in turn, the regulation of cell wall glycan arrangement dynamics in C. albicans depends on host stimuli. Candida glycans therefore play an important role in the continuous interchange that regulates the balance between saprophytism and parasitism, and resistance and infection. A goal of current research concerning the virulence attributes of C. albicans will be to det. to what extent this species is able to regulate its glycan code as a response to the host.
      >> More from SciFinder ®
      https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmt1Omsbg%253D&md5=f563b4eb9e95bb8616d8e58dc707d8c1
    37. 37
      Wheeler, R. T. and Fink, G. R. (2006) A drug-sensitive genetic network masks fungi from the immune system PLoS Pathog. 2, e35 DOI: 10.1371/journal.ppat.0020035
      There is no corresponding record for this reference.
    38. 38
      Ishibashi, K., Yoshida, M., Nakabayashi, I., Shinohara, H., Miura, N. N., Adachi, Y., and Ohno, N. (2005) Role of anti-beta-glucan antibody in host defense against fungi FEMS Immunol. 44, 99– 109 DOI: 10.1016/j.femsim.2004.12.012
      38
      Role of anti-β-glucan antibody in host defense against fungi
      Ishibashi, Ken-Ichi; Yoshida, Masaharu; Nakabayashi, Iwao; Shinohara, Hiroyasu; Miura, Noriko N.; Adachi, Yoshiyuki; Ohno, Naohito
      FEMS Immunology and Medical Microbiology (2005), 44 (1), 99-109CODEN: FIMIEV; ISSN:0928-8244. (Elsevier B.V.)
      The authors have recently detected an anti-β-glucan antibody in normal human and normal mouse sera. The anti-β-glucan antibody showed reactivity to pathogenic fungal Aspergillus and Candida cell wall glucan. Anti-β-glucan antibody could bind whole Candida cells. It also enhanced the candidacidal activity of macrophages in vitro. The anti-β-glucan antibody titer of DBA/2 mice i.v. administered either Candida or Aspergillus solubilized cell wall β-glucan decreased remarkably dependent on dose. Moreover, in deep mycosis patients, the anti-β-glucan antibody titer decreased, and this change correlated with clin. symptoms and other parameters such as C-reactive protein. It was suggested that the anti-β-glucan antibody formed an antigen-antibody complex and participated in the immune response as a mol. recognizing pathogenic fungi.
      >> More from SciFinder ®
      https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXisVajsr8%253D&md5=9ad0c2384b1b3f5833b60d8b88d9f592
    39. 39
      Kushida, H., Nakajima, S., Uchiyama, S., Nagashima, M., Kojiri, K., Kawamura, K., and Suda, H. (1999) Antifungal substances BE-49385 and process for their production. U.S. Patent 5,928,910.
      There is no corresponding record for this reference.
    40. 40
      Hirano, A., Sugiyama, E., Kondo, H., Suda, H., Ogawa, H., and Kojiri, K. (2001) Sesterterpene derivatives exhibiting antifungal activities U.S. Patent 6,303,797 B1.
      There is no corresponding record for this reference.
    41. 41
      Sütterlin, C., Escribano, M. V., Gerold, P., Maeda, Y., Mazon, M. J., Kinoshita, T., Schwarz, R. T., and Riezman, H. (1998) Saccharomyces cerevisiae GPI10, the functional homologue of human PIG-B, is required for glycosylphosphatidylinositol-anchor synthesis Biochem. J. 332, 153– 159
      There is no corresponding record for this reference.
    42. 42
      McConville, M. J. and ad Ferguson, M. A. J. (1993) The structure, biosynthesis and function of glycosylated phosphatidylinositols in the parasitic protozoa and higher eukaryotes Biochem. J. 294, 305– 324
      42
      The structure, biosynthesis and function of glycosylated phosphatidylinositols in the parasitic protozoa and higher eukaryotes
      McConville, Malcolm J.; Ferguson, Michael A. J.
      Biochemical Journal (1993), 294 (2), 305-24CODEN: BIJOAK; ISSN:0264-6021.
      A review with >200 refs. on the structure, function and biosynthesis of glycosyl-phosphatidylinositol (GPI) anchors in the title organisms. There may be significant differences in the function of GPI protein anchors in unicellular vs. metazoan organisms. Some parasitic protozoa synthesize exotic GPI-related structures which are not attached to proteins. Evolutionary aspects of the GPI family are also discussed.
      >> More from SciFinder ®
      https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXlvF2hs70%253D&md5=23f9cf6089c12012eaa42693daafc790
    43. 43
      Hata, K., Horii, T., Miyazaki, M., Watanabe, N. A., Okubo, M., Sonoda, J., Nakamoto, K., Tanaka, K., Shirotori, S., Murai, N., Inoue, S., Matsukura, M., Abe, S., Yoshimatsu, K., and Asada, M. (2011) Efficacy of oral E1210, a new broad-spectrum antifungal with a novel mechanism of action, in murine models of candidiasis, aspergillosis, and fusariosis Antimicrob. Agents Chemother. 55, 4543– 4551 DOI: 10.1128/AAC.00366-11
      43
      Efficacy of oral E1210, a new broad-spectrum antifungal with a novel mechanism of action, in murine models of candidiasis, aspergillosis, and fusariosis
      Hata, Katsura; Horii, Takaaki; Miyazaki, Mamiko; Watanabe, Nao-aki; Okubo, Miyuki; Sonoda, Jiro; Nakamoto, Kazutaka; Tanaka, Keigo; Shirotori, Syuji; Murai, Norio; Inoue, Satoshi; Matsukura, Masayuki; Abe, Shinya; Yoshimatsu, Kentaro; Asada, Makoto
      Antimicrobial Agents and Chemotherapy (2011), 55 (10), 4543-4551CODEN: AMACCQ; ISSN:0066-4804. (American Society for Microbiology)
      E1210 is a 1st-in-class, broad-spectrum antifungal with a novel mechanism of action-inhibition of fungal glycosylphosphatidylinositol biosynthesis. In this study, the efficacies of E1210 and ref. antifungals were evaluated in murine models of oropharyngeal and disseminated candidiasis, pulmonary aspergillosis, and disseminated fusariosis. Oral E1210 demonstrated dose-dependent efficacy in infections caused by Candida species, Aspergillus spp., and Fusarium solani. In the treatment of oropharyngeal candidiasis, E1210 and fluconazole each caused a significantly greater redn. in the no. of oral CFU than the control treatment. In the disseminated candidiasis model, mice treated with E1210, fluconazole, caspofungin, or liposomal amphotericin B showed significantly higher survival rates than the control mice. E1210 was also highly effective in treating disseminated candidiasis caused by azole-resistant Candida albicans or Candida tropicalis. A 24-h delay in treatment onset minimally affected the efficacy outcome of E1210 in the treatment of disseminated candidiasis. In the Aspergillus flavus pulmonary aspergillosis model, mice treated with E1210, voriconazole, or caspofungin showed significantly higher survival rates than the control mice. E1210 was also effective in the treatment of Aspergillus fumigatus pulmonary aspergillosis. In contrast to many antifungals, E1210 was also effective against disseminated fusariosis caused by F. solani. In conclusion, E1210 demonstrated consistent efficacy in murine models of oropharyngeal and disseminated candidiasis, pulmonary aspergillosis, and disseminated fusariosis. These data suggest that further studies to det. E1210's potential for the treatment of disseminated fungal infections are indicated.
      >> More from SciFinder ®
      https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtl2ns7fE&md5=ff015a73a4108a15fe6474a7411a6044
    44. 44
      Lee, A. Y., St. Onge, R. P., Proctor, M. J., Wallace, I. M., Nile, A. H., Spagnuolo, P. A., Jitkova, Y., Gronda, M., Wu, Y., Kim, M. K., Cheung-Ong, K., Torres, N. P., Spear, E. D., Han, M. K., Schlecht, U., Suresh, S., Duby, G., Heisler, L. E., Surendra, A., Fung, E., Urbanus, M. L., Gebbia, M., Lissina, E., Miranda, M., Chiang, J. H., Aparicio, A. M., Zeghouf, M., Davis, R. W., Cherfils, J., Boutry, M., Kaiser, C. A., Cummins, C. L., Trimble, W. S., Brown, G. W., Schimmer, A. D., Bankaitis, V. A., Nislow, C., Bader, G. D., and Giaever, G. (2014) Mapping the cellular response to small molecules using chemogenomic fitness signatures Science 344, 208– 211 DOI: 10.1126/science.1250217
      44
      Mapping the Cellular Response to Small Molecules Using Chemogenomic Fitness Signatures
      Lee, Anna Y.; St. Onge, Robert P.; Proctor, Michael J.; Wallace, Iain M.; Nile, Aaron H.; Spagnuolo, Paul A.; Jitkova, Yulia; Gronda, Marcela; Wu, Yan; Kim, Moshe K.; Cheung-Ong, Kahlin; Torres, Nikko P.; Spear, Eric D.; Han, Mitchell K. L.; Schlecht, Ulrich; Suresh, Sundari; Duby, Geoffrey; Heisler, Lawrence E.; Surendra, Anuradha; Fung, Eula; Urbanus, Malene L.; Gebbia, Marinella; Lissina, Elena; Miranda, Molly; Chiang, Jennifer H.; Aparicio, Ana Maria; Zeghouf, Mahel; Davis, Ronald W.; Cherfils, Jacqueline; Boutry, Marc; Kaiser, Chris A.; Cummins, Carolyn L.; Trimble, William S.; Brown, Grant W.; Schimmer, Aaron D.; Bankaitis, Vytas A.; Nislow, Corey; Bader, Gary D.; Giaever, Guri
      Science (Washington, DC, United States) (2014), 344 (6180), 208-211CODEN: SCIEAS; ISSN:0036-8075. (American Association for the Advancement of Science)
      Genome-wide characterization of the in vivo cellular response to perturbation is fundamental to understanding how cells survive stress. Identifying the proteins and pathways perturbed by small mols. affects biol. and medicine by revealing the mechanisms of drug action. We used a yeast chemogenomics platform that quantifies the requirement for each gene for resistance to a compd. in vivo to profile 3250 small mols. in a systematic and unbiased manner. We identified 317 compds. that specifically perturb the function of 121 genes and characterized the mechanism of specific compds. Global anal. revealed that the cellular response to small mols. is limited and described by a network of 45 major chemogenomic signatures. Our results provide a resource for the discovery of functional interactions among genes, chems., and biol. processes.
      >> More from SciFinder ®
      https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlslSmtbw%253D&md5=543c8d40d54c94f789521ed29859d403

  • Supporting Information

    Supporting Information

    ARTICLE SECTIONS
    Jump To

    The following file is available free of charge on the ACS Publications website at DOI: 10.1021/id5000212.

    • Tables S1–S4 contain general strain information, mammalian cytotoxicity results, and expanded bacterial spectrum testing; Figures S1–S7 contain additional data describing CaFT analysis, heterozygote spot testing, Aspergillus zones of inhibition, time–kill assays, conditional mutant response, and Mcd4 inhibitor stability in plasma (PDF)


    Terms & Conditions

    Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: http://pubs.acs.org/page/copyright/permissions.html.

PDF [ 5MB]

Pair your accounts.

Export articles to Mendeley

Get article recommendations from ACS based on references in your Mendeley library.

Pair your accounts.

Export articles to Mendeley

Get article recommendations from ACS based on references in your Mendeley library.

You’ve supercharged your research process with ACS and Mendeley!

STEP 1:
Click to create an ACS ID

Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

MENDELEY PAIRING EXPIRED
Your Mendeley pairing has expired. Please reconnect